FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Barreto, FKD
   Alencar, CH
   Araujo, FMD
   Oliveira, RDAB
   Cavalcante, JW
   Lemos, DRQ
   Farias, LABG
   Boriz, ILF
   Medeiros, LQ
   Melo, MNP
   Miyajima, F
   Siqueira, AM
   Freitas, ARR
   Cavalcanti, LPD
AF Barreto, Francisca Kalline de Almeida
   Alencar, Carlos Henrique
   Araujo, Fernanda Montenegro de Carvalho
   Oliveira, Rhaquel de Morais Alves Barbosa
   Cavalcante, John Washington
   Lemos, Daniele Rocha Queiroz
   Farias, Luis Arthur Brasil Gadelha
   Boriz, Isac Lucca Frota
   Medeiros, Leticia Queiroz
   Melo, Marcelo Nunes Pereira
   Miyajima, Fabio
   Siqueira, Andre Machado
   Freitas, Andre Ricardo Ribas
   Cavalcanti, Luciano Pamplona de Goes
TI Seroprevalence, spatial dispersion and factors associated with
   flavivirus and chikungunha infection in a risk area: a population-based
   seroprevalence study in Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Seroprevalence; Chikungunya virus; Dengue virus; Zika virus
ID VIRUS-INFECTION; DENGUE; FEVER; EPIDEMIC
AB Background The State of Ceara, in Northeastern Brazil, suffers from a triple burden of arboviruses (dengue, Zika and chikungunya). We measured the seroprevalence of chikungunya, dengue and Zika and its associated factors in the population of Juazeiro do Norte, Southern Ceara State, Brazil. Methods A cross-sectional study of analytical and spatial analysis was performed to estimate the seroprevalence of dengue, Zika and chikungunya, in the year 2018. Participants were tested for IgM and IgG against these three viruses. Those with IgM and/or IgG positive tests results were considered positive. Poisson regression was used to analyze the factors associated with positive cases, in the same way that the spatial analysis of positive cases was performed to verify whether the cases were grouped. Results Of the 404 participants, 25.0% (103/404) were positive for CHIKV, 92.0% (373/404) for flavivirus (dengue or Zika) and of these, 37.9% (153/404) samples were classified as probable dengue infection. Of those who reported having had an arbovirus in the past, positive CHIKV cases had 58.7% arthralgia (PR = 4.31; 95% CI: 2.06-9.03; p = 0.000) mainly in the hands, ankles and feet. Age over 60 years had a positive association with cases of flavivirus (PR = 1.29; 95% CI: 1.09-1.54; p = 0.000). Fever, muscle pain, joint pain and skin rash were the most reported symptoms (46.1, 41.0, 38.3 and 28.41%, respectively). The positive cases of chikungunya and dengue or Zika were grouped in space and the city center was most affected area. Conclusions Four years after the introduction of CHIKV, where DENV has been in circulation for over 30 years, 1/4 of the population has already been exposed, showing the extent of the epidemic. The measured prevalence was much higher than that reported by local epidemiological surveillance.
C1 [Barreto, Francisca Kalline de Almeida; Alencar, Carlos Henrique; Oliveira, Rhaquel de Morais Alves Barbosa; Boriz, Isac Lucca Frota; Medeiros, Leticia Queiroz; Cavalcanti, Luciano Pamplona de Goes] Univ Fed Ceara, Programa Posgrad Saude Colet, Fortaleza, Ceara, Brazil.
   [Alencar, Carlos Henrique; Cavalcante, John Washington; Cavalcanti, Luciano Pamplona de Goes] Univ Fed Ceara, Programa Posgrad Patol, Fortaleza, Ceara, Brazil.
   [Araujo, Fernanda Montenegro de Carvalho; Lemos, Daniele Rocha Queiroz; Melo, Marcelo Nunes Pereira] Ctr Univ Christus, Fac Med, Fortaleza, Ceara, Brazil.
   [Araujo, Fernanda Montenegro de Carvalho] Lab Cent Saude Publ Ceara, Fortaleza, Ceara, Brazil.
   [Cavalcante, John Washington] Secretaria Saude Estado Ceara, Serv Verificacao Obitos Dr Rocha Furtado, Fortaleza, Ceara, Brazil.
   [Farias, Luis Arthur Brasil Gadelha] Univ Fed Ceara, Fac Med, Fortaleza, Ceara, Brazil.
   [Farias, Luis Arthur Brasil Gadelha] Hosp Sao Jose Doencas Infecciosas, Fortaleza, Ceara, Brazil.
   [Miyajima, Fabio] Fundacao Oswaldo Cruz Ceara, Eusebio, Brazil.
   [Siqueira, Andre Machado] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas INI, Rio De Janeiro, Brazil.
   [Freitas, Andre Ricardo Ribas] Fac Sao Leopoldo Mand, Campinas, SP, Brazil.
RP Barreto, FKD (corresponding author), Univ Fed Ceara, Programa Posgrad Saude Colet, Fortaleza, Ceara, Brazil.
EM kallineabarreto@gmail.com
OI Barreto, Francisca Kalline de Almeida/0000-0001-9767-7154; Brasil
   Gadelha Farias, Luis Arthur/0000-0002-8978-9903
FU FUNCAP [01/2017-SUS/PPSUS-CE FUNCAPSESA-Decit/SCTIE/MS-CNPq];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [MCTIC/CNPq 28/2018]; Network of Clinical and Applied Research into
   Chikungunya (REPLICK) through funds from the Department of Science and
   Technology (DECIT); Christus University Center (UNICHRISTUS); Federal
   University of Ceara
FX This work was partially supported by the FUNCAP 01/2017-SUS/PPSUS-CE
   FUNCAPSESA-Decit/SCTIE/MS-CNPq, CNPq for financing through the Call
   MCTIC/CNPq 28/2018 and the Network of Clinical and Applied Research into
   Chikungunya (REPLICK) through funds from the Department of Science and
   Technology (DECIT). The Christus University Center (UNICHRISTUS) for its
   financial support through the costing of printed materials used in
   research and its scientific initiation scholarships for medical
   students, and the Federal University of Ceara for the scientific
   initiation scholarships for medical students.
CR Ahmed S, 2015, OPEN J PEDIAT, V5, P128, DOI [10.4236/ojped.2015.52019, DOI 10.4236/OJPED.2015.52019]
   Al-Raddadi R, 2019, ACTA TROP, V189, P54, DOI 10.1016/j.actatropica.2018.09.009
   Andrioli DC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228346
   Aubry M, 2017, EMERG INFECT DIS, V23, P669, DOI 10.3201/eid2304.161549
   Badawi A, 2018, INT J INFECT DIS, V67, P107, DOI 10.1016/j.ijid.2017.12.018
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   BRASIL, 2018, B EP MON CAS DENG FE
   BRASIL, 2017, MON DOS CAS DENG FEB, V48
   BRASIL, 2018, B EP MON DOS CAS DEN, V48
   Brasil. Ministerio da Saude. Secretaria de AtencAo a Saude. Departamento de AtencAo Basica, 2013, ESTR CUID PESS COM D
   Campos JLS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181734
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Cavalcanti LPG, 2018, J HLTH BIOL SCI, V6, P65, DOI DOI 10.12662/2317-3076JHBS.V6I1.1415.P65-82.2018
   Chepkorir E, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1176-y
   Cunha RV, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005319
   da Silva-Nunes M, 2008, AM J TROP MED HYG, V79, P485, DOI 10.4269/ajtmh.2008.79.485
   Dayan G, 2015, AM J TROP MED HYG, V93, P18, DOI 10.4269/ajtmh.13-0663
   Cavalcanti LPD, 2016, J INFECT DEV COUNTR, V10, P563, DOI 10.3855/jidc.8575
   de Souza CHM, 2017, REAS, V11, pe274, DOI [10.25248/reas.e274.2019\, DOI 10.25248/REAS.E274.2019\]
   Dias JP, 2018, EMERG INFECT DIS, V24, P617, DOI 10.3201/eid2404.171370
   Freitas LP, 2019, P ROY SOC B-BIOL SCI, V286, DOI 10.1098/rspb.2019.1867
   Fritzell C, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006533
   Furuya-Kanamori L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1417-2
   Gouel-Cheron A, 2019, ANTIVIR RES, V172, DOI 10.1016/j.antiviral.2019.104638
   Gould E, 2017, ONE HEALTH-AMSTERDAM, V4, P1, DOI 10.1016/j.onehlt.2017.06.001
   Grijalva I, 2020, BIORXIV, DOI [10.1101/2020.01.08.898403, DOI 10.1101/2020.01.08.898403]
   GuimarAes MA, 2006, R CI MED BIOL, V5, P13
   Heukelbach J, 2001, TROP MED INT HEALTH, V6, P635, DOI 10.1046/j.1365-3156.2001.00762.x
   Javelle E, 2014, BMC INFECT DIS S2, V14, pO20, DOI DOI 10.1186/1471-2334-14-S2-O20
   Kikuti M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003937
   Lorenz C, 2019, ACTA TROP, V198, DOI [10.1016/j.actatropica, 10.1016/j.actatropica.2019.105093]
   MASON P. J., 1957, TRANS ROY SOC TROP MED AND HYG, V51, P238
   Mendonça Francisco de Assis, 2009, Soc. nat., V21, P257, DOI 10.1590/S1982-45132009000300003
   Moro ML, 2010, AM J TROP MED HYG, V82, P508, DOI 10.4269/ajtmh.2010.09-0322
   Murillo-Zamora E, 2018, ARCH MED RES, V49, P65, DOI 10.1016/j.arcmed.2018.04.008
   Obaidat MM, 2018, T ROY SOC TROP MED H, V112, P279, DOI 10.1093/trstmh/try055
   OMS. OrganizacAo Mundial de saude, ORG MUND SAUD DENG S
   Paganin F, 2010, EUR RESPIR J, V35, P1407, DOI 10.1183/09031936.00172909
   PREFEITURA JUAZEIRO DO NORTE, 2019, ASPECTOS GERAIS HIST
   Proenca-Modena JL, 2018, MICROBES INFECT, V20, P661, DOI 10.1016/j.micinf.2018.02.008
   Proesmans S, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007047
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Rodriguez-Barraquer I, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003906
   Santos Simone M, 2007, INTR EST ESP SAUD PU
   Santos SM, 2007, INTRO ESTATISTICA ES, P120
   Sawadogo S, 2020, TRANSFUSION MED, V30, P37, DOI 10.1111/tme.12646
   Sergon K, 2008, AM J TROP MED HYG, V78, P333, DOI 10.4269/ajtmh.2008.78.333
   Simiao AR, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0266-2019
   Siqueira JB, 2004, AM J TROP MED HYG, V71, P646, DOI 10.4269/ajtmh.2004.71.646
   Suhrbier A, 2019, NAT REV RHEUMATOL, V15, P597, DOI 10.1038/s41584-019-0276-9
   Teixeira M.d.G., 2003, EPIDEMIOL SERV SAUDE, V12, P87
   Teixeira MD, 2002, TROP MED INT HEALTH, V7, P757, DOI 10.1046/j.1365-3156.2002.00930.x
   van Aalst M, 2017, TRAVEL MED INFECT DI, V15, P8, DOI 10.1016/j.tmaid.2017.01.004
   Vasconcelos P F, 1999, Rev Soc Bras Med Trop, V32, P171
   Vasconcelos PFC, 1998, REV SAUDE PUBL, V32, P447, DOI 10.1590/S0034-89101998000500007
   Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
NR 57
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 24
PY 2020
VL 20
IS 1
AR 881
DI 10.1186/s12879-020-05611-5
PG 14
WC Infectious Diseases
SC Infectious Diseases
GA OW0BN
UT WOS:000592563900001
PM 33234110
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Queiroz, CJS
   Song, F
   Reed, KR
   Al-Khafaji, N
   Clarke, AR
   Vimalachandran, D
   Miyajima, F
   Pritchard, DM
   Jenkins, JR
AF Queiroz, Cleberson J. S.
   Song, Fei
   Reed, Karen R.
   Al-Khafaji, Nadeem
   Clarke, Alan R.
   Vimalachandran, Dale
   Miyajima, Fabio
   Pritchard, D. Mark
   Jenkins, John R.
TI NAP1L1: A Novel Human Colorectal Cancer Biomarker Derived From Animal
   Models ofApcInactivation
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; biomarkers; Apc; prognosis; survival
ID MULTIPLE INTESTINAL NEOPLASIA; MESSENGER-RNA; ADJUVANT CHEMOTHERAPY;
   GENE-EXPRESSION; BETA-CATENIN; IMMUNOHISTOCHEMISTRY; COLON; APC;
   PROTEIN; DIFFERENTIATION
AB Introduction Colorectal cancer (CRC) is the second leading cause of cancer death worldwide and most deaths result from metastases. We have analyzed animal models in whichApc, a gene that is frequently mutated during the early stages of colorectal carcinogenesis, was inactivated and human samples to try to identify novel potential biomarkers for CRC. Materials and Methods We initially compared the proteomic and transcriptomic profiles of the small intestinal epithelium of transgenic mice in whichApcand/orMychad been inactivated. We then studied the mRNA and immunohistochemical expression of one protein that we identified to show altered expression followingApcinactivation, nucleosome assembly protein 1-like 1 (NAP1L1) in human CRC samples and performed a prognostic correlation between biomarker expression and survival in CRC patients. Results Nap1l1mRNA expression was increased in mouse small intestine followingApcdeletion in aMycdependant manner and was also increased in human CRC samples. Immunohistochemical NAP1L1 expression was decreased in human CRC samples relative to matched adjacent normal colonic tissue. In a separate cohort of 75 CRC patients, we found a strong correlation between NAP1L1 nuclear expression and overall survival in those patients who had stage III and IV cancers. Conclusion NAP1L1expression is increased in the mouse small intestine followingApcinactivation and its expression is also altered in human CRC. Immunohistochemical NAP1L1 nuclear expression correlated with overall survival in a cohort of CRC patients. Further studies are now required to clarify the role of this protein in CRC.
C1 [Queiroz, Cleberson J. S.; Song, Fei; Al-Khafaji, Nadeem; Miyajima, Fabio; Pritchard, D. Mark; Jenkins, John R.] Univ Liverpool, Inst Syst Mol & Integrat Biol, Henry Wellcome Lab, Liverpool, Merseyside, England.
   [Queiroz, Cleberson J. S.] Fed Univ Mato Grosso UFMT, Fac Med, Cuiaba, Brazil.
   [Song, Fei] INFRAFRONTIER GmbH, Neuherberg, Germany.
   [Reed, Karen R.] Cardiff Univ, Div Canc & Genet, Sch Med, Wales Gene Pk, Cardiff, Wales.
   [Reed, Karen R.; Clarke, Alan R.] Cardiff Univ, European Canc Stem Cell Res Inst, Sch Biosci, Cardiff, Wales.
   [Vimalachandran, Dale] Countess Chester Hosp NHS Fdn Trust, Dept Colorectal Surg, Chester, Cheshire, England.
   [Miyajima, Fabio] Fundacao Oswaldo Cruz, Mol Epidemiol Lab, Eusebio, Brazil.
RP Pritchard, DM (corresponding author), Univ Liverpool, Inst Syst Mol & Integrat Biol, Henry Wellcome Lab, Liverpool, Merseyside, England.
EM mark.pritchard@liverpool.ac.uk
FU Science Without Borders Programme (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior, CAPES, Ministry of Education, Brazil); Cancer
   Research UK (ARC) [C1295/A15937]
FX CQ was supported by a scholarship from the Science Without Borders
   Programme (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior,
   CAPES, Ministry of Education, Brazil). KR was supported by Cancer
   Research UK (ARC Programme grant C1295/A15937).
CR Baarsma HA, 2013, PHARMACOL THERAPEUT, V138, P66, DOI 10.1016/j.pharmthera.2013.01.002
   Bockelman C, 2015, ACTA ONCOL, V54, P5, DOI 10.3109/0284186X.2014.975839
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200
   Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063854
   Clark J, 2008, AM J PHYSIOL-LUNG C, V294, pL431, DOI 10.1152/ajplung.00316.2007
   Coghlin C, 2015, PROTEOM CLIN APPL, V9, P64, DOI 10.1002/prca.201400082
   Cordero J, 2009, CELL CYCLE, V8, P2926
   Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033
   Drozdov I, 2009, CANCER-AM CANCER SOC, V115, P1638, DOI 10.1002/cncr.24180
   Fischl H, 2019, NUCLEIC ACIDS RES, V47, P7580, DOI 10.1093/nar/gkz461
   Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709
   Hammoudi A, 2013, BIOCHEM BIOPH RES CO, V440, P364, DOI 10.1016/j.bbrc.2013.08.076
   Higgins RA, 2008, ARCH PATHOL LAB MED, V132, P441, DOI 10.1043/1543-2165(2008)132[441:AOIITD]2.0.CO;2
   Hornick JL, 2014, MODERN PATHOL, V27, pS47, DOI 10.1038/modpathol.2013.177
   Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020
   Kidd M, 2006, ANN SURG ONCOL, V13, P253, DOI 10.1245/ASO.2006.12.011
   Le Y, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0949-0
   Line A, 2002, CANCER IMMUNOL IMMUN, V51, P574, DOI 10.1007/s00262-002-0322-2
   Luzietti E, 2018, BJS OPEN, V2, P433, DOI 10.1002/bjs5.88
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Myant K, 2011, EXP CELL RES, V317, P2725, DOI 10.1016/j.yexcr.2011.08.001
   Okuwaki M, 2010, GENES CELLS, V15, P13, DOI 10.1111/j.1365-2443.2009.01361.x
   Pekar-Zlotin M, 2015, ONCOLOGIST, V20, P316, DOI 10.1634/theoncologist.2014-0389
   Pietkiewicz P, 2014, CLIN EXP DERMATOL, V39, P628, DOI 10.1111/ced.12355
   Qiao HM, 2018, CELL REP, V22, P2279, DOI 10.1016/j.celrep.2018.02.019
   Queiroz CJS., 2017, THESIS
   Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Schilsky RL, 2018, NEW ENGL J MED, V378, P1242, DOI 10.1056/NEJMe1800419
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108
   Toga T, 2004, ANTICANCER RES, V24, P1173
   Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615
   Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801
   Wang F, 2017, HUM PATHOL, V62, P108, DOI 10.1016/j.humpath.2016.12.016
   Wong SCC, 2004, CLIN CANCER RES, V10, P1401, DOI 10.1158/1078-0432.CCR-0157-03
   Wong SCC, 2003, J CLIN PATHOL-MOL PA, V56, P347, DOI 10.1136/mp.56.6.347
   Zaha DC, 2014, WORLD J CLIN ONCOL, V5, P382, DOI 10.5306/wjco.v5.i3.382
NR 41
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 11
PY 2020
VL 10
AR 1565
DI 10.3389/fonc.2020.01565
PG 11
WC Oncology
SC Oncology
GA NI8JU
UT WOS:000565594200001
PM 32850460
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-17
ER

PT J
AU Lees, EA
   Carrol, ED
   Ellaby, NAF
   Roberts, P
   Corless, CE
   Lenzi, L
   Darby, A
   O'Brien, SJ
   Cunliffe, NA
   Turner, MA
   Miyajima, F
   Pirmohamed, M
AF Lees, Emily Ann
   Carrol, Enitan D.
   Ellaby, Nicholas A. F.
   Roberts, Paul
   Corless, Caroline E.
   Lenzi, Luca
   Darby, Alistair
   O'Brien, Sarah J.
   Cunliffe, Nigel A.
   Turner, Mark A.
   Miyajima, Fabio
   Pirmohamed, Munir
TI Characterization of Circulating Clostridium difficile Strains, Host
   Response and Intestinal Microbiome in Hospitalized Children With
   Diarrhea
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE C; difficile; diarrhea; children; host response
ID ASYMPTOMATIC COLONIZATION; ANTIBODY-RESPONSE; TOXIN-A; INFECTION;
   INFANTS; EPIDEMIOLOGY; RIBOTYPE; DISEASE; COINFECTIONS; NOROVIRUS
AB Background:
   Clostridium difficile is capable of causing severe enterocolitis in adults. The significance of toxin-producing C. difficile in children with diarrhea is unclear and practice differs on whether to institute treatment. We aimed to characterize the microbiome in relation to the presence of C. difficile and co-infection with other pathogens and to describe host response to infection.
   Methods:
   Participants were children with acute diarrhea, 0-16 years of age, from whom stool samples had been submitted to the hospital laboratory for routine microbiology/virology. Convenience sampling was used for 50 prospective and 150 retrospective samples. No participants were treated for C. difficile. Rates of culture positivity for C. difficile, presence of toxin and PCR-ribotype were compared between age groups. Presence of other potential pathogens, comorbidities and complications were recorded. Microbiotal diversity was measured by 16S profiling.
   Results:
   Nineteen of 77 (25%) children <2 years of age and 13 of 119 (11%) children >2 years of age were C. difficile positive, of whom 10 (53%) and 9 (69%), respectively, carried toxigenic strains. Increased Shannon diversity was seen in children carrying C. difficile, with altered milieu. Presence of C. difficile was not associated with adverse clinical outcomes. In stools containing both Norovirus and C. difficile, there was increased relative abundance of verrucomicrobia.
   Conclusions:
   Children with diarrhea regularly carried toxigenic and non-toxigenic strains of C. difficile, demonstrating enhanced microbiotal diversity, and change in milieu, without apparent morbidity. This unexpected finding is contrary to that seen in adults with C. difficile disease.
C1 [Lees, Emily Ann; Miyajima, Fabio; Pirmohamed, Munir] Univ Liverpool, Dept Personalised Med, Inst Translat Med, Liverpool, Merseyside, England.
   [Carrol, Enitan D.; Cunliffe, Nigel A.] Inst Infect & Global Hlth, Dept Clin Infect Microbiol & Immunol, Liverpool, Merseyside, England.
   [Ellaby, Nicholas A. F.; Lenzi, Luca; Darby, Alistair] Univ Liverpool, Inst Integrat Biol, Dept Funct & Comparat Genom, Liverpool, Merseyside, England.
   [Roberts, Paul; Corless, Caroline E.] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool Clin Labs, Dept Microbiol, Liverpool, Merseyside, England.
   [O'Brien, Sarah J.] Inst Infect & Global Hlth, Dept Epidemiol & Populat Hlth, Liverpool, Merseyside, England.
   [Turner, Mark A.] Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool, Merseyside, England.
RP Lees, EA (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England.
EM emilylees@doctors.org.uk
RI ; Darby, Alistair/I-6485-2012
OI Carrol, Enitan/0000-0001-8357-7726; Darby, Alistair/0000-0002-3786-6209
FU Alder Hey Children's Charity; NIHR Academic Clinical Fellowship;
   MRCMedical Research Council UK (MRC) [MR/K000551/1]; MRC Centre for Drug
   Safety Science
FX The study was funded by Alder Hey Children's Charity. E.A.L. was
   supported by an NIHR Academic Clinical Fellowship. M.P. is an Emeritus
   NIHR Senior Investigator. F.M. and M.P. were supported by an MRC
   Programme Grant (MR/K000551/1) and the MRC Centre for Drug Safety
   Science.
CR Antharam VC, 2013, J CLIN MICROBIOL, V51, P2884, DOI 10.1128/JCM.00845-13
   Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4
   Benson L, 2007, INFECT CONT HOSP EP, V28, P1233, DOI 10.1086/520732
   Carman RJ, 2018, ANAEROBE, V52, P16, DOI 10.1016/j.anaerobe.2018.05.002
   Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047
   COOPERSTOCK M, 1983, J CLIN MICROBIOL, V17, P830, DOI 10.1128/JCM.17.5.830-833.1983
   Crobach MJT, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00021-17
   Davis MY, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0198-6
   Denno DM, 2012, CLIN INFECT DIS, V55, P897, DOI 10.1093/cid/cis553
   Depestel Daryl D, 2013, J Pharm Pract, V26, P464, DOI 10.1177/0897190013499521
   El Feghaly RE, 2013, J PEDIATR GASTR NUTR, V57, P813, DOI 10.1097/MPG.0b013e3182a3202f
   El Feghaly RE, 2013, J PEDIATR-US, V163, P1697, DOI 10.1016/j.jpeds.2013.07.029
   Eyre DW, 2013, NEW ENGL J MED, V369, P1195, DOI 10.1056/NEJMoa1216064
   Gonzalez-Del Vecchio M, 2016, PEDIATR INFECT DIS J, V35, P281, DOI 10.1097/INF.0000000000001008
   Hopkins MJ, 2002, J MED MICROBIOL, V51, P448, DOI 10.1099/0022-1317-51-5-448
   Jangi S, 2010, J PEDIATR GASTR NUTR, V51, P2, DOI 10.1097/MPG.0b013e3181d29767
   Khanna S, 2013, CLIN INFECT DIS, V56, P1401, DOI 10.1093/cid/cit075
   Kyne L, 2001, LANCET, V357, P189, DOI 10.1016/S0140-6736(00)03592-3
   Lee JH, 2014, J MED MICROBIOL, V63, P819, DOI 10.1099/jmm.0.072082-0
   Lees EA, 2016, EUR J CLIN MICROBIOL, V35, P1047, DOI 10.1007/s10096-016-2639-3
   Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMoa1408913, 10.1056/NEJMc1505190]
   Lukkarinen H, 2009, PEDIATR INFECT DIS J, V28, P847, DOI 10.1097/INF.0b013e31819d1cd9
   Manges AR, 2010, J INFECT DIS, V202, P1877, DOI 10.1086/657319
   Miyajima F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022804
   O'Donoghue C, 2011, CURR OPIN GASTROEN, V27, P38, DOI 10.1097/MOG.0b013e3283411634
   Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177
   Perez-Cobas AE, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00335
   Prevention CfDCa, 2015, BIGG THREATS
   Rousseau C, 2011, J CLIN MICROBIOL, V49, P858, DOI 10.1128/JCM.01507-10
   Schubert AM, 2014, MBIO, V5, DOI 10.1128/mBio.01021-14
   Schutze GE, 2013, PEDIATRICS, V131, P196, DOI 10.1542/peds.2012-2992
   Skraban J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058005
   Stoesser N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182307
   Stokely JN, 2016, CLIN EPIDEMIOL, V8, P253, DOI 10.2147/CLEP.S106495
   TULLUS K, 1989, EUR J CLIN MICROBIOL, V8, P390, DOI 10.1007/BF01964052
   VISCIDI R, 1983, J INFECT DIS, V148, P93, DOI 10.1093/infdis/148.1.93
   Wilcox MH, 2008, J ANTIMICROB CHEMOTH, V62, P388, DOI 10.1093/jac/dkn163
   Yu H, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00037-17
   Zhao Chunna, 2015, Zhonghua Er Ke Za Zhi, V53, P522
NR 39
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 2020
VL 39
IS 3
BP 221
EP 228
DI 10.1097/INF.0000000000002559
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA LH0VG
UT WOS:000528508000011
PM 31876614
OA Green Published
DA 2020-12-17
ER

PT J
AU Jones, LG
   Vaida, A
   Thompson, LM
   Ikuomola, FI
   Caamano, JH
   Burkitt, MD
   Miyajima, F
   Williams, JM
   Campbell, BJ
   Pritchard, DM
   Duckworth, CA
AF Jones, Lauren G.
   Vaida, Andra
   Thompson, Louise M.
   Ikuomola, Felix I.
   Caamano, Jorge H.
   Burkitt, Michael D.
   Miyajima, Fabio
   Williams, Jonathan M.
   Campbell, Barry J.
   Pritchard, D. Mark
   Duckworth, Carrie A.
TI NF-kappa B2 signalling in enteroids modulates enterocyte responses to
   secreted factors from bone marrow-derived dendritic cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; STEM-CELLS; BARRIER
   DYSFUNCTION; EPITHELIAL-CELLS; INTESTINE; MAINTENANCE; MECHANISMS;
   INDUCTION; APOPTOSIS
AB Alternative pathway NF-kappa B signalling regulates susceptibility towards developing inflammatory bowel disease (IBD), colitis-associated cancer and sepsis-associated intestinal epithelial cell apoptosis and shedding. However, the cell populations responsible for the perturbed alternative pathway NF-kappa B signalling in intestinal mucosal pathology remain unclear. In order to investigate the contribution of the epithelial compartment, we have tested whether NF-kappa B2 regulated transcription in intestinal epithelial cells controls the intestinal epithelial response to cytokines that are known to disrupt intestinal barrier permeability. Enteroids were generated from the proximal, middle and distal regions of small intestine (SI) from C57BL/6J wild-type mice and displayed region-specific morphology that was maintained during sub-culture. Enteroids treated with 100 ng/mL TNF were compared with corresponding regions of SI from C57BL/6J mice treated systemically with 0.33 mg/kg TNF for 1.5 h. TNF-induced apoptosis in all regions of the intestine in vitro and in vivo but resulted in Paneth cell degranulation only in proximal tissue-derived SI and enteroids. TNF also resulted in increased enteroid sphericity (quantified as circularity from two-dimensional bright field images). This response was dose and time-dependent and correlated with active caspase-3 immunopositivity. Proximal tissuederived enteroids generated from Nf kappa B2(-/-) mice showed a significantly blunted circularity response following the addition of TNF, IFN gamma, lipopolysaccharide (LPS) activated C57BL/6J-derived bone marrow-derived dendritic cells (BMDC) and secreted factors from LPS-activated BMDCs. However, Nf kappa B1(-/-) mouse-derived enteroids showed no significant changes in response to these stimuli. In conclusion, the selection of SI region is important when designing enteroid studies as region-specific identity and response to stimuli such as TNF are maintained in culture. Intestinal epithelial cells are at least partially responsible for regulating their own fate by modulating NF-kappa B2 signalling in response to stimuli known to be involved in multiple intestinal and systemic diseases. Future studies are warranted to investigate the therapeutic potential of intestinal epithelial NF-kappa B2 inhibition.
C1 [Jones, Lauren G.; Vaida, Andra; Thompson, Louise M.; Ikuomola, Felix I.; Burkitt, Michael D.; Campbell, Barry J.; Pritchard, D. Mark; Duckworth, Carrie A.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Gastroenterol Res Unit, Liverpool, Merseyside, England.
   [Caamano, Jorge H.] Univ Birmingham, Inst Immunol & Immunotherapy, Coll Med & Dent Sci, Birmingham, W Midlands, England.
   [Miyajima, Fabio] Univ Liverpool, Inst Translat Med, Dept Clin & Mol Pharmacol, Liverpool, Merseyside, England.
   [Miyajima, Fabio] Fundacao Oswaldo Cruz, Biotechnol Grp, Eusebio, Ceara, Brazil.
   [Williams, Jonathan M.] Royal Vet Coll, Pathobiol & Populat Sci, Hawkshead Lane, Hatfield, Herts, England.
RP Duckworth, CA (corresponding author), Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Gastroenterol Res Unit, Liverpool, Merseyside, England.
EM Carried@liverpool.ac.uk
OI Caamano, Jorge/0000-0003-3530-7056
FU Fiona Elizabeth Agnew Trust (FEAT); Physiological Society; Epistem Ltd.;
   University of Liverpool; European CommunityEuropean Community (EC)
   [305564]; Wellcome TrustWellcome Trust [105231/Z/14/Z]
FX C.A.D. was supported by the Fiona Elizabeth Agnew Trust (FEAT), The
   Physiological Society, Epistem Ltd. and by a tenure-track fellowship
   from the University of Liverpool. D.M.P., B.J.C. and M.D.B. were
   supported by the European Community's Seventh Framework Programme
   (FP7/2007-2013) under grant agreement No. 305564 (SysmedIBD). C.A.D. and
   B.J.C. were additionally supported by a Wellcome Trust 4-year PhD
   studentship to L.T. (105231/Z/14/Z) in Cellular & Molecular Physiology
   at the University of Liverpool. We thank the Biomedical Services Unit,
   University of Liverpool and the Technology Directorate for maintenance
   of mice used in this study. We are also grateful to Bristol-Myers Squibb
   for providing Nf kappa b2<SUP>-/-</SUP> mice and David Baltimore for
   providing Nf kappa b1<SUP>-/-</SUP> mice.
CR Andrews C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01270
   Artis D, 2002, J IMMUNOL, V169, P4481, DOI 10.4049/jimmunol.169.8.4481
   Bandzar S, 2013, CELL IMMUNOL, V286, P45, DOI 10.1016/j.cellimm.2013.11.003
   Bernardo D, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700931
   Bjorck S, 2015, CLIN EXP IMMUNOL, V179, P230, DOI 10.1111/cei.12454
   Bosse T, 2006, MOL CELL BIOL, V26, P9060, DOI 10.1128/MCB.00124-06
   BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J
   Burkitt MD, 2013, ONCOGENE, V32, P5563, DOI 10.1038/onc.2013.334
   Burkitt MD, 2015, J PATHOL, V236, P326, DOI 10.1002/path.4527
   Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Derricott H, 2019, CELL TISSUE RES, V375, P409, DOI 10.1007/s00441-018-2924-9
   Duckworth CA, 2013, GASTROENTEROLOGY, V145, P197, DOI 10.1053/j.gastro.2013.03.012
   Duckworth CA, 2011, METHODS MOL BIOL, V763, P105, DOI 10.1007/978-1-61779-191-8_7
   Duckworth CA, 2009, GASTROENTEROLOGY, V136, P943, DOI 10.1053/j.gastro.2008.11.036
   Fuller MK, 2012, J SURG RES, V178, P48, DOI 10.1016/j.jss.2012.03.037
   Gillespie E, 2013, J CROHNS COLITIS, V7, P403, DOI 10.1016/j.crohns.2012.08.003
   GORDON JI, 1992, FASEB J, V6, P3039
   Gross M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00254
   Gunther C, 2015, GUT, V64, P601, DOI 10.1136/gutjnl-2014-307226
   Gulec S, 2014, AM J PHYSIOL-GASTR L, V307, pG397, DOI 10.1152/ajpgi.00348.2013
   Hu CAA, 2015, ANIM NUTR, V1, P123, DOI 10.1016/j.aninu.2015.08.014
   Kallenberger SM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004738
   KAPADIA CR, 1985, ANNU REV MED, V36, P93
   Kiesslich R, 2012, GUT, V61, P1146, DOI 10.1136/gutjnl-2011-300695
   Korolkova OY, 2015, CLIN MED INSIGHTS-GA, V8, P29, DOI 10.4137/CGast.S20612
   Lepage D, 2016, SCI REP-UK, V6, DOI 10.1038/srep36776
   Marchiando AM, 2011, GASTROENTEROLOGY, V140, P1208, DOI 10.1053/j.gastro.2011.01.004
   Merga YJ, 2016, AM J PHYSIOL-GASTR L, V310, pG1081, DOI 10.1152/ajpgi.00026.2016
   Middendorp S, 2014, STEM CELLS, V32, P1083, DOI 10.1002/stem.1655
   MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705
   NICHOLLS S, 1993, J CLIN PATHOL, V46, P757, DOI 10.1136/jcp.46.8.757
   Piguet PF, 1999, LAB INVEST, V79, P495
   Piton G, 2011, INTENS CARE MED, V37, P911, DOI 10.1007/s00134-011-2172-x
   Plichta KA, 2012, CANCER RES, V72, P5856, DOI 10.1158/0008-5472.CAN-12-1635
   POTTEN CS, 1990, DEVELOPMENT, V110, P1001
   Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x
   Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852
   Sato Toshiro, 2013, Methods Mol Biol, V945, P319, DOI 10.1007/978-1-62703-125-7_19
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8
   Soufli Imene, 2016, World J Gastrointest Pharmacol Ther, V7, P353, DOI 10.4292/wjgpt.v7.i3.353
   Tappenden KA, 2014, JPEN-PARENTER ENTER, V38, p23S, DOI 10.1177/0148607114525210
   Van Hauwermeiren F, 2015, MUCOSAL IMMUNOL, V8, P828, DOI 10.1038/mi.2014.112
   Walsh JG, 2011, J BIOL CHEM, V286, P32513, DOI 10.1074/jbc.M111.225862
   Watson AJM, 2009, ANN NY ACAD SCI, V1165, P135, DOI 10.1111/j.1749-6632.2009.04027.x
   Williams JM, 2015, VET PATHOL, V52, P445, DOI 10.1177/0300985814559404
   Williams Jonathan M, 2016, Curr Protoc Mouse Biol, V6, P148, DOI 10.1002/cpmo.2
   Williams JM, 2013, DIS MODEL MECH, V6, P1388, DOI 10.1242/dmm.013284
   Woo SJ, 2013, J LEUKOCYTE BIOL, V93, P363, DOI 10.1189/jlb.0412210
   Yoseph BP, 2016, SHOCK, V46, P52, DOI 10.1097/SHK.0000000000000565
NR 51
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV 26
PY 2019
VL 10
AR 896
DI 10.1038/s41419-019-2129-5
PG 14
WC Cell Biology
SC Cell Biology
GA JR6PA
UT WOS:000499743700009
PM 31772152
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-17
ER

PT J
AU Kommers, MJ
   Rodrigues, RAS
   Miyajima, F
   Zavala, AAZ
   Ultramari, VRLM
   Fett, WCR
   Balogun, SO
   de Oliveira, RG
   Fett, CA
AF Kommers, Michelle Jalousie
   Silva Rodrigues, Rosilene Andrade
   Miyajima, Fabio
   Zavala Zavala, Arturo Alejandro
   Leite Moreno Ultramari, Viviane Regina
   Rezende Fett, Waleria Christiane
   Balogun, Sikiru Olaitan
   de Oliveira, Ruberlei Godinho
   Fett, Carlos Alexandre
TI Effects of Probiotic Use on Quality of Life and Physical Activity in
   Constipated Female University Students: A Randomized, Double-Blind
   Placebo-Controlled Study
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE intestinal constipation; probiotics; quality of life; exercise
ID RESISTANT MALTODEXTRIN; COLONIC TRANSIT; FERMENTED MILK; RISK-FACTORS;
   METAANALYSIS; SYMPTOMS; WOMEN; PREVALENCE; DISCOMFORT; MICROBIOTA
AB Objectives: To evaluate the effect of a probiotic supplement containing two genera and five species of bacteria versus placebo on the quality of life (QoL) in female university students with intestinal constipation (IC). Design: A randomized, double-blind placebo-controlled study was conducted on female university students in a single study center. Settings/Location: Two phases of interventions were carried out, the pilot and main study. All participants were female students of Federal University of Mato Grosso, Brazil. Subjects: Female students whose ages ranged from 20 to 40 years and self-reported to be suffering from IC based on a questionnaire containing Rome III criteria were included. Interventions: Interventions occurred during a period of 30 days in the pilot phase (n = 32) and 15 days in the main study phase (n = 63). The subjects were numbered and randomly divided into experimental probiotic and placebo control groups. Therefore, neither the participants nor the researchers were aware of the allocations of the treatment groups. Outcome measures: The sociodemographic, Rome III, Patient Assessment of Constipation Quality of Life (PAC-QoL) and International Physical Activity questionnaires, and anthropometric measures were utilized. The relative risk (RR) treatment effect, absolute risk reduction (ARR), RR reduction, number needed to treat (NNT), and odds ratio were calculated. Results: Improvement in the QoL (ARR = 14% and p < 0.01) and satisfaction (ARR = 44% and p < 0.01) according to the PAC-QoL questionnaire was observed in the experimental group compared with the control group. For probiotic supplementation, an NNT = 7 was obtained. This implies that for every seven constipated women treated, a worsening in the QoL is prevented in one. An NNT = 1 was obtained concerning satisfaction in the same group of women with respect to the treatment. No clinically significant observations related to the safety of the product were reported. The authors did not detect the effect of exercise intensity on the QoL of participants. Conclusion: The probiotic supplementation had a positive impact on the QoL of constipated female university students.
C1 [Kommers, Michelle Jalousie; Silva Rodrigues, Rosilene Andrade; Zavala Zavala, Arturo Alejandro; Leite Moreno Ultramari, Viviane Regina; Rezende Fett, Waleria Christiane; de Oliveira, Ruberlei Godinho; Fett, Carlos Alexandre] Univ Fed Mato Grosso, Postgrad Program, Sch Phys Educ, Cuiaba, Brazil.
   [Miyajima, Fabio] Fundacao Oswaldo Cruz Fiocruz, Dept Sci Technol Prod & Innovat Publ Hlth, Fortaleza, Ceara, Brazil.
   [Balogun, Sikiru Olaitan] Fac Noroeste Mato Grosso AJES, Juina, Brazil.
RP Kommers, MJ (corresponding author), Univ Fed Mato Grosso, Sch Phys Educ, Av Fernando Correa da Costa 2367, BR-78060900 Cuiaba, MT, Brazil.
EM michellekommers@hotmail.com
RI de Oliveira, Ruberlei Godinho/S-8828-2019; de Oliveira, Ruberlei
   Godinho/AAO-8065-2020
OI de Oliveira, Ruberlei Godinho/0000-0003-2823-7459; Balogun, Sikiru
   Olaitan/0000-0002-4797-6129
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnoligico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)/Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT)
FX The authors are grateful for the financial support from Conselho
   Nacional de Desenvolvimento Cientifico e Tecnoligico (CNPq) and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)/Fundacao de Amparo a Pesquisa do Estado de Mato Grosso
   (FAPEMAT).
CR Ruiz MSA, 2016, EUR J NUTR, V55, P2389, DOI 10.1007/s00394-015-1045-4
   Appendix B, 2012, ARQ GASTROENTEROL S1, V49, P64
   Barololoum H, 2012, REP OPIN, V4, P52
   Bharucha AE, 2013, GASTROENTEROLOGY, V144, P218, DOI 10.1053/j.gastro.2012.10.028
   Bomfim I. Q. M., 2017, Revista de Ciencias Medicas e Biologicas, V16, P79, DOI 10.9771/cmbio.v16i1.13266
   Bron PA, 2017, BRIT J NUTR, V117, P93, DOI 10.1017/S0007114516004037
   Callan NGL, 2018, MENOPAUSE, V25, P615, DOI 10.1097/GME.0000000000001057
   Callaway LK, 2019, DIABETES CARE, V42, P364, DOI 10.2337/dc18-2248
   Ceresola ER, 2018, EUR REV MED PHARMACO, V22, P7045, DOI 10.26355/eurrev_201810_16177
   CONSORT, 2010, CONSORT 2010 DIAGRAM
   Dimidi E, 2020, P NUTR SOC, V79, P147, DOI 10.1017/S0029665119000934
   Dimidi E, 2014, AM J CLIN NUTR, V100, P1075, DOI 10.3945/ajcn.114.089151
   Dong YY, 2013, PLOS ONE, V8, P1
   Dreher ML, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121833
   Eales J, 2017, THER ADV GASTROENTER, V10, P74, DOI 10.1177/1756283X16670075
   Enck P, 2017, Z GASTROENTEROL, V55, P260, DOI 10.1055/s-0043-100022
   Eskesen D, 2015, BRIT J NUTR, V114, P1638, DOI 10.1017/S0007114515003347
   Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2002, GUID EV PROB FOOD RE
   Forootan M, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010631
   Ge XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00612-y
   Husain S, 2020, BJOG-INT J OBSTET GY, V127, P275, DOI 10.1111/1471-0528.15675
   Kerry RG, 2018, J FOOD DRUG ANAL, V26, P927, DOI 10.1016/j.jfda.2018.01.002
   Laudisi F, 2019, CELL MOL GASTROENTER, V7, P457, DOI 10.1016/j.jcmgh.2018.09.002
   Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061
   Lovell RM, 2012, CLIN GASTROENTEROL H, V10, P712, DOI 10.1016/j.cgh.2012.02.029
   Malik SS, 2018, INT J FOOD PROP, V21, P655, DOI 10.1080/10942912.2018.1448994
   Markowiak P, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091021
   Marquis P, 2005, SCAND J GASTROENTERO, V40, P540, DOI 10.1080/00365520510012208
   Matsudo S. M., 2002, REV BRASILEIRA CIENC, V10, P2002
   Matsudo SM, 2001, REV BRAS ATIV FIS SA, V10, P5, DOI DOI 10.12820/RBAFS.V.6N2P5-18
   McCormick JB, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-25
   Medronho R de A, 2009, EPIDEMIOLOGY, P251
   Miller LE, 2017, ANN GASTROENTEROL, V30, P629, DOI 10.20524/aog.2017.0192
   Miller LE, 2016, WORLD J GASTROENTERO, V22, P5122, DOI 10.3748/wjg.v22.i21.5122
   Minamida K, 2015, BIOSCI BIOTECH BIOCH, V79, P300, DOI 10.1080/09168451.2014.972331
   Monteiro LS, 2017, REV SAUDE PUBL, V51, DOI [10.11606/S1518-8787.2017051006053, 10.11606/s1518-8787.2017051006053]
   Nickerson KP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101789
   Nickerson KP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052132
   Obata Y, 2016, GASTROENTEROLOGY, V151, P836, DOI 10.1053/j.gastro.2016.07.044
   Schmidt FMQ, 2015, REV ESC ENFERM USP, V49, P440, DOI 10.1590/S0080-623420150000300012
   Riezzo G, 2018, BENEF MICROBES, V9, P51, DOI 10.3920/BM2017.0049
   Sakai T, 2015, BENEF MICROBES, V6, P253, DOI 10.3920/BM2014.0076
   Schmitz L, 2019, PILOT FEASIBILITY ST, V5, P1
   Suares NC, 2011, AM J GASTROENTEROL, V106, P1582, DOI 10.1038/ajg.2011.164
   Tabrizi Reza, 2019, Probiotics Antimicrob Proteins, DOI 10.1007/s12602-019-09559-0
   Tantawy SA, 2017, DIABET METAB SYND OB, V10, P513, DOI 10.2147/DMSO.S140250
   Turan I, 2014, TURK J GASTROENTEROL, V25, P650, DOI 10.5152/tjg.2014.6990
   van Baarlen P, 2013, CURR OPIN MICROBIOL, V16, P270, DOI 10.1016/j.mib.2013.07.001
   Waitzberg DL, 2013, CLIN NUTR, V32, P27, DOI 10.1016/j.clnu.2012.08.010
   Watanabe N, 2018, CLIN EXP GASTROENTER, V11, P85, DOI 10.2147/CEG.S153924
   Watts AM, 2018, J ALTERN COMPLEM MED, V24, P833, DOI 10.1089/acm.2017.0342
   WHO (World Health Organization), 2017, NUTR GUID 2017
   DEL’ARCO Ana Paula Wolf Tasca, 2017, Arq. Gastroenterol., V54, P115, DOI [10.1590/s0004-2803.201700000-09, 10.1590/S0004-2803.201700000-09]
NR 53
TC 1
Z9 1
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD DEC
PY 2019
VL 25
IS 12
BP 1163
EP 1171
DI 10.1089/acm.2019.0134
EA OCT 2019
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA KM1UU
UT WOS:000492877400001
PM 31657615
DA 2020-12-17
ER

PT J
AU Monte, AS
   da Silva, FER
   Lima, CND
   Vasconcelos, GS
   Gomes, NS
   Miyajima, F
   Vasconcelos, SMM
   Gama, CS
   Seeman, MV
   de Lucena, DF
   Macedo, DS
AF Monte, Aline Santos
   Rodrigues da Silva, Francisco Eliclecio
   de Carvatho Lima, Camita Nayane
   Vasconcelos, Germana Silva
   Gomes, Nayana Soares
   Miyajima, Fabio
   Mendes Vasconcelos, Silvania Maria
   Gama, Clarissa S.
   Seeman, Mary, V
   de Lucena, David Freitas
   Macedo, Danielle S.
TI Sex influences in the preventive effects of N-acetylcysteine in a
   two-hit animal model of schizophrenia
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article
DE Schizophrenia; N-Acetylcysteine; sex differences; two-hit model; poly I;
   C; G protein-coupled estrogen receptor 1 (GPER)
ID PRENATAL IMMUNE ACTIVATION; ESTROGEN-RECEPTOR GPR30; OXIDATIVE STRESS;
   PREFRONTAL CORTEX; PARVALBUMIN INTERNEURONS; PREPULSE INHIBITION;
   PSYCHIATRIC-DISORDERS; PERIPUBERTAL STRESS; GENDER-DIFFERENCES;
   RAT-BRAIN
AB Background: Schizophrenia (SCZ) is a neurodevelopmental disorder influenced by patient sex. Mechanisms underlying sex differences in SCZ remain unknown. A two-hit model of SCZ combines the exposure to perinatal infection (first-hit) with peripubertal unpredictable stress (PUS, second-hit). N-acetylcysteine (NAC) has been tested in SCZ because of the involvement of glutathione mechanisms in its neurobiology. Aims: We aim to investigate whether NAC administration to peripubertal rats of both sexes could prevent behavioral and neurochemical changes induced by the two-hit model. Methods: Wistar rats were exposed to polyinosinic:polycytidylic acid (a viral mimetic) or saline on postnatal days (PND) 5-7. On PND30-59 they received saline or NAC 220 mg/kg and between PND40-48 were subjected to PUS or left undisturbed. On PND60 behavioral and oxidative alterations were evaluated in the prefrontal cortex (PFC) and striatum. Mechanisms of hippocampal memory regulation such as immune expression of G protein-coupled estrogen receptor 1 (GPER), alpha 7-nAChR and parvalbumin were also evaluated. Results: NAC prevented sensorimotor gating deficits only in females, while it prevented alterations in social interaction, working memory and locomotor activity in both sexes. Again, in rats of both sexes, NAC prevented the following neurochemical alterations: glutathione (GSH) and nitrite levels in the PFC and lipid peroxidation in the PFC and striatum. Striatal oxidative alterations in GSH and nitrite were observed in females and prevented by NAC. Two-hit induced hippocampal alterations in females, namely expression of GPER-1, alpha 7-nAChR and parvalbumin, were prevented by NAC. Conclusion: Our results highlights the influences of sex in NAC preventive effects in rats exposed to a two-hit schizophrenia model.
C1 [Monte, Aline Santos; Rodrigues da Silva, Francisco Eliclecio; de Carvatho Lima, Camita Nayane; Vasconcelos, Germana Silva; Gomes, Nayana Soares; Mendes Vasconcelos, Silvania Maria; de Lucena, David Freitas; Macedo, Danielle S.] Univ Fed Ceara, Fac Med, Drug Res & Dev Ctr, Dept Physiol & Pharmacol, Fortaleza, Ceara, Brazil.
   [Miyajima, Fabio] Fundacao Oswaldo Cruz Fiocruz CE, Fortaleza, Ceara, Brazil.
   [Gama, Clarissa S.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Lab Mol Psychiat, Programa Posgrad Psiquiatria & Ciencias Comportam, Porto Alegre, RS, Brazil.
   [Seeman, Mary, V] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
   [Macedo, Danielle S.] CNPq, Natl Inst Translat Med INCT TM, Ribeirao Preto, SP, Brazil.
RP Macedo, DS (corresponding author), Univ Fed Ceara, Dept Physiol & Pharmacol, Rua Cel Nunes de Melo 1000, BR-60430275 Fortaleza, Ceara, Brazil.
EM danielle.macedo@ufc.br
RI Macedo, Danielle/E-3424-2014
OI Macedo, Danielle/0000-0001-8980-9970
FU Brazilian Council for Scientific and Technological Development
   (CNPq)/Departamento de Ciencia e Tecnologia da Secretaria de Ciencia,
   Tecnologia e Insumos Estrategicos do Ministerio da Saude
   (Decit/SCTIE/MS) [466724/2014-4]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: the study
   was funded by the Brazilian Council for Scientific and Technological
   Development (CNPq)/Departamento de Ciencia e Tecnologia da Secretaria de
   Ciencia, Tecnologia e Insumos Estrategicos do Ministerio da Saude
   (Decit/SCTIE/MS), Grant number 466724/2014-4.
CR Abdelsalam O. M. E, 2018, REACTI OXYG SPECIES, P253
   Abdul-Monim Z, 2007, J PSYCHOPHARMACOL, V21, P198, DOI 10.1177/0269881107067097
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X
   Bean LA, 2014, NEUROSCIENTIST, V20, P534, DOI 10.1177/1073858413519865
   Behrens MM, 2007, SCIENCE, V318, P1645, DOI 10.1126/science.1148045
   Bodnar AL, 2005, J MED CHEM, V48, P905, DOI 10.1021/jm049363q
   Boess FG, 2007, J PHARMACOL EXP THER, V321, P716, DOI 10.1124/jpet.106.118976
   Botsakis K, 2016, NEUROSCIENCE, V320, P221, DOI 10.1016/j.neuroscience.2016.01.068
   Cabungcal JH, 2014, NEURON, V83, P1073, DOI 10.1016/j.neuron.2014.07.028
   Cabungcal JH, 2013, BIOL PSYCHIAT, V73, P574, DOI 10.1016/j.biopsych.2012.09.020
   Carmeli C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029341
   Conus P, 2018, SCHIZOPHRENIA BULL, V44, P317, DOI 10.1093/schbul/sbx093
   Dall'Igna OP, 2007, EXP NEUROL, V203, P241, DOI 10.1016/j.expneurol.2006.08.008
   Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057
   Dean OM, 2011, NEUROSCI LETT, V499, P149, DOI 10.1016/j.neulet.2011.05.027
   Do KQ, 2015, SCHIZOPHRENIA BULL, V41, P835, DOI 10.1093/schbul/sbv065
   DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S
   Dun SL, 2009, J NEUROSCI RES, V87, P1610, DOI 10.1002/jnr.21980
   Durieux AMS, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00343
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Gawryluk JW, 2011, INT J NEUROPSYCHOPH, V14, P123, DOI 10.1017/S1461145710000805
   Geyer MA, 2001, CURR PROTOC NEUROSCI
   Giovanoli S, 2014, BRAIN BEHAV IMMUN, V40, P48, DOI 10.1016/j.bbi.2014.04.005
   Giovanoli S, 2013, SCIENCE, V339, P1095, DOI 10.1126/science.1228261
   Gogos A, 2009, INT J NEUROPSYCHOPH, V12, P1249, DOI 10.1017/S1461145709000480
   GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927
   Jin Ye, 2017, Shanghai Arch Psychiatry, V29, P191, DOI 10.11919/j.issn.1002-0829.217044
   Kalpouzos G, 2017, CEREB CORTEX, V27, P3427, DOI 10.1093/cercor/bhx045
   Kapur S, 2005, SCHIZOPHR RES, V79, P59, DOI 10.1016/j.schres.2005.01.003
   Kerksick Chad, 2005, J Int Soc Sports Nutr, V2, P38, DOI 10.1186/1550-2783-2-2-38
   KHAN M. A., 2018, J FUNCT SPACE, V2018, P1
   Kinkead B, 2006, J NEUROSCI METH, V151, P68, DOI 10.1016/j.jneumeth.2005.07.015
   Klauser P, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0266-8
   Kulak A, 2012, BEHAV BRAIN RES, V226, P563, DOI 10.1016/j.bbr.2011.10.020
   Kumari V, 2004, SCHIZOPHR RES, V69, P219, DOI 10.1016/j.schres.2003.09.010
   Lante F, 2008, HIPPOCAMPUS, V18, P602, DOI 10.1002/hipo.20421
   Levin ED, 2012, CURR DRUG TARGETS, V13, P602, DOI 10.2174/138945012800398937
   Lewis DA, 2012, TRENDS NEUROSCI, V35, P57, DOI 10.1016/j.tins.2011.10.004
   Li HB, 2014, CAN J PSYCHIAT, V59, P107
   Li Rena, 2016, J Transl Neurosci (Beijing), V1, P37
   Lin H, 2014, MOL CELL NEUROSCI, V61, P163, DOI 10.1016/j.mcn.2014.06.007
   Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x
   Lu D, 2016, BIOCHEM BIOPH RES CO, V477, P209, DOI 10.1016/j.bbrc.2016.06.044
   Ribeiro BMM, 2013, SCHIZOPHR RES, V151, P12, DOI 10.1016/j.schres.2013.10.040
   Macri S, 2010, PSYCHONEUROENDOCRINO, V35, P1374, DOI 10.1016/j.psyneuen.2010.03.012
   Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7
   Minarini A, 2017, EXPERT OPIN DRUG MET, V13, P279, DOI 10.1080/17425255.2017.1251580
   Monte AS, 2017, BEHAV BRAIN RES, V331, P30, DOI 10.1016/j.bbr.2017.04.057
   Borella VCM, 2016, DEV NEUROBIOL, V76, P519, DOI 10.1002/dneu.22329
   Ng F, 2008, INT J NEUROPSYCHOPH, V11, P851, DOI 10.1017/S1461145707008401
   Nucifora LG, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.178
   Paylor R, 1998, LEARN MEMORY, V5, P302
   Perlstein WM, 2001, AM J PSYCHIAT, V158, P1105, DOI 10.1176/appi.ajp.158.7.1105
   Phensy A, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00106
   Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122
   Radenovic L, 2005, BRAIN RES BULL, V67, P133, DOI 10.1016/j.brainresbull.2005.06.019
   Radyushkin K, 2009, GENES BRAIN BEHAV, V8, P416, DOI 10.1111/j.1601-183X.2009.00487.x
   Ralph RJ, 2001, J PHARMACOL EXP THER, V298, P148
   Ratnayake U, 2014, DEV NEUROSCI-BASEL, V36, P83, DOI 10.1159/000362205
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Redrobe JR, 2009, EUR J PHARMACOL, V602, P58, DOI 10.1016/j.ejphar.2008.09.035
   Ross NR, 2002, DEV BRAIN RES, V137, P23, DOI 10.1016/S0165-3806(02)00364-4
   Rubin RD, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00742
   Sadock B, 2016, COMPENDIO PSIQUIATRI
   Schiavone S, 2009, BIOL PSYCHIAT, V66, P384, DOI 10.1016/j.biopsych.2009.04.033
   Seeman MV, 2019, PSYCHIAT QUART, V90, P173, DOI 10.1007/s11126-018-9619-y
   Seeman MV, 2004, AM J PSYCHIAT, V161, P1324, DOI 10.1176/appi.ajp.161.8.1324
   Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001
   Shahripour RB, 2014, BRAIN BEHAV, V4, P108, DOI 10.1002/brb3.208
   Shungu DC, 2012, BIOL PSYCHIAT, V71, P937, DOI 10.1016/j.biopsych.2012.03.025
   Sotonyi P, 2010, REPROD SCI, V17, P1077, DOI 10.1177/1933719110379651
   Spary EJ, 2013, NEUROSIGNALS, V21, P14, DOI 10.1159/000333296
   Swerdlow NR, 2001, BRAIN RES, V898, P195, DOI 10.1016/S0006-8993(01)02143-6
   Tosic M, 2006, AM J HUM GENET, V79, P586, DOI 10.1086/507566
   Van den Buuse M, 2001, EUR J PHARMACOL, V425, P33, DOI 10.1016/S0014-2999(01)01139-6
   van Os J, 2010, NATURE, V468, P203, DOI 10.1038/nature09563
   Vicens P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/952719
   Wible CG, 2001, PSYCHIAT RES-NEUROIM, V108, P65, DOI 10.1016/S0925-4927(01)00109-3
   Wu YC, 2013, NEUROSCIENCE, V239, P67, DOI 10.1016/j.neuroscience.2012.10.024
   Wu YC, 2014, PSYCHONEUROENDOCRINO, V45, P167, DOI 10.1016/j.psyneuen.2014.03.016
   Yao JK, 2006, DIS MARKERS, V22, P83, DOI 10.1155/2006/248387
   Young JW, 2009, PHARMACOL THERAPEUT, V122, P150, DOI 10.1016/j.pharmthera.2009.02.004
   Zhang XF, 2015, BRAIN RES BULL, V116, P16, DOI 10.1016/j.brainresbull.2015.05.003
   Zlatkovic J, 2014, MOL CELL BIOCHEM, V393, P43, DOI 10.1007/s11010-014-2045-z
NR 85
TC 3
Z9 3
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
EI 1461-7285
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD JAN
PY 2020
VL 34
IS 1
BP 125
EP 136
AR 0269881119875979
DI 10.1177/0269881119875979
EA SEP 2019
PG 12
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA KA5HD
UT WOS:000489388400001
PM 31556775
DA 2020-12-17
ER

PT J
AU de Aguiar, GPCG
   Leite, CMGD
   Dias, B
   Vasconcelos, SMM
   de Moraes, RA
   de Moraes, MEA
   Vallinoto, ACR
   Macedo, DS
   Cavalcanti, LPD
   Miyajima, F
AF Costa Gomes de Aguiar, Gabriella Pequeno
   Goncalves da Silva Leite, Claudio Manuel
   Dias, Beatriz
   Mendes Vasconcelos, Silvania Maria
   de Moraes, Renata Amaral
   Amaral de Moraes, Maria Elisabete
   Rosario Vallinoto, Antonio Carlos
   Macedo, Danielle Silveira
   de Goes Cavalcanti, Luciano Pamplona
   Miyajima, Fabio
TI Evidence for Host Epigenetic Signatures Arising From Arbovirus
   Infections: A Systematic Review
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE systematic review; host epigenetics; microRNAs; histone modifications;
   arbovirus
ID JAPANESE ENCEPHALITIS-VIRUS; DENGUE-VIRUS; MICRORNA EXPRESSION;
   ANTIVIRAL ACTIVITY; RNA INTERFERENCE; PROTECTIVE ROLE; ACUTE-PHASE;
   REPLICATION; CHIKUNGUNYA; MECHANISM
AB Background: Arbovirus infections have steadily become a major pandemic threat. This study aimed at investigating the existence of host epigenetic markers arising from the principal arboviruses infections impacting on human health. We set to systematically review all published evidence describing any epigenetic modifications associated with infections from arboviruses, including, but not limited to, microRNAs, DNA methylation, and histone modifications.
   Methods: A comprehensive search was conducted using the electronic databases PubMed, Science Direct and Cochrane Library from inception to January 4th, 2018. We included reports describing original in vivo or in vitro studies investigating epigenetic changes related to arbovirus infections in either clinical subjects or human cell lines. Studies investigating epigenetic modifications related to the virus or the arthropod vector were excluded. A narrative synthesis of the findings was conducted, contextualizing comparative evidence from in vitro and in vivo studies.
   Results: A total of 853 unique references were identified and screened by two independent researchers. Thirty-two studiesmet the inclusion criteria and were reviewed. The evidence was centered mainly on microRNA and DNA methylation signatures implicated with secondary Dengue fever. Evidence for recent epidemic threats, such as the infections by Zika or Chikungunya viruses is still scant.
   Conclusions: Major epigenetic alterations found on arboviruses infections were miR-146, miR-30e and the Dicer complex. However, existing studies frequently tested distinct hypotheses resulting in a heterogeneity of methodological approaches. Whilst epigenetic signatures associated with arbovirus infections have been reported, existing studies have largely focused on a small number of diseases, particularly dengue. Validation of epigenetic signatures have an untapped potential, but concerted investigations are certainly required to deliver robust candidates of clinical utility for diagnosis, staging and prognosis of specific arboviral diseases.
C1 [Costa Gomes de Aguiar, Gabriella Pequeno; Amaral de Moraes, Maria Elisabete] Univ Fed Ceara, Fac Med, Postgrad Programme Med & Surg Sci, Fortaleza, Ceara, Brazil.
   [Goncalves da Silva Leite, Claudio Manuel; Mendes Vasconcelos, Silvania Maria; Amaral de Moraes, Maria Elisabete; Macedo, Danielle Silveira; Miyajima, Fabio] Univ Fed Ceara, Fac Med, Postgrad Programme Pharmacol, Fortaleza, Ceara, Brazil.
   [Dias, Beatriz; de Moraes, Renata Amaral; de Goes Cavalcanti, Luciano Pamplona] Unichristus Univ Ctr, Fac Med, Fortaleza, Ceara, Brazil.
   [Mendes Vasconcelos, Silvania Maria; de Moraes, Renata Amaral; Amaral de Moraes, Maria Elisabete; Macedo, Danielle Silveira] Univ Fed Ceara, Fac Med, Ctr Drug Res & Dev NPDM, Fortaleza, Ceara, Brazil.
   [de Moraes, Renata Amaral] Sao Jose Hosp Infect Dis, Fortaleza, Ceara, Brazil.
   [Rosario Vallinoto, Antonio Carlos] Fed Univ Para, Inst Biol Sci, Lab Virol, Belem, Para, Brazil.
   [de Goes Cavalcanti, Luciano Pamplona] Univ Fed Ceara, Fac Med, Dept Community Hlth, Fortaleza, Ceara, Brazil.
   [Miyajima, Fabio] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.
   [Miyajima, Fabio] Univ Fed Ceara, Fac Med, Postgrad Programme Med Sci, Fortaleza, Ceara, Brazil.
   [Miyajima, Fabio] Oswaldo Cruz Fdn Fiocruz, Branch Ceara, Eusebio, Brazil.
RP Miyajima, F (corresponding author), Univ Fed Ceara, Fac Med, Postgrad Programme Pharmacol, Fortaleza, Ceara, Brazil.; Miyajima, F (corresponding author), Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.; Miyajima, F (corresponding author), Univ Fed Ceara, Fac Med, Postgrad Programme Med Sci, Fortaleza, Ceara, Brazil.; Miyajima, F (corresponding author), Oswaldo Cruz Fdn Fiocruz, Branch Ceara, Eusebio, Brazil.
EM fabio.miyajima@fiocruz.br
RI Vallinoto, Antonio Carlos/AAL-9501-2020; Macedo, Danielle/E-3424-2014
OI Vallinoto, Antonio Carlos/0000-0003-1135-6507; Macedo,
   Danielle/0000-0001-8980-9970
CR Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003
   Andrade BB, 2005, AN ACAD BRAS CIENC, V77, P665, DOI 10.1590/S0001-37652005000400008
   Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5
   Balakrishnan L, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110346
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Bayer A, 2018, PLACENTA, V61, P33, DOI 10.1016/j.placenta.2017.11.004
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Gomes AVBT, 2016, J MED VIROL, V88, P1297, DOI 10.1002/jmv.24478
   Bogerd HP, 2014, J VIROL, V88, P8065, DOI 10.1128/JVI.00985-14
   Bruscella P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00824
   Casseb Alexandre do Rosario, 2013, Veterinaria e Zootecnia, V20, P391
   Casseb SMM, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027891
   Charrel RN, 2007, NEW ENGL J MED, V356, P769, DOI 10.1056/NEJMp078013
   Chen RF, 2014, J INFECTION, V69, P366, DOI 10.1016/j.jinf.2014.05.013
   Coffey LL, 2008, P NATL ACAD SCI USA, V105, P6970, DOI 10.1073/pnas.0712130105
   Colpitts TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024365
   Corridoni D, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00032
   Cavalcanti LPD, 2018, REV SOC BRAS MED TRO, V51, P63, DOI 10.1590/0037-8682-0440-2017
   Demir ZC, 2017, J MED VIROL, V89, P417, DOI 10.1002/jmv.24667
   Devhare P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.517
   Diosa-Toro M, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005981
   Escalera-Cueto M, 2015, VIRUS RES, V196, P105, DOI 10.1016/j.virusres.2014.11.010
   Gould E, 2017, ONE HEALTH-AMSTERDAM, V4, P1, DOI 10.1016/j.onehlt.2017.06.001
   Grassmann R, 2008, BBA-GENE REGUL MECH, V1779, P706, DOI 10.1016/j.bbagrm.2008.05.005
   Gunther VJ, 2011, VACCINE, V29, P3895, DOI 10.1016/j.vaccine.2011.03.038
   Jeewandara C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003673
   Jiang LL, 2012, J CLIN INVEST, V122, P33, DOI 10.1172/JCI58849
   Kakumani PK, 2016, GENE, V586, P7, DOI 10.1016/j.gene.2016.03.053
   Kakumani PK, 2015, BIOCHEM J, V471, P89, DOI 10.1042/BJ20150445
   Kakumani PK, 2013, J VIROL, V87, P8870, DOI 10.1128/JVI.02774-12
   Kanokudom S, 2017, ANTIVIR RES, V142, P169, DOI 10.1016/j.antiviral.2017.03.020
   KOZAK RA, 2017, VIRUSES-BASEL, V9, DOI DOI 10.3390/V9100297
   Kumari B, 2016, SCI REP-UK, V6, DOI 10.1038/srep20263
   Lichinchi G, 2016, CELL HOST MICROBE, V20, P666, DOI 10.1016/j.chom.2016.10.002
   Liu SY, 2016, CELL MOL IMMUNOL, V13, P700, DOI 10.1038/cmi.2015.52
   Mayer SV, 2017, ACTA TROP, V166, P155, DOI 10.1016/j.actatropica.2016.11.020
   Meltzer E, 2012, INFECT DIS CLIN N AM, V26, P479, DOI 10.1016/j.idc.2012.02.003
   Milavetz BI, 2015, METHODS MOL BIOL, V1238, P569, DOI 10.1007/978-1-4939-1804-1_30
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Olson KE, 2015, CURR OPIN VIROL, V15, P119, DOI 10.1016/j.coviro.2015.10.001
   Ouyang XX, 2016, INT J MED SCI, V13, P195, DOI 10.7150/ijms.13996
   Pham AM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002465
   Pierro A., 2015, New Microbes and New Infections, V7, P23, DOI 10.1016/j.nmni.2015.04.002
   Pu JY, 2017, ARCH VIROL, V162, P3645, DOI 10.1007/s00705-017-3516-9
   Qi YM, 2013, MOL MED REP, V7, P791, DOI 10.3892/mmr.2013.1288
   Rastogi M, 2018, J MED VIROL, V90, P648, DOI 10.1002/jmv.24995
   Saba R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00578
   Saxena T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079886
   Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137
   Selvamani SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103624
   Sharma N, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0249-0
   Slonchak A, 2016, J VIROL, V90, P2388, DOI 10.1128/JVI.02608-15
   Tambyah PA, 2016, ANN CLIN BIOCHEM, V53, P466, DOI 10.1177/0004563215604001
   Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wu N, 2014, MICROBES INFECT, V16, P911, DOI 10.1016/j.micinf.2014.08.011
   Wu SY, 2013, J INFECTION, V67, P329, DOI 10.1016/j.jinf.2013.05.003
   Zhu B, 2015, J IMMUNOL, V195, P2251, DOI 10.4049/jimmunol.1500370
   Zhu X, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003088
NR 59
TC 0
Z9 0
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 31
PY 2019
VL 10
AR 1207
DI 10.3389/fimmu.2019.01207
PG 14
WC Immunology
SC Immunology
GA IB3NI
UT WOS:000470173800003
PM 31214179
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Rodrigues, FTS
   de Souza, MRM
   Lima, CND
   da Silva, FER
   Costa, DVD
   dos Santos, CC
   Miyajima, F
   de Sousa, FCF
   Vasconcelos, SMM
   Barichello, T
   Quevedo, J
   Maes, M
   de Lucena, DF
   Macedo, D
AF Sousa Rodrigues, Francisca Taciana
   Matos de Souza, Marcos Romario
   de Carvalho Lima, Camila Nayane
   Rodrigues da Silva, Francisco Eliclecio
   da Silva Costa, Deiziane Viana
   dos Santos, Claudio Costa
   Miyajima, Fabio
   de Sousa, Francisca Clea F.
   Mendes Vasconcelos, Silvania Maria
   Barichello, Tatiana
   Quevedo, Joao
   Maes, Michael
   de Lucena, David F.
   Macedo, Danielle
TI Major depression model induced by repeated and intermittent
   lipopolysaccharide administration: Long-lasting behavioral, neuroimmune
   and neuroprogressive alterations
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Chronic depression; Neuroinflammation; Tryptophan catabolism; LPS; SAT1;
   Forced swimming test
ID FORCED SWIMMING TEST; NEUROTROPHIC FACTOR; ANIMAL-MODEL; BRAIN;
   EXPRESSION; MICE; ACTIVATION; IDO; LPS; PATHOPHYSIOLOGY
AB Major depressed patients show increased bacterial translocation with elevated plasma levels of lipopolysaccharide (LPS), which may trigger immune-inflammatory and neuro-oxidative responses. Recently, an animal model based on chronic LPS administration was developed which was associated with long-lasting depressive like and neuro-oxidative alterations in female mice. The aim of the current study was to investigate behavioral, neuroimmune and neuroprogressive alterations in female mice 6 weeks after LPS chronic exposure. Female mice received increasing doses of LPS during 5 days at one-month intervals repeated for 4 consecutive months. Six weeks after the last LPS-exposure, we assessed behavioral despair and anhedonia, microglial activation, alterations in tryptophan, 5-HT, kynurenine, quinolinic acid (QUIN) levels and spermidine/spermine N1-acetyl-transferase (SAT1) expression in the hippocampus, both with and without fluoxetine administration. Our results show that six weeks post-LPS, mice present behavioral despair and anhedonia in association with increased IBA1 expression (a microglia activation marker), NF-kB p65 and IL-1 beta levels, indoleamine 2,3-dioxygenase (IDO1) mRNA expression, kynurenine, QUIN levels and QUIN/tryptophan ratio, and lowered tryptophan, 5-HT levels and SAT1 mRNA expression. Fluoxetine reversed the behavioral and neuroimmune alterations but had no effect in the reversal of IDO1 increased expression, QUIN levels and QUIN/tryptophan ratio. In conclusion, our results support the validity of the chronic LPS model of major depression and additionally shows its translational relevance with respect to neuroimmune and neuroprogressive pathways.
C1 [Sousa Rodrigues, Francisca Taciana; Matos de Souza, Marcos Romario; de Carvalho Lima, Camila Nayane; Rodrigues da Silva, Francisco Eliclecio; Miyajima, Fabio; de Sousa, Francisca Clea F.; Mendes Vasconcelos, Silvania Maria; de Lucena, David F.; Macedo, Danielle] Univ Fed Ceara, Dept Physiol & Pharmacol, Fac Med, Neuropharmacol Lab,Drug Res & Dev Ctr, Fortaleza, CE, Brazil.
   [da Silva Costa, Deiziane Viana] Univ Fed Ceara, Fac Med, Dept Morphol, Fortaleza, CE, Brazil.
   [dos Santos, Claudio Costa] Univ Fed Semiarido, Ctr Engenharias, Dept Engn & Tecnol, Mossoro, RN, Brazil.
   [Miyajima, Fabio] FIOCRUZ CE, Fundacao Oswaldo Cruz, Fortaleza, Ceara, Brazil.
   [Barichello, Tatiana; Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Psychiat & Behav Sci, Translat Psychiat Program, 1941 East Rd, Houston, TX 77054 USA.
   [Barichello, Tatiana; Quevedo, Joao] Univ Southern Santa Catarina UNESC, Hlth Sci Unit, Grad Program Hlth Sci, Lab Neurosci, Criciuma, SC, Brazil.
   [Barichello, Tatiana; Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Psychiat & Behav Sci, Ctr Excellence Mood Disorders, Houston, TX 77030 USA.
   [Maes, Michael] Deakin Univ, Impact Strateg Res Ctr, Geelong, Vic, Australia.
   [Maes, Michael] Chulalongkorn Univ, Fac Med, Bangkok, Thailand.
   [Macedo, Danielle] CNPq, Natl Inst Translat Med INCT TM, Ribeirao Preto, Brazil.
RP Macedo, D (corresponding author), Univ Fed Ceara, Dept Physiol & Pharmacol, Drug Res & Dev Ctr, Rua Cel Nunes Melo 1000, BR-60431270 Fortaleza, CE, Brazil.
EM taciana7maia@gmail.com; romariomattos@gmail.com;
   camilacarvalhoenf@yahoo.com.br; elicleciors@gmail.com;
   deiziane2009@gmail.com; claudio.costa@ufersa.edu.br; fabiom@ufc.br;
   silvania_vasconcelos@yahoo.com.br; tatiana.Barichello@uth.tmc.edu;
   Joao.L.DeQuevedo@uth.tmc.edu; dr.michaelmaes@hotmail.com;
   daviddelucena@me.com; daniellesilmacedo@gmail.com
RI Barichello, Tatiana/E-2725-2013; Costa, Deiziane VS/C-4727-2017; Macedo,
   Danielle/E-3424-2014; Maes, Michael/B-8546-2011; de Sousa, Francisca
   Clea Florenco/ABA-5683-2020; de Quevedo, Joao Luciano/E-5491-2013
OI Costa, Deiziane VS/0000-0001-6402-8908; Macedo,
   Danielle/0000-0001-8980-9970; Maes, Michael/0000-0002-2012-871X; de
   Quevedo, Joao Luciano/0000-0003-3114-6611; Barichello,
   Tatiana/0000-0001-7776-8454; De Souza, Marcos/0000-0002-9365-3224
FU Brazilian Funding Agency: CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian Funding Agency: CAPESCAPES;
   Brazilian Funding Agency: FUNCAP; Department of Psychiatry and
   Behavioral Sciences, McGovern Medical School, The University of Texas
   Health Science Center at Houston (UTHealth); CNPqNational Council for
   Scientific and Technological Development (CNPq); Instituto Cerebro e
   Mente; UNESC; FAPESC
FX The present study was funded by grants from the Brazilian Funding
   Agencies: CNPq, CAPES and FUNCAP. The authors declare no conflict of
   interests.; The Translational Psychiatry Program (USA) is funded by the
   Department of Psychiatry and Behavioral Sciences, McGovern Medical
   School, The University of Texas Health Science Center at Houston
   (UTHealth).; Translational Psychiatry Laboratory (Brazil) is one of the
   centers of the National Institute for Molecular Medicine (INCT-MM) and
   one of the members of the Center of Excellence in Applied Neurosciences
   of Santa Catarina (NENASC). Its research is supported by grants from
   CNPq, FAPESC; Instituto Cerebro e Mente and UNESC.
CR ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Bonaccorso S, 2001, PSYCHIAT RES, V105, P45, DOI 10.1016/S0165-1781(01)00315-8
   Brites D, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00476
   Carroll BJ, 2007, ACTA PSYCHIAT SCAND, V115, P90, DOI 10.1111/j.1600-0447.2007.00967.x
   Casero RA, 2009, BIOCHEM J, V421, P323, DOI 10.1042/BJ20090598
   Castren E, 2010, DEV NEUROBIOL, V70, P289, DOI 10.1002/dneu.20758
   Cazareth J, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-132
   CLARKE JR, 1991, J MED VIROL, V34, P212, DOI 10.1002/jmv.1890340403
   Custodio CS, 2013, EUR J PHARMACOL, V713, P31, DOI 10.1016/j.ejphar.2013.04.040
   Dias ICD, 2016, MOL NEUROBIOL, V53, P6997, DOI 10.1007/s12035-015-9617-0
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   Detke MJ, 1997, EXP CLIN PSYCHOPHARM, V5, P107, DOI 10.1037/1064-1297.5.2.107
   Drewes JL, 2015, J NEUROVIROL, V21, P449, DOI 10.1007/s13365-015-0334-2
   Du RH, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw037
   Mello BSF, 2013, J PSYCHIATR RES, V47, P1521, DOI 10.1016/j.jpsychires.2013.06.008
   Fiori LM, 2008, J PSYCHIATR NEUROSCI, V33, P102
   Genedani S, 2001, NEUROREPORT, V12, P3939, DOI 10.1097/00001756-200112210-00017
   Goggi J, 2002, BRAIN RES, V941, P34, DOI 10.1016/S0006-8993(02)02505-2
   Hamon M, 2013, PROG NEURO-PSYCHOPH, V45, P54, DOI 10.1016/j.pnpbp.2013.04.009
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002
   Huang TL, 2007, PSYCHIAT CLIN NEUROS, V61, P415, DOI 10.1111/j.1440-1819.2007.01686.x
   Iarashi K, 2010, INT J BIOCHEM CELL B, V42, P39, DOI 10.1016/j.biocel.2009.07.009
   Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
   Kaufmann FN, 2017, BRAIN BEHAV IMMUN, V64, P367, DOI 10.1016/j.bbi.2017.03.002
   Kubera M, 2013, BRAIN BEHAV IMMUN, V31, P96, DOI 10.1016/j.bbi.2013.01.001
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Macs M, 2008, NEUROENDOCRINOL LETT
   MAES M, 1994, NEUROPSYCHOBIOLOGY, V29, P157, DOI 10.1159/000119080
   MAES M, 1993, PSYCHIAT RES, V49, P11, DOI 10.1016/0165-1781(93)90027-E
   MAES M, 1995, PROG NEURO-PSYCHOPH, V19, P11, DOI 10.1016/0278-5846(94)00101-M
   Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P702, DOI 10.1016/j.pnpbp.2010.12.017
   MAES M, 1994, ACTA PSYCHIAT SCAND, V89, P346, DOI 10.1111/j.1600-0447.1994.tb01527.x
   MAES M, 1993, AM J PSYCHIAT, V150, P1189
   MAES M, 1991, NEUROPSYCHOBIOLOGY, V24, P115, DOI 10.1159/000119472
   Maes M, 2008, NEUROENDOCRINOL LETT, V29, P117
   Maes M, 2007, NEUROENDOCRINOL LETT, V28, P826
   Maes M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-66
   Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P664, DOI 10.1016/j.pnpbp.2010.06.014
   Mao QQ, 2014, BEHAV BRAIN RES, V261, P140, DOI 10.1016/j.bbr.2013.12.020
   Moreno R. O. A., 2013, THEOR BIOL MED MODEL, V10, P59, DOI DOI 10.1186/1742-4682-10-59
   Moylan S, 2014, NEUROSCI BIOBEHAV R, V45, P46, DOI 10.1016/j.neubiorev.2014.05.007
   Mylnt A, 2005, J AFFECT DISORDERS, V88, P167, DOI [10.1016/j.jad.2005.07.008, DOI 10.1016/J.JAD.2005.07.008]
   National Institute of Health, 1996, GUIDE CARE USE LAB A
   Nibuya M, 1996, J NEUROSCI, V16, P2365
   NODA Y, 1995, BRIT J PHARMACOL, V116, P2531, DOI 10.1111/j.1476-5381.1995.tb15106.x
   Pantazatos SP, 2015, NEUROBIOL DIS, V79, P123, DOI 10.1016/j.nbd.2015.04.014
   Pollack M. H, 2005, J CLIN PSYCHIAT
   PORSOLT RD, 1978, EUR J PHARMACOL, V51, P291, DOI 10.1016/0014-2999(78)90414-4
   Presits P, 2003, CHROMATOGRAPHIA, V57, pS87, DOI 10.1007/BF02492089
   Costa APR, 2013, PROG NEURO-PSYCHOPH, V45, P150, DOI 10.1016/j.pnpbp.2013.05.002
   Reichenberg A, 2001, ARCH GEN PSYCHIAT, V58, P445, DOI 10.1001/archpsyc.58.5.445
   Remus J. L, 2016, INT J NEUROPSYCHOPH, DOI [10.1093/finp/pyw028, DOI 10.1093/FINP/PYW028]
   Sanchez-Jimenez F, 2013, BRIT J PHARMACOL, V170, P4, DOI 10.1111/bph.12109
   Savitz J, 2015, BRAIN BEHAV IMMUN, V46, P55, DOI 10.1016/j.bbi.2015.02.007
   Shirey KA, 2006, J INTERF CYTOK RES, V26, P53, DOI 10.1089/jir.2006.26.53
   Soulet D, 2003, J CELL BIOL, V162, P257, DOI 10.1083/jcb.200301097
   Steiner J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-94
   Stevens B. R, 2017, GUT GUTJNL, DOI [10.1136/gutjn1-2017-314759, DOI 10.1136/GUTJN1-2017-314759]
   TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533
   Wang YL, 2006, J BIOCHEM, V139, P17, DOI 10.1093/jb/mvj021
   Yadav MC, 2007, GLIA, V55, P1385, DOI 10.1002/glia.20544
   Yirmiya R, 1996, BRAIN RES, V711, P163, DOI 10.1016/0006-8993(95)01415-2
   Zhang MH, 1999, MOL MED, V5, P595, DOI 10.1007/BF03402072
NR 65
TC 7
Z9 7
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD DEC
PY 2018
VL 107
BP 57
EP 67
DI 10.1016/j.jpsychires.2018.10.003
PG 11
WC Psychiatry
SC Psychiatry
GA HC0LV
UT WOS:000451490800008
PM 30326340
DA 2020-12-17
ER

PT J
AU de Oliveira, RG
   Miyajima, F
   Castilho, GRD
   Damazo, AS
   Macho, A
   Martins, DTD
AF de Oliveira, Ruberlei Godinho
   Miyajima, Fabio
   de Campos Castilho, Geovane Roberto
   Damazo, Amilcar Sabino
   Macho, Antonio
   de Oliveira Martins, Domingos Tabajara
TI Dilodendron bipinnatum Radlk. ameliorates airway inflammation through
   multiple targets in a murine model of ovalbumin-induced allergic airway
   disease
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Dilodendron bipinnatwn; Airway inflammatory disease; Lipoxygenase
   inhibition; IgE inhibition; Th2 cytokines; Anti-inflammatory
ID HYDROETHANOLIC EXTRACT; TH2 CYTOKINES; GALLIC ACID; ASTHMA; IGE
AB Ethnopharmacological relevance: Dilodendron bipinnatum Radlk., Sapindaceae, a tree of the Mato Grosso Pantanal, is popularly known as "mulher-pobre". The decoction or infusion of its inner stem bark is used for treating inflammatory conditions.
   Aim of the study: To determine if a 70% hydroethanolic extract of Dilodendron bipinnatum stem bark (HEDb) is able to reduce allergic airway inflammation in a murine model of ovalbumin (OVA)-induced allergic asthma.
   Material and methods: The inner stem bark powder was macerated in a 70% hydroethanolic solution (1:3 w/v) to obtain HEDb. The induction of experimental asthma was accomplished as follows: on days 1 and 10, Swiss mice were sensitized by an intraperitoneal injection of OVA (100 mu g/mL) and aluminum hydroxide (10 mu g/mL). From day 19 to 24, animals (n = 6/per group) were treated (p.o.) twice a day with either vehicle (distilled water), HEDb (20, 100 and 500 mg/kg) or dexamethasone (0.5 mg/kg). Sham group animals were intraperitoneally injected and challenged with saline solution (0.9%) instead of OVA and received distilled water orally instead of HEDb, whereas the other groups were challenged with OVA (3% in saline) by aerosolization. On day 25, bronchoalveolar lavage fluid (BALF) was collected for the quantification of total leukocytes, neutrophils, eosinophils, mononuclear cells and Th2 cytokines (IL-4, IL-5, and IL-13). The lungs were collected for histopathological analysis and blood was assayed to determine serum IgE levels. The anti-inflammatory activity of HEDb was additionally confirmed by a lipoxygenase (LO) inhibitory assay in vitro.
   Results: Compared to the sham group, the OVA group showed significantly greater numbers of total leukocytes, neutrophils, eosinophils, and mononuclear cells, as well as inflammatory cytokines in BALF, and also IgE in the serum. HEDb treated mice showed a significant decrease in inflammatory cell accumulation in BALF, with the maximum response observed at 500 mg/kg. Furthermore, the levels of IL-4, IL-5 and IL-13 in BALF, and of IgE in serum, were also considerably reduced as compared to the OVA group. The histopathological examination of the lungs of mice in the vehicle group showed a significant increase in hemorrhagic damage, mucus, perivascular and peribronchial inflammatory cell infiltrates, as well as mast cell degranulation compared to sham. HEDb (100 and 500 mg/kg) remarkably decreased all these parameters, presenting at the highest dose an anti-inflammatory effect comparable to that of dexamethasone (0.5 mg/kg). HEDb also had notable direct anti-inflammatory properties demonstrated by the inhibition of 15-LO activity in vitro (IC50 = 1.0-5.0 mu g/mL).
   Conclusions: These results somewhat agree on the popular use of the inner stem bark of D. bipinnatum as a treatment for allergic asthma. The HEDb exhibits significant anti-inflammatory activity in the OVA-induced mouse model of allergic asthma, possibly due to the down-regulation of the Th2 responses and LO inhibition, resulting in improvements in all analyzed inflammatory parameters.
C1 [de Oliveira, Ruberlei Godinho; de Campos Castilho, Geovane Roberto; Macho, Antonio; de Oliveira Martins, Domingos Tabajara] Univ Fed Mato Grosso, Fac Med, Area Farmacol, Dept Ciencias Basicas Saude, Cuiaba, MT, Brazil.
   [Miyajima, Fabio] Univ Fed Ceara, Grp Neurofarmacol, Ctr Pesquisa & Desenvolvimento Med NPDM, Fortaleza, Ceara, Brazil.
   [Damazo, Amilcar Sabino] Univ Fed Mato Grosso, Fac Med, Dept Ciencias Basicas Saude, Area Histol & Biol Celular, Cuiaba, MT, Brazil.
RP Martins, DTD (corresponding author), Univ Fed Mato Grosso, Av Fernando Correa da Costa 2367, BR-78060900 Cuiaba, Mato Grosso, Brazil.
EM taba@terra.com.br
RI de Oliveira, Ruberlei Godinho/AAO-8065-2020; Damazo, Amilcar
   S/B-6659-2014; Quiros, Antonio Macho/H-1403-2012; de Oliveira, Ruberlei
   Godinho/S-8828-2019
OI de Oliveira, Ruberlei Godinho/0000-0003-2823-7459; Damazo, Amilcar
   S/0000-0003-2323-008X; Quiros, Antonio Macho/0000-0002-9294-8709; 
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES
   Pro-Amazonia - Biodiversidade e Sustentabilidade)CAPES
   [23038.000731/2013-56]; Fundacao de Amparo a Pesquisa do Estado de Mato
   Grosso (FAPEMAT) [157552/2014]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq/BIONORTE)National Council for Scientific
   and Technological Development (CNPq) [551737/2010-7]; Instituto Nacional
   de Ciencia e Tecnologia em Areas Umidas (INAU-INCT-MCTI/CNPq/CAPES/FAPs)
   [16/2014]; CAPESCAPES
FX The present research was funded by Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES Pro-Amazonia - Biodiversidade e
   Sustentabilidade, grant no. 23038.000731/2013-56), Fundacao de Amparo a
   Pesquisa do Estado de Mato Grosso (FAPEMAT - grant no. 157552/2014),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq/BIONORTE - grant no. 551737/2010-7) and Instituto Nacional de
   Ciencia e Tecnologia em Areas Umidas (INAU-INCT-MCTI/CNPq/CAPES/FAPs no.
   16/2014). Ruberlei G. de Oliveira and Antonio Macho receive,
   respectively, a doctoral and post-doctoral fellowship from CAPES.
CR Agra LC, 2016, EUR J PHARMACOL, V780, P232, DOI 10.1016/j.ejphar.2016.03.056
   [Anonymous], 2017, GLOB STRAT ASTHM MAN
   [Anonymous], 2012, J BRAS PNEUMOL S1, V38, pS1
   Bani D, 2006, J PHARMACOL EXP THER, V317, P1002, DOI 10.1124/jpet.106.102178
   Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130
   Mahon CPCDN, 2014, J ETHNOPHARMACOL, V155, P665, DOI 10.1016/j.jep.2014.06.018
   Corren J, 2013, CURR ALLERGY ASTHM R, V13, P415, DOI 10.1007/s11882-013-0373-9
   Bieski IGC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/272749
   Morel LJF, 2017, J ETHNOPHARMACOL, V198, P226, DOI 10.1016/j.jep.2016.12.008
   de Oliveira RG, 2017, J ETHNOPHARMACOL, V202, P127, DOI 10.1016/j.jep.2017.02.026
   de Oliveira RG, 2014, J ETHNOPHARMACOL, V155, P387, DOI 10.1016/j.jep.2014.05.041
   DORSCH W, 1992, INT ARCH ALLERGY IMM, V97, P1, DOI 10.1159/000236088
   dos Santos JC, 2010, QUIM NOVA, V33, P2080, DOI 10.1590/S0100-40422010001000014
   Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053
   Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755
   GENTRY AH, 1987, ANN MO BOT GARD, V74, P533, DOI 10.2307/2399320
   Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273
   Hambly N, 2014, CURR OPIN PULM MED, V20, P87, DOI 10.1097/MCP.0000000000000007
   Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731
   Kato K, 2001, YAKUGAKU ZASSHI, V121, P451, DOI 10.1248/yakushi.121.451
   Kumar RK, 2008, CURR DRUG TARGETS, V9, P485, DOI 10.2174/138945008784533561
   Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049
   Leung E, 2017, EXPERT OPIN DRUG SAF, V16, P397, DOI 10.1080/14740338.2017.1286327
   Lorenzi H, 2002, PLANTAS MED BRASIL N
   Nader MA, 2012, N-S ARCH PHARMACOL, V385, P909, DOI 10.1007/s00210-012-0772-9
   Olin JT, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5517
   Postma DS, 2015, NEW ENGL J MED, V373, P1241, DOI 10.1056/NEJMra1411863
   Queiroz C. J., 2014, INFECT AGENTS CANCER, V21, P9
   Shergis JL, 2016, J ASTHMA, V53, P650, DOI 10.3109/02770903.2015.1101473
   Skloot GS, 2016, CURR OPIN PULM MED, V22, P3, DOI 10.1097/MCP.0000000000000225
NR 30
TC 1
Z9 1
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD NOV 15
PY 2018
VL 226
BP 17
EP 25
DI 10.1016/j.jep.2018.07.025
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA GT8LX
UT WOS:000444790100003
PM 30053531
DA 2020-12-17
ER

PT J
AU Mello, BSF
   Chaves, AJM
   Custodio, CS
   Cordeiro, RC
   Miyajima, F
   de Sousa, FCF
   Vasconcelos, SMM
   de Lucena, DF
   Macedo, D
AF Ferreira Mello, Bruna Stefania
   Maia Chaves Filho, Adriano Jose
   Custodio, Charllyany Sabino
   Cordeiro, Rafaela Carneiro
   Miyajima, Fabio
   Florenco de Sousa, Francisca Clea
   Mendes Vasconcelos, Silvania Maria
   de Lucena, David Freitas
   Macedo, Danielle
TI Sex influences in behavior and brain inflammatory and oxidative
   alterations in mice submitted to lipopolysaccharide-induced inflammatory
   model of depression
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE Depression; Lipopolysaccharide; Inflammation; Sex; Oxidative stress;
   Lipid peroxidation
ID CHRONIC MILD STRESS; GENDER-DIFFERENCES; PSYCHOLOGICAL STRESS;
   PREFRONTAL CORTEX; MOOD DISORDERS; ANXIETY-LIKE; PLUS-MAZE;
   MYELOPEROXIDASE; GLUTATHIONE; RATS
AB Peripheral inflammation induced by lipopolysaccharide (LPS) causes a behavioral syndrome with translational relevance for depression. This mental disorder is twice more frequent among women. Despite this, the majority of experimental studies investigating the neurobiological effects of inflammatory models of depression have been performed in males. Here, we sought to determine sex influences in behavioral and oxidative changes in brain regions implicated in the pathophysiology of mood disorders (hypothalamus, hippocampus and prefrontal cortex - PFC) in adult mice 24 h post LPS challenge. Myeloperoxidase (MPO) activity and interleukin (IL)-1 beta levels were measured as parameters of active inflammation, while reduced glutathione (GSH) and lipid peroxidation as parameters of oxidative imbalance. We observed that male mice presented behavioral despair, while females anxiety-like alterations. Both sexes were vulnerable to LPS-induced anhedonia. Both sexes presented increased MPO activity in the PFC, while male only in the hippocampus. IL-1 beta increased in the PFC and hypothalamus of animals of both sexes, while in the hippocampus a relative increase of this cytokine in males compared to females was detected. GSH levels were decreased in all brain areas investigated in animals of both sexes, while increased lipid peroxidation was observed in the hypothalamus of females and in the hippocampus of males after LPS exposure. Therefore, the present study gives additional evidence of sex influence in LPS-induced behavioral alterations and, for the first time, in the oxidative changes in brain areas relevant for mood regulation.
C1 [Ferreira Mello, Bruna Stefania; Maia Chaves Filho, Adriano Jose; Custodio, Charllyany Sabino; Cordeiro, Rafaela Carneiro; Miyajima, Fabio; Florenco de Sousa, Francisca Clea; Mendes Vasconcelos, Silvania Maria; de Lucena, David Freitas; Macedo, Danielle] Univ Fed Ceara, Fac Med, Dept Physiol & Pharmacol, Neuropharmacol Lab,Drug Res & Dev Ctr, Fortaleza, Ceara, Brazil.
   [Macedo, Danielle] CNPq, INCT TM, Natl Inst Translat Med, Ribeirao Preto, Brazil.
RP Macedo, D (corresponding author), Univ Fed Ceara, Dept Physiol & Pharmacol, Drug Res & Dev Ctr, Rua Cel Nunes de Melo 1000, BR-60431270 Fortaleza, Ceara, Brazil.
EM danielle.macedo@ufc.br
RI Macedo, Danielle/E-3424-2014; de Sousa, Francisca Clea
   Florenco/ABA-5683-2020; Chaves-Filho, Adriano/AAZ-1390-2020; Miyajima,
   Fabio/K-6587-2012
OI Macedo, Danielle/0000-0001-8980-9970; Lucena, David/0000-0002-1547-3711;
   Miyajima, Fabio/0000-0002-1347-4825; Florenco, Francisca
   Clea/0000-0002-9140-1795
FU Brazilian Institution CAPESCAPES; Brazilian Institution FUNCAP;
   Brazilian Institution CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX The authors thank the Brazilian Institutions CAPES, FUNCAP and CNPq for
   the financial support. The authors are grateful for the technical
   assistance of Maria Vilani Bastos.
CR ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X
   Arnhold J, 2010, ARCH BIOCHEM BIOPHYS, V500, P92, DOI 10.1016/j.abb.2010.04.008
   Avitsur R, 1999, PHARMACOL BIOCHEM BE, V64, P787, DOI 10.1016/S0091-3057(99)00165-3
   Badala F., 2008, NEUROPSYCHOPHARMACOL, V144, P724, DOI [10.1038/jid.2014.371, DOI 10.1038/JID.2014.371]
   Bassi GS, 2012, BASIC CLIN PHARMACOL, V110, P359, DOI 10.1111/j.1742-7843.2011.00824.x
   Bellanti F, 2013, REDOX BIOL, V1, P340, DOI 10.1016/j.redox.2013.05.003
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Cai KC, 2016, BRAIN BEHAV IMMUN, V58, P327, DOI 10.1016/j.bbi.2016.08.002
   Cakir OK, 2017, PHYSIOL BEHAV, V168, P1, DOI 10.1016/j.physbeh.2016.10.010
   Silva MCC, 2016, PROG NEURO-PSYCHOPH, V64, P142, DOI 10.1016/j.pnpbp.2015.08.002
   Cullen SP, 2015, CELL REP, V11, P1535, DOI 10.1016/j.celrep.2015.05.003
   Custodio CS, 2013, EUR J PHARMACOL, V713, P31, DOI 10.1016/j.ejphar.2013.04.040
   Dalla C, 2010, BASIC CLIN PHARMACOL, V106, P226, DOI 10.1111/j.1742-7843.2009.00516.x
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   Doremus-Fitzwater TL, 2009, PHYSIOL BEHAV, V97, P484, DOI 10.1016/j.physbeh.2009.03.025
   Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059
   Duval ER, 2015, THER CLIN RISK MANAG, V11, P115, DOI 10.2147/TCRM.S48528
   Farooq RK, 2017, BIOMED REP, V6, P15, DOI 10.3892/br.2016.807
   Felgner J, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005679
   Mello BSF, 2013, J PSYCHIATR RES, V47, P1521, DOI 10.1016/j.jpsychires.2013.06.008
   Frenois F, 2007, PSYCHONEUROENDOCRINO, V32, P516, DOI 10.1016/j.psyneuen.2007.03.005
   Fuchs P., 2014, DIABETES OXIDATIVE S, P15, DOI [DOI 10.1016/B978-0-12-405885-9.00002-4, 10.1016/B978-0-12-405885-9.00002-4]
   Gawel Stefan, 2004, Wiad Lek, V57, P453
   Gawryluk JW, 2011, INT J NEUROPSYCHOPH, V14, P123, DOI 10.1017/S1461145710000805
   Gorwood Philip, 2008, Dialogues Clin Neurosci, V10, P291
   Greenberg PE, 2015, J CLIN PSYCHIAT, V76, P155, DOI 10.4088/JCP.14m09298
   Han SC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/720457
   Iwasaki-Sekino A, 2009, PSYCHONEUROENDOCRINO, V34, P226, DOI 10.1016/j.psyneuen.2008.09.003
   Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
   Kohler CA, 2017, ACTA PSYCHIAT SCAND, V135, P373, DOI 10.1111/acps.12698
   Koo JW, 2008, P NATL ACAD SCI USA, V105, P751, DOI 10.1073/pnas.0708092105
   Li CL, 2017, ACS CHEM NEUROSCI, V8, P2005, DOI 10.1021/acschemneuro.7b00154
   Lisowski P, 2013, J MOL NEUROSCI, V50, P33, DOI 10.1007/s12031-012-9850-1
   Lucca G, 2009, NEUROCHEM INT, V54, P358, DOI 10.1016/j.neuint.2009.01.001
   Maes M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-66
   Maes M, 2011, NEUROENDOCRINOL LETT, V32, P133
   Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004
   Mao QQ, 2014, BEHAV BRAIN RES, V261, P140, DOI 10.1016/j.bbr.2013.12.020
   Marcus SM, 2005, J AFFECT DISORDERS, V87, P141, DOI 10.1016/j.jad.2004.09.008
   Massafra C, 2002, CLIN ENDOCRINOL, V57, P663, DOI 10.1046/j.1365-2265.2002.01657.x
   McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006
   Merali Z, 2003, PSYCHOPHARMACOLOGY, V165, P413, DOI 10.1007/s00213-002-1273-1
   Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029
   NIH, 2011, GUIDE CARE USE LAB A, DOI [10.17226/12910, DOI 10.17226/12910]
   Pattison DI, 2012, FREE RADICAL RES, V46, P975, DOI 10.3109/10715762.2012.667566
   PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6
   Pitychoutis PM, 2009, NEUROSCIENCE, V159, P1216, DOI 10.1016/j.neuroscience.2009.01.072
   PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0
   Pulli B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067976
   RAMAMOORTHY S, 1995, BIOCHEM BIOPH RES CO, V216, P560, DOI 10.1006/bbrc.1995.2659
   Ramos-Loyo J, 2013, PROG NEURO-PSYCHOPH, V44, P154, DOI 10.1016/j.pnpbp.2013.02.007
   Reichenberg A, 2001, ARCH GEN PSYCHIAT, V58, P445, DOI 10.1001/archpsyc.58.5.445
   Remus JL, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw028
   RODGERS RJ, 1993, PHYSIOL BEHAV, V54, P729, DOI 10.1016/0031-9384(93)90084-S
   Rosenblat JD, 2014, PROG NEURO-PSYCHOPH, V53, P23, DOI 10.1016/j.pnpbp.2014.01.013
   Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI 10.1038/nrn3381
   Salazar A, 2012, HORM BEHAV, V62, P202, DOI 10.1016/j.yhbeh.2012.03.010
   Savignac HM, 2016, BRAIN BEHAV IMMUN, V52, P120, DOI 10.1016/j.bbi.2015.10.007
   Sayd A, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu111
   Scholz H, 2017, J NEUROIMMUNOL, V310, P107, DOI 10.1016/j.jneuroim.2017.07.004
   Schuch JJJ, 2014, J AFFECT DISORDERS, V156, P156, DOI 10.1016/j.jad.2013.12.011
   SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4
   Sens J, 2017, PHARMACOL BIOCHEM BE, V153, P168, DOI 10.1016/j.pbb.2016.12.016
   Singh Tanvir, 2006, Psychiatry (Edgmont), V3, P33
   Suarez EC, 2004, PSYCHONEUROENDOCRINO, V29, P1119, DOI 10.1016/j.psyneuen.2004.01.002
   SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2
   Talarowska M, 2015, ADV MED SCI-POLAND, V60, P1, DOI 10.1016/j.advms.2014.06.001
   Tao WW, 2016, BEHAV BRAIN RES, V308, P177, DOI 10.1016/j.bbr.2016.04.039
   Todorovic N, 2017, NEUROSCIENCE, V355, P49, DOI 10.1016/j.neuroscience.2017.04.044
   UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1
   Vaccarino V, 2008, BIOL PSYCHIAT, V64, P476, DOI 10.1016/j.biopsych.2008.04.023
   Vieira JO, 2018, PROG NEURO-PSYCHOPH, V81, P426, DOI 10.1016/j.pnpbp.2017.08.014
   Vogelzangs N, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.92
   Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1
   World Health Organization, 2015, DEPRESSION
   Zhang D, 2009, J ETHNOPHARMACOL, V123, P55, DOI 10.1016/j.jep.2009.02.029
NR 77
TC 7
Z9 8
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD JUL 15
PY 2018
VL 320
BP 133
EP 142
DI 10.1016/j.jneuroim.2018.04.009
PG 10
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA GI8CH
UT WOS:000434748900019
PM 29681406
DA 2020-12-17
ER

PT J
AU Custodio, CS
   Mello, BSF
   Chaves, AJM
   Lima, CND
   Cordeiro, RC
   Miyajima, F
   Reus, GZ
   Vasconcelos, SMM
   Barichello, T
   Quevedo, J
   de Oliveira, AC
   de Lucena, DF
   Macedo, DS
AF Custodio, Charllyany Sabino
   Ferreira Mello, Bruna Stefania
   Maia Chaves Filho, Adriano Jose
   de Carvalho Lima, Camila Nayane
   Cordeiro, Rafaela Carneiro
   Miyajima, Fabio
   Reus, Gislaine Z.
   Mendes Vasconcelos, Silvania Maria
   Barichello, Tatiana
   Quevedo, Joao
   de Oliveira, Antonio Carlos
   de Lucena, David Freitas
   Macedo, Danielle S.
TI Neonatal Immune Challenge with Lipopolysaccharide Triggers Long-lasting
   Sex- and Age-related Behavioral and Immune/Neurotrophic Alterations in
   Mice: Relevance to Autism Spectrum Disorders
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Immune activation; Lipopolysaccharide; Autism spectrum disorder; Sex
   differences; Age; Immune-inflammatory alterations
ID PRENATAL LPS-EXPOSURE; PREPULSE INHIBITION; BRAIN-DEVELOPMENT;
   MICROGLIAL ACTIVATION; NEUROTROPHIC FACTOR; SPATIAL WORKING; MODEL;
   SCHIZOPHRENIA; ANXIETY; RATS
AB Early-life challenges, particularly infections and stress, are related to neuropsychiatric disorders such as autism and schizophrenia. Here, we conducted a wide range of behavioral tests in periadolescent (postnatal day (PN) 35) and adult (PN70) Swiss mice neonatally challenged with LPS on PN5 and -7, to unveil behavioral alterations triggered by LPS exposure. Immune and neurotrophic (brain-derived neurotrophic factor-BDNF) alterations were determined in the prefrontal cortex (PFC), hippocampus (HC), and hypothalamus (HT). Since the incidence and clinical manifestations of neurodevelopmental disorders present significant sex-related differences, we sought to distinctly evaluate male and female mice. While on PN35, LPS-challenged male mice presented depressive, anxiety-like, repetitive behavior, and working memory deficits; on PN70, only depressive- and anxiety-like behaviors were observed. Conversely, females presented prepulse inhibition (PPI) deficits in both ages studied. Behavioral changes in periadolescence and adulthood were accompanied, in both sexes, by increased levels of interleukin (IL-4) (PFC, HC, and HT) and decreased levels of IL-6 (PFC, HC, and HT). BDNF levels increased in both sexes on PN70. LPS-challenged male mice presented, in both ages evaluated, increased HC myeloperoxidase activity (MPO); while when adult increased levels of interferon gamma (IFN gamma), nitrite and decreased parvalbumin were observed. Alterations in innate immunity and parvalbumin were the main LPS-induced remarks between males and females in our study. We concluded that neonatal LPS challenge triggers sex-specific behavioral and neurochemical alterations that resemble autism spectrum disorder, constituting in a relevant model for the mechanistic investigation of sex bias associated with the development of this disorder.
C1 [Custodio, Charllyany Sabino; Ferreira Mello, Bruna Stefania; Maia Chaves Filho, Adriano Jose; de Carvalho Lima, Camila Nayane; Cordeiro, Rafaela Carneiro; Miyajima, Fabio; Mendes Vasconcelos, Silvania Maria; de Lucena, David Freitas; Macedo, Danielle S.] Univ Fed Ceara, Drug Res & Dev Ctr, Neuropsychopharmacol Lab, Fac Med, Rua Cel Nunes de Melo 1000, BR-60430270 Fortaleza, Ceara, Brazil.
   [Custodio, Charllyany Sabino; Ferreira Mello, Bruna Stefania; Cordeiro, Rafaela Carneiro; Macedo, Danielle S.] Univ Fed Ceara, Med Microbiol Postgrad Program, Fac Med, Fortaleza, Ceara, Brazil.
   [Miyajima, Fabio] Univ Liverpool, Wolfson Ctr, Inst Translat Med, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
   [Reus, Gislaine Z.] Univ Southern Santa Catarina UNESC, Grad Program Hlth Sci, Hlth Sci Unit, Lab Neurosci, Criciuma, SC, Brazil.
   [Barichello, Tatiana; Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Psychiat & Behav Sci, Translat Psychiat Program, Houston, TX USA.
   [Barichello, Tatiana; Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Psychiat & Behav Sci, Ctr Excellence Mood Disorders, Houston, TX USA.
   [Barichello, Tatiana; Quevedo, Joao] Univ Texas Grad Sch Biomed Sci Houston, Neurosci Grad Program, Houston, TX USA.
   [de Oliveira, Antonio Carlos] Univ Fed Minas Gerais, Inst Biol Sci, Dept Pharmacol, Belo Horizonte, MG, Brazil.
   [Macedo, Danielle S.] Natl Sci & Technol Inst Translat Med INCT TM, Houston, TX USA.
RP Macedo, DS (corresponding author), Univ Fed Ceara, Drug Res & Dev Ctr, Neuropsychopharmacol Lab, Fac Med, Rua Cel Nunes de Melo 1000, BR-60430270 Fortaleza, Ceara, Brazil.; Macedo, DS (corresponding author), Univ Fed Ceara, Med Microbiol Postgrad Program, Fac Med, Fortaleza, Ceara, Brazil.; Macedo, DS (corresponding author), Natl Sci & Technol Inst Translat Med INCT TM, Houston, TX USA.
EM daniellesilmacedo@gmail.com
RI Barichello, Tatiana/E-2725-2013; Chaves-Filho, Adriano/AAZ-1390-2020; de
   Quevedo, Joao Luciano/E-5491-2013; Macedo, Danielle/E-3424-2014; de
   Oliveira, Antonio CP/F-1661-2013
OI de Quevedo, Joao Luciano/0000-0003-3114-6611; Macedo,
   Danielle/0000-0001-8980-9970; de Oliveira, Antonio
   CP/0000-0003-3217-4294; Lucena, David/0000-0002-1547-3711; Chaves-Filho,
   Adriano Jose Maia/0000-0003-1018-0431; Barichello,
   Tatiana/0000-0001-7776-8454
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FUNCAP
FX The authors acknowledge the Brazilian Governmental Institutions CAPES,
   CNPq, and FUNCAP for the financial support of this study (scholarships
   and research grant).
CR Al-Asmari AK, 2014, HUM EXP TOXICOL, V33, P115, DOI 10.1177/0960327113493305
   Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1177/09680519010070030101
   Alleva E, 1998, EUR J NEUROSCI, V10, P3664, DOI 10.1046/j.1460-9568.1998.00377.x
   Andersen SL, 2003, NEUROSCI BIOBEHAV R, V27, P3, DOI 10.1016/S0149-7634(03)00005-8
   Andersen SL, 2004, INT J DEV NEUROSCI, V22, P423, DOI 10.1016/j.ijdevneu.2004.06.002
   ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X
   Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P40, DOI 10.1016/j.bbi.2010.08.003
   Baier PC, 2009, BEHAV BRAIN RES, V200, P192, DOI 10.1016/j.bbr.2009.01.013
   Barendse EM, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-14
   Beggiato A, 2017, AUTISM RES, V10, P680, DOI 10.1002/aur.1715
   Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810
   Chalfant AM, 2007, J AUTISM DEV DISORD, V37, P1842, DOI 10.1007/s10803-006-0318-4
   CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008
   Clancy B, 2007, NEUROTOXICOLOGY, V28, P931, DOI 10.1016/j.neuro.2007.01.014
   Custodio CS, 2013, EUR J PHARMACOL, V713, P31, DOI 10.1016/j.ejphar.2013.04.040
   DellaGioia N, 2013, BRAIN BEHAV IMMUN, V31, P197, DOI 10.1016/j.bbi.2012.10.008
   Dinel AL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0155-x
   Dworzynski K, 2012, J AM ACAD CHILD PSY, V51, P788, DOI 10.1016/j.jaac.2012.05.018
   Feleder C, 2010, BIOL PSYCHIAT, V67, P386, DOI 10.1016/j.biopsych.2009.09.028
   Gadani SP, 2012, J IMMUNOL, V189, P4213, DOI 10.4049/jimmunol.1202246
   Goines PE, 2013, NEUROTOXICOL TERATOL, V36, P67, DOI 10.1016/j.ntt.2012.07.006
   Halladay AK, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0019-y
   Hashemi E, 2017, CEREB CORTEX, V27, P1931, DOI 10.1093/cercor/bhw021
   Kasarpalkar NJ, 2014, ANN NEUROSCI, V21, P129, DOI 10.5214/ans.0972.7531.210403
   Kessler RC, 1997, PSYCHOL MED, V27, P1101, DOI 10.1017/S0033291797005588
   Kirsten TB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082244
   Kirsten TB, 2011, PHYSIOL BEHAV, V104, P417, DOI 10.1016/j.physbeh.2011.04.049
   Kohl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092372
   Kumar H, 2016, BRAIN RES BULL, V124, P27, DOI 10.1016/j.brainresbull.2016.03.013
   Lai MC, 2015, J AM ACAD CHILD PSY, V54, P11, DOI 10.1016/j.jaac.2014.10.003
   Lazic SE, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-37
   Levin R, 2011, PROG NEURO-PSYCHOPH, V35, P1748, DOI 10.1016/j.pnpbp.2011.06.003
   Li BJ, 2010, EUR J PHARMACOL, V628, P104, DOI 10.1016/j.ejphar.2009.11.036
   Ribeiro BMM, 2013, SCHIZOPHR RES, V151, P12, DOI 10.1016/j.schres.2013.10.040
   Mao QQ, 2014, BEHAV BRAIN RES, V261, P140, DOI 10.1016/j.bbr.2013.12.020
   Murray AJ, 2011, NAT NEUROSCI, V14, P297, DOI 10.1038/nn.2751
   National Institute of Health, 1996, GUIDE CARE USE LAB A
   NODA Y, 1995, BRIT J PHARMACOL, V116, P2531, DOI 10.1111/j.1476-5381.1995.tb15106.x
   Novacek DM, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00666
   Pang Y, 2003, DEV BRAIN RES, V140, P205, DOI 10.1016/S0165-3806(02)00606-5
   Pang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164403
   PAPP M, 1991, PSYCHOPHARMACOLOGY, V104, P255, DOI 10.1007/BF02244188
   Perry W, 2007, BIOL PSYCHIAT, V61, P482, DOI 10.1016/j.biopsych.2005.09.025
   Pilakka-Kanthikeel S, 2014, JAIDS-J ACQ IMM DEF, V66, P16, DOI 10.1097/QAI.0000000000000096
   Piontkewitz Y, 2011, SCHIZOPHRENIA BULL, V37, P1257, DOI 10.1093/schbul/sbq040
   PORSOLT RD, 1978, EUR J PHARMACOL, V51, P291, DOI 10.1016/0014-2999(78)90414-4
   Powell Susan B, 2012, Curr Top Behav Neurosci, V12, P251, DOI 10.1007/7854_2011_195
   Pulli B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067976
   Radyushkin K, 2009, GENES BRAIN BEHAV, V8, P416, DOI 10.1111/j.1601-183X.2009.00487.x
   Rose S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.61
   Roth TL, 2009, BIOL PSYCHIAT, V65, P760, DOI 10.1016/j.biopsych.2008.11.028
   Samuelsson AM, 2006, AM J PHYSIOL-REG I, V290, pR1345, DOI 10.1152/ajpregu.00268.2005
   SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843
   Scholes KE, 2009, BEHAV BRAIN RES, V205, P456, DOI 10.1016/j.bbr.2009.07.031
   Schwarz E, 2011, MOL PSYCHIATR, V16, P1213, DOI 10.1038/mp.2010.102
   Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001
   Shattuck PT, 2007, J AUTISM DEV DISORD, V37, P1735, DOI 10.1007/s10803-006-0307-7
   Spratt EG, 2012, J AUTISM DEV DISORD, V42, P75, DOI 10.1007/s10803-011-1214-0
   Staples LG, 2010, NEUROBIOL LEARN MEM, V94, P435, DOI 10.1016/j.nlm.2010.09.009
   Steullet P, 2010, J NEUROSCI, V30, P2547, DOI 10.1523/JNEUROSCI.3857-09.2010
   Stolp HB, 2013, MOL CELL NEUROSCI, V53, P63, DOI 10.1016/j.mcn.2012.08.009
   Stone William S, 2011, N Am J Med Sci (Boston), V4, P124
   SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2
   Sweeten TL, 2004, BIOL PSYCHIAT, V55, P434, DOI 10.1016/j.biopsych.2003.09.001
   Temmingh H, 2015, CNS DRUGS, V29, P819, DOI 10.1007/s40263-015-0282-7
   Tomaz VS, 2014, NEUROSCIENCE, V268, P236, DOI 10.1016/j.neuroscience.2014.03.025
   Vassallo M, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-174
   Walker AK, 2009, PSYCHONEUROENDOCRINO, V34, P1515, DOI 10.1016/j.psyneuen.2009.05.010
   Walker FR, 2004, BEHAV BRAIN RES, V154, P63, DOI 10.1016/j.bbr.2004.01.019
   Wei HG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-52
   Wischhof L, 2015, PROG NEURO-PSYCHOPH, V57, P17, DOI 10.1016/j.pnpbp.2014.10.004
   ZANGROSSI H, 1992, BRAIN RES BULL, V29, P381, DOI 10.1016/0361-9230(92)90072-6
   Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641
   Zheng K, 2011, P NATL ACAD SCI USA, V108, P17201, DOI 10.1073/pnas.1114241108
   Zhu FR, 2014, BRAIN BEHAV IMMUN, V38, P166, DOI 10.1016/j.bbi.2014.01.017
NR 75
TC 25
Z9 26
U1 1
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD MAY
PY 2018
VL 55
IS 5
BP 3775
EP 3788
DI 10.1007/s12035-017-0616-1
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA GB7EY
UT WOS:000429238900013
PM 28536974
OA Green Published
DA 2020-12-17
ER

PT J
AU Knetsch, CW
   Kumar, N
   Forster, SC
   Connor, TR
   Browne, HP
   Harmanus, C
   Sanders, IM
   Harris, SR
   Turner, L
   Morris, T
   Perry, M
   Miyajima, F
   Roberts, P
   Pirmohamed, M
   Songer, JG
   Weese, JS
   Indra, A
   Corver, J
   Rupnik, M
   Wren, BW
   Riley, TV
   Kuijper, EJ
   Lawley, TD
AF Knetsch, C. W.
   Kumar, N.
   Forster, S. C.
   Connor, T. R.
   Browne, H. P.
   Harmanus, C.
   Sanders, I. M.
   Harris, S. R.
   Turner, L.
   Morris, T.
   Perry, M.
   Miyajima, F.
   Roberts, P.
   Pirmohamed, M.
   Songer, J. G.
   Weese, J. S.
   Indra, A.
   Corver, J.
   Rupnik, M.
   Wren, B. W.
   Riley, T. V.
   Kuijper, E. J.
   Lawley, T. D.
TI Zoonotic Transfer of Clostridium difficile Harboring Antimicrobial
   Resistance between Farm Animals and Humans
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE Clostridium difficile; RT078; intercontinental transmission; interhost
   transmission; accessory genome; One Health concept; antibiotic
   resistance
ID EVOLUTION; INFECTION; ALGORITHMS; EMERGENCE; STRAIN; TREES
AB The emergence of Clostridium difficile as a significant human diarrheal pathogen is associated with the production of highly transmissible spores and the acquisition of antimicrobial resistance genes (ARGs) and virulence factors. Unlike the hospital-associated C. difficile RT027 lineage, the community-associated C. difficile RT078 lineage is isolated from both humans and farm animals; however, the geographical population structure and transmission networks remain unknown. Here, we applied whole-genome phylogenetic analysis of 248 C. difficile RT078 strains from 22 countries. Our results demonstrate limited geographical clustering for C. difficile RT078 and extensive coclustering of human and animal strains, thereby revealing a highly linked intercontinental transmission network between humans and animals. Comparative whole-genome analysis reveals indistinguishable accessory genomes between human and animal strains and a variety of antimicrobial resistance genes in the pangenome of C. difficile RT078. Thus, bidirectional spread of C. difficile RT078 between farm animals and humans may represent an unappreciated route disseminating antimicrobial resistance genes between humans and animals. These results highlight the importance of the "One Health" concept to monitor infectious disease emergence and the dissemination of antimicrobial resistance genes.
C1 [Knetsch, C. W.; Harmanus, C.; Sanders, I. M.; Corver, J.; Kuijper, E. J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Sect Expt Bacteriol, Leiden, Netherlands.
   [Kumar, N.; Forster, S. C.; Browne, H. P.; Lawley, T. D.] Wellcome Trust Sanger Inst, Host Microbiota Interact Lab, Hinxton, England.
   [Forster, S. C.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia.
   [Forster, S. C.] Monash Univ, Dept Mol & Translat Sci, Clayton, Vic, Australia.
   [Connor, T. R.] Cardiff Sch Biosci, Sir Martin Evans Bldg, Cardiff, S Glam, Wales.
   [Harris, S. R.] Wellcome Trust Sanger Inst, Pathogen Genom, Hinxton, England.
   [Turner, L.; Morris, T.; Perry, M.] Publ Hlth Wales, Microbiol, Cardiff, S Glam, Wales.
   [Miyajima, F.; Roberts, P.; Pirmohamed, M.] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.
   [Songer, J. G.] Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ USA.
   [Weese, J. S.] Univ Guelph, Canada Vet Coll, Dept Pathobiol, Guelph, ON, Canada.
   [Indra, A.] Osterreich Agentur Gesundheit & Ernahrungssicherh, Inst Med Microbiol & Hyg, Vienna, Austria.
   [Rupnik, M.] Univ Maribor, Fac Med, Maribor, Slovenia.
   [Rupnik, M.] Natl Lab Hlth Environm & Food, Maribor, Slovenia.
   [Wren, B. W.] Univ London, London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London, England.
   [Riley, T. V.] Queen Elizabeth II Med Ctr, PathWest Lab Med, Dept Microbiol, Nedlands, WA, Australia.
   [Riley, T. V.] Univ Western Australia, Sch Pathol & Lab Med, Microbiol & Immunol, Nedlands, WA, Australia.
RP Lawley, TD (corresponding author), Wellcome Trust Sanger Inst, Host Microbiota Interact Lab, Hinxton, England.
EM tl2@sanger.ac.uk
RI Connor, Thomas/ABE-5989-2020; Pirmohamed, Munir/H-6004-2011; Forster,
   Samuel/F-4206-2014
OI Connor, Thomas/0000-0003-2394-6504; Pirmohamed,
   Munir/0000-0002-7534-7266; Harmanus, Celine/0000-0002-5328-3273;
   Knetsch, Wilco/0000-0001-8569-3456; Browne, Hilary/0000-0002-1305-2470;
   Corver, Jeroen/0000-0002-9262-5475; Forster, Samuel/0000-0003-4144-2537
FU Wellcome TrustWellcome Trust [098051]; United Kingdom Medical Research
   CouncilMedical Research Council UK (MRC) [PF451, MR/L015080/1,
   MR/K000551/1]; Australian National Health and Medical Research
   CouncilNational Health and Medical Research Council of Australia
   [1091097]; Victorian Government's Operational and Infrastructure Support
   Program; ZonMw grant [125020004]; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/L015080/1, G0902453, MR/K000551/1] Funding
   Source: researchfish
FX We acknowledge the Wellcome Trust (grant 098051), the United Kingdom
   Medical Research Council (grants PF451 to T.D.L., MR/L015080/1 to
   T.R.C., and MR/K000551/1 to F.M., M.P., B.W.W. and T.D.L.), the
   Australian National Health and Medical Research Council (grant 1091097
   to S.C.F.), and the Victorian Government's Operational and
   Infrastructure Support Program (to S.C.F.) for financial support. C.W.K.
   was supported by a ZonMw grant (125020004).
CR Argimon S, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000093
   Bakker D, 2010, J CLIN MICROBIOL, V48, P3744, DOI 10.1128/JCM.01171-10
   Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4
   Boetzer M, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r56
   Boetzer M, 2011, BIOINFORMATICS, V27, P578, DOI 10.1093/bioinformatics/btq683
   Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545
   Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478
   Goorhuis A, 2008, CLIN INFECT DIS, V47, P1162, DOI 10.1086/592257
   Harris SR, 2010, SCIENCE, V327, P469, DOI 10.1126/science.1182395
   He M, 2013, NAT GENET, V45, P109, DOI 10.1038/ng.2478
   He M, 2010, P NATL ACAD SCI USA, V107, P7527, DOI 10.1073/pnas.0914322107
   Keel K, 2007, J CLIN MICROBIOL, V45, P1963, DOI 10.1128/JCM.00224-07
   Keessen EC, 2011, VET MICROBIOL, V153, P205, DOI 10.1016/j.vetmic.2011.03.020
   Knetsch CW, 2014, EUROSURVEILLANCE, V19, P30, DOI 10.2807/1560-7917.ES2014.19.45.20954
   Kuijper EJ, 2006, CLIN MICROBIOL IN S6, V12, pS2, DOI [10.1111/j.1469-0691.2006.01580.x, DOI 10.1111/J.1469-0691.2006.01580.X]
   Leffler DA, 2015, NEW ENGL J MED, V373, P287, DOI 10.1056/NEJMc1506004
   Lessa FC, 2015, NEW ENGL J MED, V372, P2368, DOI DOI 10.1056/NEJMC1505190
   Letunic I, 2011, NUCLEIC ACIDS RES, V39, pW475, DOI 10.1093/nar/gkr201
   Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639
   Mather AE, 2013, SCIENCE, V341, P1514, DOI 10.1126/science.1240578
   Page AJ, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000056
   Page AJ, 2015, BIOINFORMATICS, V31, P3691, DOI 10.1093/bioinformatics/btv421
   Price MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/molbev/msp077
   Quail MA, 2008, NAT METHODS, V5, P1005, DOI 10.1038/nmeth.1270
   Rupnik M, 2008, J CLIN MICROBIOL, V46, P2146, DOI 10.1128/JCM.00598-08
   Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153
   Squire MM, 2013, CURR TOP MICROBIOL, V365, P299, DOI 10.1007/82_2012_237
   Stubbs SLJ, 1999, J CLIN MICROBIOL, V37, P461, DOI 10.1128/JCM.37.2.461-463.1999
   Walker AS, 2013, CLIN INFECT DIS, V56, P1589, DOI 10.1093/cid/cit127
   Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107
NR 30
TC 41
Z9 41
U1 2
U2 24
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAR
PY 2018
VL 56
IS 3
AR e01384-17
DI 10.1128/JCM.01384-17
PG 8
WC Microbiology
SC Microbiology
GA FX1WJ
UT WOS:000425843200007
PM 29237792
OA Green Accepted, Green Published
DA 2020-12-17
ER

PT J
AU Manca, M
   Pessoa, V
   Lopez, AI
   Harrison, PT
   Miyajima, F
   Sharp, H
   Pickles, A
   Hill, J
   Murgatroyd, C
   Bubb, VJ
   Quinn, JP
AF Manca, Maurizio
   Pessoa, Veridiana
   Lopez, Ana Illera
   Harrison, Patrick T.
   Miyajima, Fabio
   Sharp, Helen
   Pickles, Andrew
   Hill, Jonathan
   Murgatroyd, Chris
   Bubb, Vivien J.
   Quinn, John P.
TI The Regulation of Monoamine Oxidase A Gene Expression by Distinct
   Variable Number Tandem Repeats
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE MAOA; Isoforms; VNTR; Gene expression; Transcription; Haplotype
ID MAO-A; CELL-LINE; POLYMORPHISM; GENOTYPE; DISORDER; PROMOTER; UVNTR;
   SCHIZOPHRENIA; ASSOCIATIONS; INTERPLAY
AB The monoamine oxidase A (MAOA) uVNTR (upstream variable number tandem repeat) is one of the most often cited examples of a gene by environment interaction (GxE) in relation to behavioral traits. However, MAOA possesses a second VNTR, 500 bp upstream of the uVNTR, which is termed d- or distal VNTR. Furthermore, genomic analysis indicates that there are a minimum of two transcriptional start sites (TSSs) for MAOA, one of which encompasses the uVNTR within the 5' untranslated region of one of the isoforms. Through expression analysis in semi-haploid HAP1 cell lines genetically engineered in order to knockout (KO) either the uVNTR, dVNTR, or both VNTRs, we assessed the effect of the two MAOA VNTRs, either alone or in combination, on gene expression directed from the different TSSs. Complementing our functional analysis, we determined the haplotype variation of these VNTRs in the general population. The expression of the two MAOA isoforms was differentially modulated by the two VNTRs located in the promoter region. The most extensively studied uVNTR, previously considered a positive regulator of the MAOA gene, did not modulate the expression of what it is considered the canonical isoform, while we found that the dVNTR positively regulated this isoform in our model. In contrast, both the uVNTR and the dVNTR were found to act as negative regulators of the second less abundant MAOA isoform. The haplotype analysis for these two VNTRs demonstrated a bias against the presence of one of the potential variants. The uVNTR and dVNTR differentially affect expression of distinct MAOA isoforms, and thus, their combined profiling offers new insights into gene-regulation, GxE interaction, and ultimately MAOA-driven behavior.
C1 [Manca, Maurizio; Pessoa, Veridiana; Lopez, Ana Illera; Miyajima, Fabio; Bubb, Vivien J.; Quinn, John P.] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England.
   [Manca, Maurizio; Pessoa, Veridiana; Sharp, Helen] Univ Liverpool, Inst Psychol Hlth & Soc, Liverpool, Merseyside, England.
   [Manca, Maurizio] Univ Huddersfield, Biomarker Res Lab, Huddersfield HD1 3DH, W Yorkshire, England.
   [Miyajima, Fabio] Univ Fed Ceara, Dept Physiol & Pharmacol, Drug Dev & Res Ctr, Fac Med, Fortaleza, Ceara, Brazil.
   [Harrison, Patrick T.] Univ Coll Cork, BioSci Inst, Dept Physiol, Cork, Ireland.
   [Pickles, Andrew] Kings Coll London, Inst Psychiat, MRC Social Genet & Dev Psychiat Res Ctr, London, England.
   [Hill, Jonathan] Univ Reading, Sch Psychol & Clin Language Sci, Reading, Berks, England.
   [Murgatroyd, Chris] Manchester Metropolitan Univ, Sch Healthcare Sci, Manchester, Lancs, England.
RP Quinn, JP (corresponding author), Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England.
EM jquinn@liverpool.ac.uk
RI Quinn, John/A-2972-2010; Pickles, Andrew/A-9625-2011
OI Quinn, John/0000-0003-3551-7803; Harrison, Patrick/0000-0002-2319-0949;
   Murgatroyd, Chris/0000-0002-6885-7794; Pickles,
   Andrew/0000-0003-1283-0346; Pessoa Miyajima,
   Veridiana/0000-0002-2821-652X
FU UK Medical Research CouncilMedical Research Council UK (MRC) [G0400577];
   Wellcome TrustWellcome Trust [109095/Z/15/Z]
FX This study was funded by a grant from the UK Medical Research Council,
   G0400577 (JQ, HS, JH, AP, CM) and Wellcome Trust Grant ref.
   109095/Z/15/Z (AL).
CR Aslund C, 2011, BEHAV GENET, V41, P262, DOI 10.1007/s10519-010-9356-y
   Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348
   Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290
   Chester DS, 2015, BEHAV BRAIN RES, V283, P97, DOI 10.1016/j.bbr.2015.01.034
   De Colibus L, 2005, P NATL ACAD SCI USA, V102, P12684, DOI 10.1073/pnas.0505975102
   Du LS, 2002, NEUROREPORT, V13, P1195, DOI 10.1097/00001756-200207020-00025
   Edwards AC, 2010, J CHILD PSYCHOL PSYC, V51, P679, DOI 10.1111/j.1469-7610.2009.02196.x
   Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114
   Fan JB, 2005, MOL PSYCHIATR, V10, P928, DOI 10.1038/sj.mp.4001690
   Fergusson DM, 2012, BRIT J PSYCHIAT, V200, P116, DOI 10.1192/bjp.bp.111.093328
   Frazzetto G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000486
   Gaunt TR, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-227
   Hill J, 2013, GENES BRAIN BEHAV, V12, P388, DOI 10.1111/gbb.12033
   Ho LW, 2000, AM J MED GENET, V96, P36
   Lee BT, 2008, NEUROREPORT, V19, P515, DOI 10.1097/WNR.0b013e3282f94294
   Lung FW, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-74
   Melas PA, 2013, INT J NEUROPSYCHOPH, V16, P1513, DOI 10.1017/S1461145713000102
   Michelhaugh SK, 2001, J NEUROCHEM, V79, P1033, DOI 10.1046/j.1471-4159.2001.00647.x
   Nikulina V, 2012, BIOL PSYCHIAT, V71, P350, DOI 10.1016/j.biopsych.2011.09.008
   Philibert RA, 2008, AM J MED GENET B, V147B, P565, DOI 10.1002/ajmg.b.30778
   Philibert RA, 2011, BIOL PSYCHOL, V87, P366, DOI 10.1016/j.biopsycho.2011.04.007
   Pickles A, 2013, J CHILD PSYCHOL PSYC, V54, P1308, DOI 10.1111/jcpp.12081
   Reif A, 2008, EUR J NEUROL, V15, P637, DOI 10.1111/j.1468-1331.2008.02142.x
   Reif A, 2014, MOL PSYCHIATR, V19, P122, DOI 10.1038/mp.2012.172
   Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816
   Samochowiec J, 2004, PSYCHIAT RES, V128, P21, DOI 10.1016/j.psychres.2004.05.012
   Spengler BA, 2002, CANCER GENET CYTOGEN, V138, P177, DOI 10.1016/S0165-4608(02)00523-X
   Vasiliou SA, 2012, ADDICT BIOL, V17, P156, DOI 10.1111/j.1369-1600.2010.00288.x
   Warburton A, 2016, SCHIZOPHRENIA BULL, V42, P1003, DOI 10.1093/schbul/sbv144
NR 29
TC 6
Z9 6
U1 0
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD MAR
PY 2018
VL 64
IS 3
BP 459
EP 470
DI 10.1007/s12031-018-1044-z
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA GA8HD
UT WOS:000428579400014
PM 29542091
OA Green Accepted, Green Published, Other Gold
DA 2020-12-17
ER

PT J
AU Cavalcanti, LPD
   D'angelo, SM
   Lemos, DRQ
   Barreto, FKD
   Siqueira, AM
   Miyajima, F
AF de Goes Cavalcanti, Luciano Pamplona
   D'angelo, Sara Mendes
   Queiroz Lemos, Daniele Rocha
   de Almeida Barreto, Francisca Kalline
   Siqueira, Andre Machado
   Miyajima, Fabio
TI Is the recent increment in attributable deaths to type-2 diabetes (T2D)
   associated with the latest chikungunya outbreak in a major epidemic area
   in Brazil?
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Chikungunya; Diabetes; Arbovirus; Deaths
ID INFECTIOUS REPORTER VIRUS; YELLOW-FEVER-VIRUS; PARTICLES; EFFICIENT;
   17DD
AB Introduction: Chikungunya virus (CHIKV) can negatively influence outcomes in patients with pre-existing conditions. We investigated the association between the recent CHIKV outbreak and increased type 2 diabetes (T2D)-attributable deaths. Methods: Monthly averages of T2D-attributable deaths between 2001 and 2016 were determined and compared to the equivalent data for 2017 and the recent CHIKV outbreak. Results: CHKV outbreak peaked in April 2017 with 4,394.4 cases/100,000 inhabitants, while T2D-attributable deaths in the same period increased by 35.2%. Conclusions: T2D-attributable deaths significantly increased compared to the previous data, which overlapped with CHIKV incidence. The pathophysiology of this association warrants further investigations.
C1 [de Goes Cavalcanti, Luciano Pamplona; D'angelo, Sara Mendes; de Almeida Barreto, Francisca Kalline] Univ Fed Ceara, Programa Posgrad Saude Publ, Fortaleza, Ce, Brazil.
   [Queiroz Lemos, Daniele Rocha] Ctr Univ Christus, Fortaleza, CE, Brazil.
   [Siqueira, Andre Machado] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Miyajima, Fabio] Univ Fed Ceara, Ctr Pesquisas Desenvolvimento Medicamentos, Fortaleza, CE, Brazil.
   [Miyajima, Fabio] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.
RP Cavalcanti, LPD (corresponding author), Univ Fed Ceara, Programa Posgrad Saude Publ, Fortaleza, Ce, Brazil.
EM pamplona.luciano@gmail.com
RI Siqueira, Andre M/G-1340-2010; Cavalcanti, Luciano/N-4391-2015
OI Siqueira, Andre M/0000-0003-2208-0294; Cavalcanti,
   Luciano/0000-0002-3440-1182
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Instituto Aggeu Magalhaes/Fundacao Oswaldo Cruz (Fiocruz, PE)
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and
   Instituto Aggeu Magalhaes/Fundacao Oswaldo Cruz (Fiocruz, PE).
CR Delekta PC, 2015, J BIOMOL SCREEN, V20, P673, DOI 10.1177/1087057114564868
   Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
   Lindenbach B., 2013, FIELDS VIROLOGY, V1, P712
   Mason PW, 2006, VIROLOGY, V351, P432, DOI 10.1016/j.virol.2006.04.003
   Ministerio da Saude (MS). Secretaria de Vigilancia em Saude. COES-Febre Amarela. Portal da Saude, 2017, 392017 MS SECR VIG S
   Mukherjee S, 2014, METHODS MOL BIOL, V1138, P75, DOI 10.1007/978-1-4939-0348-1_6
   Patkar CG, 2007, J VIROL, V81, P6471, DOI 10.1128/JVI.02120-06
   Pereira RC, 2015, VACCINE, V33, P4261, DOI 10.1016/j.vaccine.2015.03.077
   Shustov AV, 2007, J VIROL, V81, P11737, DOI 10.1128/JVI.01112-07
   Shustov AV, 2010, VIROLOGY, V400, P8, DOI 10.1016/j.virol.2009.12.015
   Silva JVJ, 2014, BRAZ J MICROBIOL, V45, P1555, DOI 10.1590/S1517-83822014000400054
   Suzuki R, 2009, J VIROL, V83, P1870, DOI 10.1128/JVI.01891-08
   Thomas RE, 2012, AM J TROP MED HYG, V86, P359, DOI 10.4269/ajtmh.2012.11-0525
   Yoshii K, 2005, VACCINE, V23, P3946, DOI 10.1016/j.vaccine.2005.03.004
   Zhang HL, 2017, ANTIVIR RES, V141, P38, DOI 10.1016/j.antiviral.2017.02.006
NR 15
TC 8
Z9 8
U1 0
U2 2
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JAN-FEB
PY 2018
VL 51
IS 1
BP 63
EP 70
DI 10.1590/0037-8682-0440-2017
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA FY6FP
UT WOS:000426938800011
PM 29513844
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Felgner, J
   Jain, A
   Nakajima, R
   Liang, L
   Jasinskas, A
   Gotuzzo, E
   Vinetz, JM
   Miyajima, F
   Pirmohamed, M
   Hassan-Hanga, F
   Umoru, D
   Jibir, BW
   Gambo, S
   Olateju, K
   Felgner, PL
   Obaro, S
   Davies, DH
AF Felgner, Jiin
   Jain, Aarti
   Nakajima, Rie
   Liang, Li
   Jasinskas, Algis
   Gotuzzo, Eduardo
   Vinetz, Joseph M.
   Miyajima, Fabio
   Pirmohamed, Munir
   Hassan-Hanga, Fatimah
   Umoru, Dominic
   Jibir, Binta Wudil
   Gambo, Safiya
   Olateju, Kudirat
   Felgner, Philip L.
   Obaro, Stephen
   Davies, D. Huw
TI Development of ELISAs for diagnosis of acute typhoid fever in Nigerian
   children
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID POLYSACCHARIDE-PROTEIN CONJUGATE; LINKED-IMMUNOSORBENT-ASSAY; O-SPECIFIC
   POLYSACCHARIDE; BLOOD-STREAM INFECTIONS; PLASMODIUM-FALCIPARUM;
   SALMONELLA BACTEREMIA; ANTIBODY-RESPONSES; FUTURE-DIRECTIONS; IGA;
   LIPOPOLYSACCHARIDE
AB Improved serodiagnostic tests for typhoid fever (TF) are needed for surveillance, to facilitate patient management, curb antibiotic resistance, and inform public health programs. To address this need, IgA, IgM and IgG ELISAs using Salmonella enterica serovar Typhi (S. Typhi) lipopolysaccharide (LPS) and hemolysin E (t1477) protein were conducted on 86 Nigerian pediatric TF and 29 non-typhoidal Salmonella (NTS) cases, 178 culture-negative febrile cases, 28 "other" (i.e., non-Salmonella) pediatric infections, and 48 healthy Nigerian children. The best discrimination was achieved between TF and healthy children. LPS-specific IgA and IgM provided receiver operator characteristic areas under the curve (ROC AUC) values of 0.963 and 0.968, respectively, and 0.978 for IgA+M combined. Similar performance was achieved with t1477-specific IgA and IgM (0.968 and 0.968, respectively; 0.976 combined). IgG against LPS and t1477 was less accurate for discriminating these groups, possibly as a consequence of previous exposure, although ROC AUC values were still high (0.928 and 0.932, respectively). Importantly, discrimination between TF and children with other infections was maintained by LPS-specific IgA and IgM (AUC = 0.903 and 0.934, respectively; 0.938 combined), and slightly reduced for IgG (0.909), while t1477-specific IgG performed best (0.914). A similar pattern was seen when comparing TF with other infections from outside Nigeria. The t1477 may be recognized by cross-reactive antibodies from other acute infections, although a robust IgG response may provide some diagnostic utility in populations where incidence of other infections is low, such as in children. The data are consistent with IgA and IgM against S. Typhi LPS being specific markers of acute TF.
C1 [Felgner, Jiin; Jain, Aarti; Nakajima, Rie; Liang, Li; Jasinskas, Algis; Felgner, Philip L.; Davies, D. Huw] Univ Calif Irvine, Sch Med, Div Infect Dis, Irvine, CA 92717 USA.
   [Gotuzzo, Eduardo; Vinetz, Joseph M.] Univ Peruana Cayetano Heredia, Alexander von Humboldt Inst Trop Med, Lima, Peru.
   [Gotuzzo, Eduardo] Hosp Nacl Cayetano Heredia, Lima, Peru.
   [Vinetz, Joseph M.] Univ Calif San Diego, Dept Med, Div Infect Dis, La Jolla, CA 92093 USA.
   [Miyajima, Fabio; Pirmohamed, Munir] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Hassan-Hanga, Fatimah; Obaro, Stephen] Aminu Kano Teaching Hosp, Dept Pediat, Kano, Nigeria.
   [Umoru, Dominic] Maitama Dist Hosp, Abuja, Nigeria.
   [Jibir, Binta Wudil] Hasiya Bayero Pediat Hosp, Kano, Nigeria.
   [Gambo, Safiya] Murtala Specialist Hosp, Dept Pediat, Kano, Nigeria.
   [Olateju, Kudirat; Obaro, Stephen] Univ Abuja, Teaching Hosp, Gwagwalada, Nigeria.
   [Obaro, Stephen] Univ Nebraska Med Ctr, Dept Pediat, Omaha, NE USA.
   [Obaro, Stephen] Int Fdn Infect Dis Nigeria IFAIN, Abuja, Nigeria.
RP Davies, DH (corresponding author), Univ Calif Irvine, Sch Med, Div Infect Dis, Irvine, CA 92717 USA.
EM ddavies@uci.edu
RI Miyajima, Fabio/K-6587-2012; Pirmohamed, Munir/H-6004-2011
OI Miyajima, Fabio/0000-0002-1347-4825; Pirmohamed,
   Munir/0000-0002-7534-7266
FU National Institutes of Health, National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI097493, U01AI075420]; Bill
   and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1034619]; Fogarty International grantUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43TW007120]; UK Medical Research
   Council, Grant [MR/K000551/1]; Medical Research CouncilMedical Research
   Council UK (MRC) [MR/K000551/1, MR/L006758/1] Funding Source:
   researchfish; National Institute for Health ResearchNational Institute
   for Health Research (NIHR) [NF-SI-0512-10064] Funding Source:
   researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI097493, R01AI097493, R01AI097493,
   R01AI097493] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health, National
   Institute of Allergy and Infectious Diseases, grant number AI097493
   awarded to SO (https://www.niaid.nih.gov/), the Bill and Melinda Gates
   Foundation, grant number OPP1034619 awarded to SO
   (http://www.gatesfoundation.org), National Institutes of Health,
   National Institute of Allergy and Infectious Diseases, grant number
   U01AI075420 awarded to JMV, Fogarty International grant D43TW007120
   awarded to JMV (https://www.fic.nih.gov/Pages/Default.aspx), and the UK
   Medical Research Council, Grant ref. MR/K000551/1 awarded to FM and MP
   (http://www.mrc.ac.uk/). The funders had no role in study design, data
   collection, data analysis, decision to publish, or preparation of the
   manuscript.
CR Andrews JR, 2015, VACCINE, V33, pC8, DOI 10.1016/j.vaccine.2015.02.030
   Becker D, 2006, NATURE, V440, P303, DOI 10.1038/nature04616
   Buckle Geoffrey C, 2012, J Glob Health, V2, P010401, DOI 10.7189/jogh.02.010401
   Cannella AP, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00001
   Cannella AP, 2012, J CLIN MICROBIOL, V50, P922, DOI 10.1128/JCM.05298-11
   Charles RC, 2014, CLIN VACCINE IMMUNOL, V21, P280, DOI 10.1128/CVI.00661-13
   Charles RC, 2010, CLIN VACCINE IMMUNOL, V17, P1188, DOI 10.1128/CVI.00104-10
   Cheng AC, 2006, T ROY SOC TROP MED H, V100, P64, DOI 10.1016/j.trstmh.2005.04.019
   Chin KL, 2016, J CLIN DIAGN RES, V10, pDM1, DOI 10.7860/JCDR/2016/17801.7909
   CHOO KE, 1994, CLIN INFECT DIS, V19, P172, DOI 10.1093/clinids/19.1.172
   Corbel M J, 1979, Contrib Microbiol Immunol, V5, P50
   Crompton PD, 2010, P NATL ACAD SCI USA, V107, P6958, DOI 10.1073/pnas.1001323107
   Crump JA, 2010, CLIN INFECT DIS, V50, P241, DOI 10.1086/649541
   Davies DH, 2016, AM J TROPICAL MED HY
   Dent AE, 2015, J INFECT DIS, V212, P1429, DOI 10.1093/infdis/jiv224
   Emmerzaal A, 2002, VET QUART, V24, P40, DOI 10.1080/01652176.2002.9695123
   Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0
   Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2
   Felgner J, 2015, PARASITOLOGY, V142, P827, DOI 10.1017/S0031182014001978
   GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z
   Gordon MA, 2002, AIDS, V16, P1633, DOI 10.1097/00002030-200208160-00009
   Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146
   Graham SM, 2000, T ROY SOC TROP MED H, V94, P310, DOI 10.1016/S0035-9203(00)90337-7
   Graham SM, 2000, PEDIATR INFECT DIS J, V19, P1189, DOI 10.1097/00006454-200012000-00016
   Hapfelmeier S, 2010, SCIENCE, V328, P1705, DOI 10.1126/science.1188454
   Herath HMTU, 2003, J CLIN PATHOL, V56, P694, DOI 10.1136/jcp.56.9.694
   House D, 2005, J CLIN MICROBIOL, V43, P4889, DOI 10.1128/JCM.43.9.4889-4890.2005
   Hunt S, 2010, ADV EXP MED BIOL, V677, P116
   Iperepolu O H, 2008, West Afr J Med, V27, P127
   Jain A, 2016, PROTEOMICS
   Jazani NH, 2005, CAN J MICROBIOL, V51, P319, DOI 10.1139/W05-008
   King CL, 2015, AM J TROP MED HYG, V93, P16, DOI 10.4269/ajtmh.15-0037
   Levine MM, 2006, VACCINE, V24, P3865, DOI 10.1016/j.vaccine.2006.03.039
   Liang L, 2013, SCI REP-UK, V3, DOI 10.1038/srep01043
   Liang L, 2011, J PROTEOME RES, V10, P4813, DOI 10.1021/pr200619r
   Liang L, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000673
   MacLennan CA, 2008, J CLIN INVEST, V118, P1553, DOI 10.1172/JCI33998
   Macpherson AJ, 2012, IMMUNOL REV, V245, P132, DOI 10.1111/j.1600-065X.2011.01072.x
   Micoli F, 2014, CARBOHYD RES, V385, P1, DOI 10.1016/j.carres.2013.12.003
   Nakajima R, 2016, J CLIN MICROBIOL, V54, P1755, DOI 10.1128/JCM.02784-15
   NARDIELLO S, 1984, J CLIN MICROBIOL, V20, P718, DOI 10.1128/JCM.20.4.718-721.1984
   Nelson M, 2004, J MED MICROBIOL, V53, P1177, DOI 10.1099/jmm.0.45766-0
   Nielsen K, 2007, J IMMUNOASS IMMUNOCH, V28, P289, DOI 10.1080/15321810701454904
   Obaro S, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-137
   Obaro SK, 2015, CLIN INFECT DIS, V61, pS325, DOI 10.1093/cid/civ745
   Olopoenia LA, 2000, POSTGRAD MED J, V76, P80, DOI 10.1136/pmj.76.892.80
   Ong EBB, 2015, MICROBIOL IMMUNOL, V59, P43, DOI 10.1111/1348-0421.12211
   Peters RPH, 2004, TROP MED INT HEALTH, V9, P928, DOI 10.1111/j.1365-3156.2004.01288.x
   Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4
   REYNOLDS DW, 1970, J AMER MED ASSOC, V214, P2192, DOI 10.1001/jama.214.12.2192
   Stanisic DI, 2015, INFECT IMMUN, V83, P646, DOI 10.1128/IAI.02398-14
   Strid MA, 2007, CLIN VACCINE IMMUNOL, V14, P741, DOI 10.1128/CVI.00192-06
   Swale A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106118
   Tennant SM, 2016, VACCINE, V34, P2907, DOI 10.1016/j.vaccine.2016.03.072
   Thomas RM, 2007, INFECT IMMUN, V75, P371, DOI 10.1128/IAI.01241-06
   WATSON DC, 1992, INFECT IMMUN, V60, P4679, DOI 10.1128/IAI.60.11.4679-4686.1992
   Xiong N, 2015, CELL MOL LIFE SCI, V72, P2645, DOI 10.1007/s00018-015-1892-4
   Xu P, 2011, BIOCONJUGATE CHEM, V22, P2179, DOI 10.1021/bc2001984
   Zaka-ur-Rab Z, 2012, ARCH DIS CHILD, V97, P236, DOI 10.1136/adc.2011.300622
   Zuniga J, 2005, J CLIN MICROBIOL, V43, P4545, DOI 10.1128/JCM.43.9.4545-4550.2005
NR 60
TC 7
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2017
VL 11
IS 6
AR e0005679
DI 10.1371/journal.pntd.0005679
PG 24
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EZ9WL
UT WOS:000405080700056
PM 28640809
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU de Oliveira, RG
   Castilho, GRD
   da Cunha, AL
   Miyajima, F
   Martins, DTD
AF de Oliveira, Ruberlei Godinho
   de Campos Castilho, Geovane Roberto
   da Cunha, Andre Luiz
   Miyajima, Fabio
   de Oliveira Martins, Domingos Tabajara
TI Dilodendron bipinnatum Radlk. inhibits pro-inflammatory mediators
   through the induction of MKP-1 and the down-regulation of
   MAPKp38/JNK/NF-kappa B pathways and COX-2 in LPS-activated RAW 264.7
   cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
ID NF-KAPPA-B; HYDROETHANOLIC EXTRACT; MAPK; MACROPHAGES; EXPRESSION
AB Ethnopharmacological relevance: The stem bark of Dilodendron bipinnatum Radlk. (Sapindaceae), a tree native to Pantanal of Mato Grosso, Brazil, popularly known as "mulher-pobre" (poor woman), has been historically used by the locals, after decoction and maceration, for the treatment of inflammatory conditions. We have recently shown that these preparations indeed possess anti-inflammatory properties, which are mediated by the inhibition of cell migration and the modulation of Th1 and Th2 cytokines. The NO pathway was not affected.
   Aim of the present study: The aim of the present study was to further investigate the mechanisms responsible for the anti-inflammatory properties of the hydroethanolic extract of the stem bark of Dilodendron bipinnatum (HEDb).
   Materials and methods: HEDb was obtained by maceration of the stem bark of D. bipinnatum as previously described. The corresponding effects on a macrophage-like cell line, RAW 264.7, were investigated. The apoptosis of RAW 264.7 upon treatment with LPS, HEDb and N-acetyl-L-cysteine (NAC) was assessed by flow cytometry, using an Annexin V-PE kit. The production of inflammatory cytokines (TNF-alpha, IL-1 beta and IL-10) and PGE(2) were evaluated by ELISA, after cell challenge with LPS. The intracellular redox state and changes in mitochondrial membrane potential were also assessed by flow cytometry, using DCFH-DA and JC-1 as probes. The protein expression levels of MAPK p-p38, p-ERK, p-JNK, MKP-1 and COX-2 were analysed by western blotting. Nuclear translocation of NF-kappa B was assessed by immunofluorescence microscopy. The quantified results are presented as a nuclear:cytoplasmic ratio.
   Results: LPS, HEDb and NAC did not appear to decrease the number of viable cells in comparison to control treatment. HEDb attenuated the production of pro-inflammatory cytokines and TNF-a) and PGE2 induced by LPS but did not affect IL-10. The production of ROS was also inhibited by HEDb (1, 5 or 20 mu g/mL), even at the lowest concentration; at 20 mu g/mL, HEDb was more effective than NAC, which was used as a positive control (74.1% and 66.2% inhibition of LPS's effect, respectively). LPS induced an increase in Delta Psi m (19.2%, p < 0.001), while HEDb inhibited the change in Delta Psi m (7.7% at 20 g/mL, p < 0.001). The results of western blotting showed that HEDb inhibited the expression of MAPK p-p38, p-JNK and COX-2, while the expression of MKP-1 was increased. p-ERK was not affected. LPS promoted the nuclear translocation of NF-kappa B p65 (67%, p < 0.01) in RAW 264.7 cells, in comparison to baseline (33%). Pre-treatment with HEDb inhibited this translocation of NF-kappa B p65 (58% at 20 mu g/mL, p < 0.001).
   Conclusion: HEDb has a potent anti-inflammatory activity and acts on multiple targets and biological pathways of potential therapeutic relevance.
C1 [de Oliveira, Ruberlei Godinho; de Campos Castilho, Geovane Roberto; de Oliveira Martins, Domingos Tabajara] Fed Univ Mato Grosso UFMT, Fac Med, Dept Basic Hlth Sci, Ave Fernando Correa da Costa 2367, BR-78060900 Cuiaba, Mato Grosso, Brazil.
   [de Oliveira, Ruberlei Godinho] Univ Cuiaba, Fac Farm, Ave Beira Rio 3100, BR-78025190 Cuiaba, MT, Brazil.
   [da Cunha, Andre Luiz] Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, BR-04044020 Sao Paulo, SP, Brazil.
   [Miyajima, Fabio] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool L69 3GL, Merseyside, England.
   [Miyajima, Fabio] Fed Univ Ceara NPDM UFC, Drug Res & Dev Ctr, Grp Neuropharmacol, Fortaleza, CE, Brazil.
   [de Oliveira Martins, Domingos Tabajara] Univ Fed Mato Grosso, Ave Fernando Correa da Costa, BR-78060900 Cuiaba, Mato Grosso, Brazil.
RP Martins, DTD (corresponding author), Fed Univ Mato Grosso UFMT, Fac Med, Dept Basic Hlth Sci, Ave Fernando Correa da Costa 2367, BR-78060900 Cuiaba, Mato Grosso, Brazil.; Martins, DTD (corresponding author), Univ Fed Mato Grosso, Ave Fernando Correa da Costa, BR-78060900 Cuiaba, Mato Grosso, Brazil.
EM taba@terra.com.br
RI de Oliveira, Ruberlei Godinho/S-8828-2019; de Oliveira, Ruberlei
   Godinho/AAO-8065-2020; Miyajima, Fabio/K-6587-2012
OI de Oliveira, Ruberlei Godinho/0000-0003-2823-7459; Miyajima,
   Fabio/0000-0002-1347-4825
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES/Pro-Amazonia) [23038.000731/2013-56]; Fundacao de Amparo a
   Pesquisa do Estado de Mato Grosso (FAPEMAT) [157552/2014]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq/BIONORTE)National Council for Scientific and Technological
   Development (CNPq) [551737/2010-7]
FX The present research was funded by Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES/Pro-Amazonia, proc. no.
   23038.000731/2013-56), Fundacao de Amparo a Pesquisa do Estado de Mato
   Grosso (FAPEMAT - proc. no. 157552/2014) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq/BIONORTE - proc. no.
   551737/2010-7).
CR Astolfi A, 2015, MOLECULES, V20, P15842, DOI 10.3390/molecules200915842
   Bognar E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065355
   Cheng BCY, 2014, J ETHNOPHARMACOL, V153, P922, DOI 10.1016/j.jep.2014.02.029
   Mahon CPCDN, 2014, J ETHNOPHARMACOL, V155, P665, DOI 10.1016/j.jep.2014.06.018
   Bieski IGC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/272749
   de Oliveira RG, 2014, J ETHNOPHARMACOL, V155, P387, DOI 10.1016/j.jep.2014.05.041
   Diaz-Gonzalez F, 2015, EUR J IMMUNOL, V45, P679, DOI 10.1002/eji.201445222
   dos Santos JC, 2010, QUIM NOVA, V33, P2080, DOI 10.1590/S0100-40422010001000014
   Dzoyem JP, 2015, J ETHNOPHARMACOL, V160, P194, DOI 10.1016/j.jep.2014.11.034
   Ermert L, 2000, AM J PATHOL, V156, P1275, DOI 10.1016/S0002-9440(10)64998-X
   GENTRY AH, 1987, ANN MO BOT GARD, V74, P533, DOI 10.2307/2399320
   Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324
   Guma Monica, 2012, Open Rheumatol J, V6, P220, DOI 10.2174/1874312901206010220
   Hernandez-Ledesma B, 2009, BIOCHEM BIOPH RES CO, V390, P803, DOI 10.1016/j.bbrc.2009.10.053
   Hou X., 2015, J CELL SIGNAL, V1, P104
   Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017
   Kasahara E, 2011, FEBS LETT, V585, P2263, DOI 10.1016/j.febslet.2011.05.049
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Manetsch M, 2012, CELL SIGNAL, V24, P907, DOI 10.1016/j.cellsig.2011.12.013
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Noursadeghi M, 2008, J IMMUNOL METHODS, V329, P194, DOI 10.1016/j.jim.2007.10.015
   Park HH, 2013, INT IMMUNOPHARMACOL, V15, P296, DOI 10.1016/j.intimp.2012.12.005
   Park J, 2015, NEUROSCI LETT, V584, P191, DOI 10.1016/j.neulet.2014.10.016
   RBG Kew, 2016, STAT WORLDS PLANTS R
   Shi XL, 2015, NEUROSCI LETT, V594, P105, DOI 10.1016/j.neulet.2015.03.045
   Somner G.V., 2016, DILODENDRON LISTA ES
   Suffness M., 1990, METHODS PLANT BIOCH, P71
   Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004
   Tucsek Z, 2011, J LEUKOCYTE BIOL, V89, P105, DOI 10.1189/jlb.0610355
   Veranth JM, 2006, ENVIRON HEALTH PERSP, V114, P341, DOI 10.1289/ehp.8360
   White ES, 2013, J PATHOL, V229, P141, DOI 10.1002/path.4126
   Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914
   Yokota T, 2016, GENE, V575, P369, DOI 10.1016/j.gene.2015.09.030
   Zimmermann M, 2011, METHODS MOL BIOL, V740, P57, DOI 10.1007/978-1-61779-108-6_8
NR 34
TC 6
Z9 6
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD APR 18
PY 2017
VL 202
BP 127
EP 137
DI 10.1016/j.jep.2017.02.026
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA ET3YN
UT WOS:000400216000016
PM 28238828
OA Bronze
DA 2020-12-17
ER

PT J
AU Lemos, LMS
   Miyajima, F
   Castilho, GRC
   Martins, DTO
   Pritchard, DM
   Burkitt, MD
AF Lemos, Larissa M. S.
   Miyajima, Fabio
   Castilho, Geovane R. C.
   Martins, Domingos Tabajara O.
   Pritchard, D. Mark
   Burkitt, Michael D.
TI Hexane Extracts of Calophyllum brasiliense Inhibit the Development of
   Gastric Preneoplasia in Helicobacter fells Infected INS-Gas Mice
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Helicobacter; preneoplasia; chromanones; chemoprevention; stomach
   neoplasms
ID PYLORI; ACIDS
AB Objectives: Indigenous Latin American populations have used extracts from Calophyllum brasiliense, a native hardwood, to treat gastrointestinal symptoms for generations. The hexane extract of Calophyllum brasiliense stem bark (HECb) protects against ethanol mediated gastric ulceration in Swiss-Webster mice. We investigated whether HECb inhibits the development of gastric epithelial pathology following Helicobacter fells infection of INS-Gas mice.
   Materials and Methods: Groups of five male, 6-week-old INS-Gas mice were colonized with H. fells by gavage. From 2 weeks after colonization their drinking water was supplemented with 2% Tween20 (vehicle), low dose HECb (33 mg/L, IHECb) or high dose HECb (133 mg/L, hHECb). Equivalent uninfected groups were studied. Animals were culled 6 weeks after H. fells colonization. Preneoplastic pathology was quantified using established histological criteria. Gastric epithelial cell turnover was quantified by immunohistochemistry for Ki67 and active-caspase 3. Cytokines were quantified using an electrochemiluminescence assay.
   Results: Vehicle treated H. fells infected mice exhibited higher gastric atrophy scores than similarly treated uninfected mice (mean atrophy score 5.6 +/- 0.87 SEM vs. 2.2 +/- 0.58. p<0.01). The same pattern was observed following IHECb. Following hHECb treatment, H. fells status did not significantly alter atrophy scores. Gastric epithelial apoptosis was not altered by H. fells or HECb administration. Amongst vehicle-treated mice, gastric epithelial cell proliferation was increased 2.8-fold in infected compared to uninfected animals (p < 0.01). Administration of either IHECb or hHECb reduced proliferation in infected mice to levels similar to uninfected mice. A T(h)17 polarized response to H. fells infection was observed in all infected groups. hHECb attenuated IFN-gamma, IL-6, and TNF production following H. fells infection [70% (p < 0.01), 67% (13 < 0.01), and 41% (p < 0.05) reduction vs. vehicle, respectively].
   Conclusion: HECb modulates gastric epithelial pathology following H. fells infection of INS-Gas mice. Further studies are indicated to confirm the mechanisms underlying these observations.
C1 [Lemos, Larissa M. S.; Pritchard, D. Mark; Burkitt, Michael D.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Gastroenterol Res Unit, Liverpool, Merseyside, England.
   [Lemos, Larissa M. S.; Castilho, Geovane R. C.; Martins, Domingos Tabajara O.] Univ Fed Mato Grosso, Dept Basic Sci Hlth, Cuiaba, MG, Brazil.
   [Miyajima, Fabio] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Miyajima, Fabio] Univ Fed Ceara, Drug Res & Dev Ctr, Grp Neuropharmacol, Fortaleza, Ceara, Brazil.
RP Burkitt, MD (corresponding author), Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Gastroenterol Res Unit, Liverpool, Merseyside, England.
EM m.d.burkitt@liverpool.ac.uk
RI Miyajima, Fabio/K-6587-2012; Lemos, Larissa/AAM-7217-2020
OI Miyajima, Fabio/0000-0002-1347-4825; Pritchard, David
   Mark/0000-0001-7971-3561
FU Wellcome Trust Institutional Strategic Support FundWellcome Trust
   [097826/Z/11/Z]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Institute Nacional de Ciencia e Tecnologia em Areas
   Umidas (INAU); Fundactio de Amparo a Pesquisa do Estado de Mato Grosso
   (EAPEMNE); University of Liverpool; Science without Borders programme
FX MDB received financial support from the University of Liverpool and
   Wellcome Trust Institutional Strategic Support Fund through grant
   agreement number 097826/Z/11/Z. LL wishes to acknowledge the Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) for the
   research project financial support and scholarship through Science
   without Borders programme; the Institute Nacional de Ciencia e
   Tecnologia em Areas Umidas (INAU) for further financial support and to
   Fundactio de Amparo a Pesquisa do Estado de Mato Grosso (EAPEMNE) for
   scholarship funding.
CR *ANG PHYL GROUP, 2016, BOT J LINN SOC, V181, P1, DOI [DOI 10.1111/BOJ.12385, 10.1111/boj.12385]
   Bauer K, 2015, J GASTRIC CANCER, V15, P10, DOI 10.5230/jgc.2015.15.1.10
   Burkitt MD, 2013, ONCOGENE, V32, P5563, DOI 10.1038/onc.2013.334
   Burkitt MD, 2017, DIS MODEL MECH, V10, P89, DOI 10.1242/dmm.027649
   Correa M., 1978, DICIONARIO PLANTAS U, V6
   Cottiglia F, 2004, J NAT PROD, V67, P537, DOI 10.1021/np030438n
   do Nascimento AM, 2007, Z NATURFORSCH C, V62, P353
   Duckworth CA, 2015, AM J PHYSIOL-GASTR L, V309, pG420, DOI 10.1152/ajpgi.00404.2014
   Duckworth Carrie A, 2015, Curr Protoc Pharmacol, V69, DOI 10.1002/0471141755.ph1434s69
   Ferlay J, 2013, GLOBOCAN 2012 V1 0 C
   Ford AC, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3174
   Kanokmedhakul S, 2002, PLANTA MED, V68, P834, DOI 10.1055/s-2002-34415
   KONIECZNY M, 1976, Archivum Immunologiae et Therapiae Experimentalis, V24, P603
   Lee H, 2005, BIOORG MED CHEM LETT, V15, P2745, DOI 10.1016/j.bmcl.2005.03.118
   Lemos LMS, 2016, NAT PROD RES, V30, P2720, DOI 10.1080/14786419.2015.1137568
   Mesia-Vela S, 2001, PHYTOMEDICINE, V8, P481, DOI 10.1078/S0944-7113(04)70070-7
   NAGAO T, 1972, CHEM PHARM BULL, V20, P82
   Neto G. G., 2012, REMEA, V17, P71
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Reyes-Chilpa R, 2006, J ETHNOPHARMACOL, V105, P167, DOI 10.1016/j.jep.2005.10.014
   Rogers Arlin B, 2012, Methods Mol Biol, V921, P189
   Sartori NT, 1999, J ETHNOPHARMACOL, V67, P149, DOI 10.1016/S0378-8741(98)00244-X
   Lemos LMS, 2012, J ETHNOPHARMACOL, V141, P432, DOI 10.1016/j.jep.2012.03.006
   Shiota S, 2015, CLIN GASTROENTEROL H, V13, P1616, DOI 10.1016/j.cgh.2015.02.005
   Tanaka N, 2009, PHYTOCHEMISTRY, V70, P141, DOI 10.1016/j.phytochem.2008.11.006
   Thomson MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050194
   Wang R, 2014, DRUG DISCOV THER, V8, P76, DOI 10.5582/ddt.8.76
   Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4
   WANG TC, 1993, J CLIN INVEST, V92, P1349, DOI 10.1172/JCI116708
   Xu ZQ, 1998, BIOORG MED CHEM LETT, V8, P2179
NR 30
TC 4
Z9 4
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 27
PY 2017
VL 8
AR 92
DI 10.3389/fphar.2017.00092
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EL6PI
UT WOS:000394744100003
PM 28289390
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Fjeld, K
   Beer, S
   Johnstone, M
   Zimmer, C
   Mossner, J
   Ruffert, C
   Krehan, M
   Zapf, C
   Njolstad, PR
   Johansson, S
   Bugert, P
   Miyajima, F
   Liloglou, T
   Brown, LJ
   Winn, SA
   Davies, K
   Latawiec, D
   Gunson, BK
   Criddle, DN
   Pirmohamed, M
   Grutzmann, R
   Michl, P
   Greenhalf, W
   Molven, A
   Sutton, R
   Rosendahl, J
AF Fjeld, Karianne
   Beer, Sebastian
   Johnstone, Marianne
   Zimmer, Constantin
   Moessner, Joachim
   Ruffert, Claudia
   Krehan, Mario
   Zapf, Christian
   Njolstad, Pal Rasmus
   Johansson, Stefan
   Bugert, Peter
   Miyajima, Fabio
   Liloglou, Triantafillos
   Brown, Laura J.
   Winn, Simon A.
   Davies, Kelly
   Latawiec, Diane
   Gunson, Bridget K.
   Criddle, David N.
   Pirmohamed, Munir
   Gruetzmann, Robert
   Michl, Patrick
   Greenhalf, William
   Molven, Anders
   Sutton, Robert
   Rosendahl, Jonas
TI Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester
   Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis
   but Not Alcoholic Chronic Pancreatitis
SO PLOS ONE
LA English
DT Article
ID SALT-STIMULATED LIPASE; ACID ETHYL-ESTER; HEREDITARY PANCREATITIS;
   VARIANTS; ASSOCIATION; MUTATIONS; RISK; POLYMORPHISM; DYSFUNCTION;
   INHIBITOR
AB Background
   Carboxyl-ester lipase (CEL) contributes to fatty acid ethyl ester metabolism, which is implicated in alcoholic pancreatitis. The CEL gene harbours a variable number of tandem repeats (VNTR) region in exon 11. Variation in this VNTR has been linked to monogenic pancreatic disease, while conflicting results were reported for chronic pancreatitis (CP). Here, we aimed to investigate a potential association of CEL VNTR lengths with alcoholic CP.
   Methods
   Overall, 395 alcoholic CP patients, 218 patients with alcoholic liver cirrhosis (ALC) serving as controls with a comparable amount of alcohol consumed, and 327 healthy controls from Germany and the United Kingdom (UK) were analysed by determination of fragment lengths by capillary electrophoresis. Allele frequencies and genotypes of different VNTR categories were compared between the groups.
   Results
   Twelve repeats were overrepresented in UK ACP patients (P = 0.04) compared to controls, whereas twelve repeats were enriched in German ALC compared to alcoholic CP patients (P = 0.03). Frequencies of CEL VNTR lengths of 14 and 15 repeats differed between German ALC patients and healthy controls (P = 0.03 and 0.008, respectively). However, in the genotype and pooled analysis of VNTR lengths no statistical significant association was depicted. Additionally, the 16-16 genotype as well as 16 repeats were more frequent in UK ALC than in alcoholic CP patients (P = 0.034 and 0.02, respectively). In all other calculations, including pooled German and UK data, allele frequencies and genotype distributions did not differ significantly between patients and controls or between alcoholic CP and ALC.
   Conclusions
   We did not obtain evidence that CEL VNTR lengths are associated with alcoholic CP. However, our results suggest that CEL VNTR lengths might associate with ALC, a finding that needs to be clarified in larger cohorts.
C1 [Fjeld, Karianne; Njolstad, Pal Rasmus; Johansson, Stefan; Molven, Anders] Univ Bergen, Dept Clin Sci, KG Jebsen Ctr Diabet Res, Bergen, Norway.
   [Fjeld, Karianne; Johansson, Stefan] Haukeland Hosp, Ctr Med Genet & Mol Med, Bergen, Norway.
   [Beer, Sebastian; Zimmer, Constantin; Moessner, Joachim; Krehan, Mario; Zapf, Christian] Univ Leipzig, Div Gastroenterol & Rheumatol, Dept Internal Med Neurol & Dermatol, Leipzig, Germany.
   [Johnstone, Marianne; Brown, Laura J.; Winn, Simon A.; Davies, Kelly; Latawiec, Diane; Greenhalf, William; Sutton, Robert] Univ Liverpool, Royal Liverpool Univ Hosp, Inst Translat Med, NIHR Liverpool Pancreas Biomed Res Unit, Liverpool, Merseyside, England.
   [Ruffert, Claudia; Michl, Patrick; Rosendahl, Jonas] Univ Halle Wittenberg, Dept Internal Med 1, Halle, Germany.
   [Njolstad, Pal Rasmus] Haukeland Hosp, Dept Pediat, Bergen, Norway.
   [Bugert, Peter] Heidelberg Univ, Med Fac Mannheim, Inst Transfus Med & Immunol, German Red Cross Blood Serv Baden Wurttemberg Hes, Mannheim, Germany.
   [Miyajima, Fabio; Pirmohamed, Munir] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Liloglou, Triantafillos] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England.
   [Gunson, Bridget K.] Queen Elizabeth Hosp, NIHR Birmingham Liver Biomed Res Unit, Birmingham, W Midlands, England.
   [Gunson, Bridget K.] Univ Birmingham, Birmingham, W Midlands, England.
   [Criddle, David N.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Liverpool, Merseyside, England.
   [Gruetzmann, Robert] Univ Erlangen Nurnberg, Dept Surg, Erlangen, Germany.
   [Molven, Anders] Univ Bergen, Dept Clin Med, Gade Lab Pathol, Bergen, Norway.
   [Molven, Anders] Haukeland Hosp, Dept Pathol, Bergen, Norway.
RP Rosendahl, J (corresponding author), Univ Halle Wittenberg, Dept Internal Med 1, Halle, Germany.
EM jonas.rosendahl@uk-halle.de
RI Miyajima, Fabio/K-6587-2012; Greenhalf, William/A-2680-2013; Johansson,
   Stefan/C-4394-2011; Pirmohamed, Munir/H-6004-2011; Fjeld,
   Karianne/Q-7122-2018; Hollyman, Marianne/J-8362-2016
OI Miyajima, Fabio/0000-0002-1347-4825; Johansson,
   Stefan/0000-0002-2298-7008; Pirmohamed, Munir/0000-0002-7534-7266;
   Fjeld, Karianne/0000-0003-0441-1475; Hollyman,
   Marianne/0000-0002-5972-0454
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [RO
   3929/1-1, RO 3939/2-1]; Colora Stiftung gGmbH; KG Jebsen Foundation;
   Regional Health Authority of Western Norway; Norwegian Research
   CouncilResearch Council of Norway; Royal College of Surgeons of England;
   National Institute for Health ResearchNational Institute for Health
   Research (NIHR); Cancer Research UKCancer Research UK [16812] Funding
   Source: researchfish; National Institute for Health ResearchNational
   Institute for Health Research (NIHR) [NF-SI-0515-10084,
   NF-SI-0512-10064] Funding Source: researchfish
FX This work was supported by the Deutsche Forschungsgemeinschaft RO
   3929/1-1 & RO 3939/2-1, by a grant of the Colora Stiftung gGmbH (to
   J.R.), by grants from the KG Jebsen Foundation, Regional Health
   Authority of Western Norway and Norwegian Research Council (to A.M. and
   P.R.N), by the Royal College of Surgeons of England and Biomedical
   Research Unit funding scheme from the National Institute for Health
   Research. M.J. was supported by a Fellowship from the Royal College of
   Surgeons of England. Robert Sutton is an NIHR Senior Investigator. No
   sources of funding have influenced the study in any regard.
CR Aparisi L, 2008, WORLD J GASTROENTERO, V14, P6171, DOI 10.3748/wjg.14.6171
   Bengtsson-Ellmark SH, 2004, EUR J HUM GENET, V12, P627, DOI 10.1038/sj.ejhg.5201204
   Buch S, 2015, NAT GENET, V47, P1443, DOI 10.1038/ng.3417
   Buchner AM, 2001, AM J GASTROENTEROL, V96, P2231, DOI 10.1111/j.1572-0241.2001.03941.x
   Criddle DN, 2004, P NATL ACAD SCI USA, V101, P10738, DOI 10.1073/pnas.0403431101
   Criddle DN, 2006, GASTROENTEROLOGY, V130, P781, DOI 10.1053/j.gastro.2005.12.031
   Fjeld K, 2015, NAT GENET, V47, P518, DOI 10.1038/ng.3249
   Forsmark CE, 2008, CLIN GASTROENTEROL H, V6, P1291, DOI 10.1016/j.cgh.2008.08.008
   Higuchi S, 2002, J HUM GENET, V47, P213, DOI 10.1007/s100380200027
   Huang W, 2014, GUT, V63, P1313, DOI 10.1136/gutjnl-2012-304058
   Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200
   Le Marechal C, 2006, NAT GENET, V38, P1372, DOI 10.1038/ng1904
   Lindquist S, 2002, EUR J BIOCHEM, V269, P759, DOI 10.1046/j.0014-2956.2001.02666.x
   Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5
   Miyasaka K, 2005, PANCREAS, V30, pE87, DOI 10.1097/01.mpa.0000160960.21580.mL
   Nakamura Y, 2004, J GASTROENTEROL, V39, P879, DOI 10.1007/s00535-004-1405-y
   Pace A, 2009, CLIN GASTROENTEROL H, V7, P1241, DOI 10.1016/j.cgh.2009.06.010
   Raeder H, 2006, NAT GENET, V38, P54, DOI 10.1038/ng1708
   Ragvin A, 2013, PANCREATOLOGY, V13, P29, DOI 10.1016/j.pan.2012.12.059
   RENNER IG, 1984, DIGEST DIS SCI, V29, P593, DOI 10.1007/BF01347290
   Rosendahl J, 2008, NAT GENET, V40, P78, DOI 10.1038/ng.2007.44
   Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001
   SINGER MV, 1985, GASTROENTEROLOGY, V89, P683, DOI 10.1016/0016-5085(85)90468-8
   Stromqvist M, 1997, ARCH BIOCHEM BIOPHYS, V347, P30, DOI 10.1006/abbi.1997.0307
   Torsvik J, 2010, HUM GENET, V127, P55, DOI 10.1007/s00439-009-0740-8
   TSUJITA T, 1994, EUR J BIOCHEM, V224, P57, DOI 10.1111/j.1432-1033.1994.tb19994.x
   Whitcomb DC, 2012, NAT GENET, V44, P1349, DOI 10.1038/ng.2466
   Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141
   Witt H, 2000, NAT GENET, V25, P213, DOI 10.1038/76088
   Witt H, 2001, JAMA-J AM MED ASSOC, V285, P2716, DOI 10.1001/jama.285.21.2716-a
   Witt H, 2006, NAT GENET, V38, P668, DOI 10.1038/ng1797
   Witt H, 2007, GASTROENTEROLOGY, V132, P1557, DOI 10.1053/j.gastro.2007.03.001
   Witt H, 2013, NAT GENET, V45, P1216, DOI 10.1038/ng.2730
NR 33
TC 8
Z9 8
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 1
PY 2016
VL 11
IS 11
AR e0165567
DI 10.1371/journal.pone.0165567
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EA6CX
UT WOS:000386714200027
PM 27802312
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Mirza, N
   Vasieva, O
   Appleton, R
   Burn, S
   Carr, D
   Crooks, D
   du Plessis, D
   Duncan, R
   Farah, JO
   Josan, V
   Miyajima, F
   Mohanraj, R
   Shukralla, A
   Sills, GJ
   Marson, AG
   Pirmohamed, M
AF Mirza, Nasir
   Vasieva, Olga
   Appleton, Richard
   Burn, Sasha
   Carr, Daniel
   Crooks, Daniel
   du Plessis, Daniel
   Duncan, Roderick
   Farah, Jibril Osman
   Josan, Vivek
   Miyajima, Fabio
   Mohanraj, Rajiv
   Shukralla, Arif
   Sills, Graeme J.
   Marson, Anthony G.
   Pirmohamed, Munir
TI An integrative in silico system for predicting dysregulated genes in the
   human epileptic focus: Application to SLC transporters
SO EPILEPSIA
LA English
DT Article
DE Computational gene prioritization; Convergent functional genomics;
   Hippocampal sclerosis; Epilepsy; Solute carrier transporters;
   Microarray; Pharmacoresistance
ID K-CL COTRANSPORTER; MIGRATING PARTIAL SEIZURES; NEURONAL-SPECIFIC
   ISOFORM; BRAIN-INJURY; EXON ARRAYS; ENCEPHALOPATHY; EXPRESSION;
   SLC25A22; MICE; KCC2
AB Objective: Many different gene families are currently being investigated for their potential role in epilepsy and in the response to antiepileptic drugs. A common research challenge is identifying the members of a gene family that are most significantly dysregulated within the human epileptic focus, before taking them forward for resource-intensive functional studies. Published data about transcriptomic changes within the human epileptic focus remains incomplete. A need exists for an accurate in silico system for the prediction of dysregulated genes within the epileptic focus. We present such a bioinformatic system. We demonstrate the validity of our approach by applying it to the solute carrier (SLC) gene family. There are >400 known SLCs. SLCs have never been systematically studied in epilepsy.
   Methods: Using our in silico system, we predicted the SLCs likely to be dysregulated in the epileptic focus. We validated our in silico predictions by identifying ex vivo the SLCs dysregulated in epileptic foci, and determining the overlap between our in silico and ex vivo results. For the ex vivo analysis, we used a custom oligonucleotide microarray containing exon probes for all known SLCs to analyze 24 hippocampal samples obtained from surgery for pharmacoresistant mesial temporal lobe epilepsy and 24 hippocampal samples from normal postmortem controls.
   Results: There was a highly significant (p < 9.99 x 10(-7)) overlap between the genes identified by our in silico and ex vivo strategies. The SLCs identified were either metal ion exchangers or neurotransmitter transporters, which are likely to play a part in epilepsy by influencing neuronal excitability.
   Significance: The identified SLCs are most likely to mediate pharmacoresistance in epilepsy by enhancing the intrinsic severity of epilepsy, but further functional work will be needed to fully evaluate their role. Our successful in silico strategy can be adapted in order to prioritize genes relevant to epilepsy from other gene families.
C1 [Mirza, Nasir; Carr, Daniel; Miyajima, Fabio; Sills, Graeme J.; Marson, Anthony G.; Pirmohamed, Munir] Univ Liverpool, Dept Mol & Clin Pharmacol, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
   [Vasieva, Olga] Univ Liverpool, Inst Integrat Biol, Liverpool, Merseyside, England.
   [Appleton, Richard] Alder Hey Childrens NHS Fdn Trust, Paediat Neurosci Fdn, Roald Dahl EEG Unit, Liverpool, Merseyside, England.
   [Burn, Sasha] Alder Hey Childrens NHS Fdn Trust, Dept Neurosurg, Liverpool, Merseyside, England.
   [Crooks, Daniel] Walton Ctr NHS Fdn Trust, Dept Neuropathol, Liverpool, Merseyside, England.
   [du Plessis, Daniel] Salford Royal NHS Fdn Trust, Dept Cellular Pathol, Salford, Lancs, England.
   [Duncan, Roderick] Christchurch Hosp, Dept Neurol, Christchurch, New Zealand.
   [Farah, Jibril Osman] Walton Ctr NHS Fdn Trust, Dept Neurosurg, Liverpool, Merseyside, England.
   [Josan, Vivek] Salford Royal NHS Fdn Trust, Dept Neurosurg, Salford, Lancs, England.
   [Mohanraj, Rajiv; Shukralla, Arif] Salford Royal NHS Fdn Trust, Dept Neurol, Salford, Lancs, England.
RP Mirza, N (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
EM nasir.mirza@liv.ac.uk
RI Marson, Anthony/AAW-9776-2020; Pirmohamed, Munir/H-6004-2011; Miyajima,
   Fabio/K-6587-2012
OI Marson, Anthony/0000-0002-6861-8806; Pirmohamed,
   Munir/0000-0002-7534-7266; Miyajima, Fabio/0000-0002-1347-4825; Sills,
   Graeme/0000-0002-3389-8713; Carr, Daniel/0000-0001-8028-4282; Mohanraj,
   Rajiv/0000-0002-2559-148X
FU Medical Research CouncilMedical Research Council UK (MRC); National
   Health Service Chair of Pharmacogenetics; Medical Research Council
   Centre for Drug Safety Science; Medical Research CouncilMedical Research
   Council UK (MRC) [MR/L006758/1, G0900385] Funding Source: researchfish;
   National Institute for Health ResearchNational Institute for Health
   Research (NIHR) [NF-SI-0512-10064] Funding Source: researchfish
FX NM was funded by a Medical Research Council Research Training
   Fellowship. MP is an National Institute for Health Research Senior
   Investigator, and acknowledges support from the National Health Service
   Chair of Pharmacogenetics and the Medical Research Council Centre for
   Drug Safety Science.
CR Chayasirisobhon Sirichai, 2009, Acta Neurol Taiwan, V18, P155
   Cohen R, 2014, EUR J PAEDIATR NEURO, V18, P801, DOI 10.1016/j.ejpn.2014.06.007
   Dibbens LM, 2007, GENES BRAIN BEHAV, V6, P593, DOI 10.1111/j.1601-183X.2007.00333.x
   Dobson PD, 2008, NAT REV DRUG DISCOV, V7, P205, DOI 10.1038/nrd2438
   Engel Jerome Jr, 2003, Epilepsy Curr, V3, P37, DOI 10.1046/j.1535-7597.2003.03201.x
   Fung C, 2010, J NEUROSCI RES, V88, P3386, DOI 10.1002/jnr.22487
   Gursoy S, 2016, J CHILD NEUROL, V31, P523, DOI 10.1177/0883073815599262
   Huang Y, 2006, CANCER LETT, V239, P168, DOI 10.1016/j.canlet.2005.07.032
   Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5
   Kapur K, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r82
   Le-Niculescu H, 2007, NEUROSCI BIOBEHAV R, V31, P897, DOI 10.1016/j.neubiorev.2007.05.008
   Lockstone HE, 2011, BRIEF BIOINFORM, V12, P634, DOI 10.1093/bib/bbq086
   Lottaz C, 2006, BIOINFORMATICS, V22, P2315, DOI 10.1093/bioinformatics/btl385
   Lu J, 1999, J NEUROBIOL, V39, P558, DOI 10.1002/(SICI)1097-4695(19990615)39:4<558::AID-NEU9>3.3.CO;2-X
   McTague A, 2013, BRAIN, V136, P1578, DOI 10.1093/brain/awt073
   Mirza N, 2011, HUM MOL GENET, V20, P4381, DOI 10.1093/hmg/ddr365
   Molinari F, 2005, AM J HUM GENET, V76, P334, DOI 10.1086/427564
   Molinari F, 2009, CLIN GENET, V76, P188, DOI 10.1111/j.1399-0004.2009.01236.x
   Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245
   Poduri A, 2013, ANN NEUROL, V74, P873, DOI 10.1002/ana.23998
   Sander JW, 2003, EPILEPSIA, V44, P17
   Schmidt D, 2009, EPILEPSY CURR, V9, P47, DOI 10.1111/j.1535-7511.2008.01289.x
   Shorvon SD, 1996, EPILEPSIA, V37, pS1, DOI 10.1111/j.1528-1157.1996.tb06027.x
   Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699
   Tranchevent LC, 2008, NUCLEIC ACIDS RES, V36, pW377, DOI 10.1093/nar/gkn325
   Williams JR, 1999, J BIOL CHEM, V274, P12656, DOI 10.1074/jbc.274.18.12656
   Woo NS, 2002, HIPPOCAMPUS, V12, P258, DOI 10.1002/hipo.10014
   Xing Y, 2007, MOL BIOL EVOL, V24, P1283, DOI 10.1093/molbev/msm061
   Zhao Y, 2010, MOL PSYCHIATR, V15, P286, DOI 10.1038/mp.2009.51
NR 29
TC 1
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2016
VL 57
IS 9
BP 1467
EP 1474
DI 10.1111/epi.13473
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA EB8QJ
UT WOS:000387655600021
PM 27421837
OA Bronze, Green Accepted
DA 2020-12-17
ER

PT J
AU Lees, EA
   Miyajima, F
   Pirmohamed, M
   Carrol, ED
AF Lees, E. A.
   Miyajima, F.
   Pirmohamed, M.
   Carrol, E. D.
TI The role of Clostridium difficile in the paediatric and neonatal gut - a
   narrative review
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Review
ID TOXIN-A; NOSOCOMIAL DIARRHEA; CYTO-TOXIN; ASYMPTOMATIC COLONIZATION;
   INTESTINAL COLONIZATION; ACUTE GASTROENTERITIS; ANTIBODY-RESPONSE;
   HEALTHY INFANTS; RISK-FACTORS; INFECTION
AB Clostridium difficile is an important nosocomial pathogen in adults. Its significance in children is less well defined, but cases of C. difficile infection (CDI) appear to be increasingly prevalent in paediatric patients. This review aims to summarize reported Clostridium difficile carriage rates across children of different age groups, appraise the relationship between CDI and factors such as method of delivery, type of infant feed, antibiotic use, and co-morbidities, and review factors affecting the gut microbiome in children and the host immune response to C. difficile. Searches of PubMed and Google Scholar using the terms 'Clostridium difficile neonates' and 'Clostridium difficile children' were completed, and reference lists of retrieved publications screened for further papers. In total, 88 papers containing relevant data were included. There was large inter-study variation in reported C. difficile carriage rates. There was an association between CDI and recent antibiotic use, and co-morbidities such as immunosuppression and inflammatory bowel disease. C. difficile was also found in stools of children with diarrhoea attributed to other pathogens (e.g. rotavirus). The role of C. difficile in the paediatric gut remains unclear; is it an innocent bystander in diarrhoeal disease caused by other organisms, or a pathogen causing subclinical to severe symptoms? Further investigation of the development of serological and local host response to C. difficile carriage may shed new light on disease mechanisms. Work is underway on defining a framework for diagnosis and management of paediatric CDI.
C1 [Lees, E. A.; Miyajima, F.; Pirmohamed, M.] Univ Liverpool, Inst Translat Med, Wolfson Ctr, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
   [Carrol, E. D.] Inst Infect & Global Hlth, Dept Clin Infect Microbiol & Immunol, Ronald Ross Bldg,West Derby St, Liverpool L69 7BE, Merseyside, England.
RP Lees, EA (corresponding author), Univ Liverpool, Inst Translat Med, Wolfson Ctr, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
EM emilylees@doctors.org.uk
RI Pirmohamed, Munir/H-6004-2011; Miyajima, Fabio/K-6587-2012
OI Pirmohamed, Munir/0000-0002-7534-7266; Miyajima,
   Fabio/0000-0002-1347-4825; Carrol, Enitan/0000-0001-8357-7726
FU National Institute for Health ResearchNational Institute for Health
   Research (NIHR); Medical Research CouncilMedical Research Council UK
   (MRC) [MR/L006758/1] Funding Source: researchfish; National Institute
   for Health ResearchNational Institute for Health Research (NIHR)
   [NF-SI-0512-10064] Funding Source: researchfish
FX EAL is an Academic Clinical Fellow supported by the National Institute
   for Health Research.
CR ALJUMAILI IJ, 1984, J CLIN MICROBIOL, V19, P77, DOI 10.1128/JCM.19.1.77-78.1984
   Alrifai S. B., 2009, Eastern Mediterranean Health Journal, V15, P1111
   Aslam S, 2005, LANCET INFECT DIS, V5, P549, DOI 10.1016/S1473-3099(05)70215-2
   Banaszkiewicz A, 2010, INFLAMM BOWEL DIS, V16, P554, DOI 10.1002/ibd.21056
   BENNET R, 1987, INFECTION, V15, P332, DOI 10.1007/BF01647733
   BLAKEY JL, 1982, J MED MICROBIOL, V15, P519, DOI 10.1099/00222615-15-4-519
   BOLTON RP, 1984, ARCH DIS CHILD, V59, P466, DOI 10.1136/adc.59.5.466
   Borali E, 2015, DIGEST LIVER DIS, V47, P842, DOI 10.1016/j.dld.2015.06.002
   BRADY MT, 1989, AM J INFECT CONTROL, V17, P77, DOI 10.1016/0196-6553(89)90021-7
   Burgner D, 1997, PEDIATR INFECT DIS J, V16, P1131, DOI 10.1097/00006454-199712000-00006
   Castagnola E, 2009, SUPPORT CARE CANCER, V17, P321, DOI 10.1007/s00520-008-0507-0
   Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047
   COOPERSTOCK M, 1983, J CLIN MICROBIOL, V17, P830, DOI 10.1128/JCM.17.5.830-833.1983
   Crews JD, 2015, PEDIATR INFECT DIS J, V34, P919, DOI 10.1097/INF.0000000000000767
   de Graaf H, 2015, EUR J CLIN MICROBIOL, V34, P1281, DOI 10.1007/s10096-015-2367-0
   DELMEE M, 1988, EUR J PEDIATR, V147, P36, DOI 10.1007/BF00442608
   Denno DM, 2005, PEDIATR INFECT DIS J, V24, P142, DOI 10.1097/01.inf.0000151031.47761.6d
   Deshpande A, 2015, INFECT CONT HOSP EP, V36, P452, DOI 10.1017/ice.2014.88
   DONTA ST, 1982, J PEDIATR-US, V100, P431, DOI 10.1016/S0022-3476(82)80454-X
   Dubberke ER, 2014, INFECT CONT HOSP EP, V35, P628, DOI [10.1086/676023, 10.1017/S0899823X00193857]
   Duleba K, 2014, EUR J CLIN MICROBIOL, V33, P201, DOI 10.1007/s10096-013-1946-1
   EGLOW R, 1992, J CLIN INVEST, V90, P822, DOI 10.1172/JCI115957
   El Feghaly RE, 2013, J PEDIATR GASTR NUTR, V57, P813, DOI 10.1097/MPG.0b013e3182a3202f
   El Feghaly RE, 2013, J PEDIATR-US, V163, P1697, DOI 10.1016/j.jpeds.2013.07.029
   El-Mahallawy HA, 2004, PEDIATR BLOOD CANCER, V42, P338, DOI 10.1002/pbc.10394
   ELLIS ME, 1984, BRIT MED J, V288, P524, DOI 10.1136/bmj.288.6416.524
   Enoch DA, 2011, J INFECTION, V63, P105, DOI 10.1016/j.jinf.2011.05.016
   Eyre DW, 2013, NEW ENGL J MED, V369, P1195, DOI 10.1056/NEJMoa1216064
   Faust SN, 2015, CLIN INFECT DIS, V60, P912, DOI 10.1093/cid/ciu936
   Ferraris L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030594
   Ferreira CEA, 2003, MEM I OSWALDO CRUZ, V98, P451, DOI 10.1590/S0074-02762003000400003
   Gogate A, 2005, INDIAN J MED RES, V122, P518
   Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007
   GRYBOSKI JD, 1991, AM J GASTROENTEROL, V86, P685
   HAN VKM, 1983, PEDIATRICS, V71, P935
   HOLST E, 1981, SCAND J INFECT DIS, V13, P41, DOI 10.1080/00365548.1981.11690365
   HOLTON AF, 1989, J ANTIMICROB CHEMOTH, V24, P811, DOI 10.1093/jac/24.5.811
   Jacquot A, 2011, J PEDIATR-US, V158, P390, DOI 10.1016/j.jpeds.2010.09.007
   Jangi S, 2010, J PEDIATR GASTR NUTR, V51, P2, DOI 10.1097/MPG.0b013e3181d29767
   KATO H, 1994, J CLIN MICROBIOL, V32, P2067, DOI 10.1128/JCM.32.9.2067-2070.1994
   Khanna S, 2013, CLIN INFECT DIS, V56, P1401, DOI 10.1093/cid/cit075
   Kim J, 2012, PEDIATR INFECT DIS J, V31, P134, DOI 10.1097/INF.0b013e3182352e2c
   KIM KH, 1989, J CLIN MICROBIOL, V27, P1192, DOI 10.1128/JCM.27.6.1192-1196.1989
   Klein EJ, 2006, CLIN INFECT DIS, V43, P807, DOI 10.1086/507335
   Kuipers EJ, 2008, LANCET, V371, P1486, DOI 10.1016/S0140-6736(08)60635-2
   Kyne L, 2000, NEW ENGL J MED, V342, P390, DOI 10.1056/NEJM200002103420604
   Kyne L, 2001, LANCET, V357, P189, DOI 10.1016/S0140-6736(00)03592-3
   Lamont J Thomas, 2002, Trans Am Clin Climatol Assoc, V113, P167
   Lamouse-Smith ESN, 2013, J PEDIATR GASTR NUTR, V57, P293, DOI 10.1097/MPG.0b013e3182999990
   Langley JM, 2002, INFECT CONT HOSP EP, V23, P660, DOI 10.1086/501990
   LARSON HE, 1982, J INFECT DIS, V146, P727, DOI 10.1093/infdis/146.6.727
   Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995
   Leav BA, 2010, VACCINE, V28, P965, DOI 10.1016/j.vaccine.2009.10.144
   LEUNG DYM, 1991, J PEDIATR-US, V118, P633, DOI 10.1016/S0022-3476(05)83393-1
   Lukkarinen H, 2009, PEDIATR INFECT DIS J, V28, P847, DOI 10.1097/INF.0b013e31819d1cd9
   MALAMOULADAS H, 1983, J CLIN PATHOL, V36, P88, DOI 10.1136/jcp.36.1.88
   MARTIROSIAN G, 1995, J CLIN MICROBIOL, V33, P2016, DOI 10.1128/JCM.33.8.2016-2021.1995
   Matsuki S, 2005, INT MICROBIOL, V8, P43
   MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402
   MERIDA V, 1986, EUR J PEDIATR, V144, P494, DOI 10.1007/BF00441746
   Miyajima F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022804
   Morelli L, 2008, J NUTR, V138, p1791S
   Morgan XC, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002808
   Mullane K, 2014, THER ADV CHRONIC DIS, V5, P69, DOI 10.1177/2040622313511285
   Naaber P, 1997, CLIN INFECT DIS, V25, pS189, DOI 10.1086/516183
   NASH JQ, 1982, J CLIN PATHOL, V35, P561, DOI 10.1136/jcp.35.5.561
   National Institute for Health and Care Excellence, 2012, EV SUMM CLOSTR DIFF
   O'Donoghue C, 2011, CURR OPIN GASTROEN, V27, P38, DOI 10.1097/MOG.0b013e3283411634
   Oguz F, 2001, SCAND J INFECT DIS, V33, P731, DOI 10.1080/003655401317074509
   Pai S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051728
   Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177
   Pant C, 2013, CURR MED RES OPIN, V29, P967, DOI 10.1185/03007995.2013.803058
   Pascarella F, 2009, J PEDIATR-US, V154, P854, DOI 10.1016/j.jpeds.2008.12.039
   Penders J, 2005, FEMS MICROBIOL LETT, V243, P141, DOI 10.1016/j.femsle.2004.11.052
   Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824
   Pinto LJF, 2003, J MED MICROBIOL, V52, P1095, DOI 10.1099/jmm.0.05308-0
   Pohl JF, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/345012
   Pokorn M, 2008, PEDIATR INFECT DIS J, V27, P944, DOI 10.1097/INF.0b013e3181723d32
   Public Health England, 2014, VOL SURV CLOSTR DIFF, V9
   RICHARDSON SA, 1983, BRIT MED J, V287, P878, DOI 10.1136/bmj.287.6396.878
   Riggs MM, 2007, CLIN INFECT DIS, V45, P992, DOI 10.1086/521854
   Rigsbee L, 2012, AM J GASTROENTEROL, V107, P1740, DOI 10.1038/ajg.2012.287
   ROLFE RD, 1995, J MED MICROBIOL, V42, P10, DOI 10.1099/00222615-42-1-10
   ROTIMI VO, 1985, J HYG-CAMBRIDGE, V94, P309, DOI 10.1017/S0022172400061532
   Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515
   Rousseau C, 2011, J MED MICROBIOL, V60, P1112, DOI 10.1099/jmm.0.029736-0
   Rousseau C, 2011, J CLIN MICROBIOL, V49, P858, DOI 10.1128/JCM.01507-10
   Salminen S, 2004, GUT, V53, P1388, DOI 10.1136/gut.2004.041640
   Sammons JS, 2013, JAMA PEDIATR, V167, P567, DOI 10.1001/jamapediatrics.2013.441
   Sandora TJ, 2011, PEDIATR INFECT DIS J, V30, P580, DOI 10.1097/INF.0b013e31820bfb29
   SCHULLER I, 1995, ARCH DIS CHILD, V72, P219, DOI 10.1136/adc.72.3.219
   Schutze GE, 2013, PEDIATRICS, V131, P196, DOI 10.1542/peds.2012-2992
   Shastri S, 1998, J CLIN MICROBIOL, V36, P2571, DOI 10.1128/JCM.36.9.2571-2574.1998
   Simon A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-70
   STARK PL, 1982, INFECT IMMUN, V35, P895, DOI 10.1128/IAI.35.3.895-899.1982
   Svedhem A, 1982, Eur J Clin Microbiol, V1, P29, DOI 10.1007/BF02014137
   TABAQCHALI S, 1984, J MED MICROBIOL, V18, P47, DOI 10.1099/00222615-18-1-47
   Tang P, 2005, DIAGN MICR INFEC DIS, V52, P91, DOI 10.1016/j.diagmicrobio.2005.01.003
   Tonooka T, 2005, MICROBIOL IMMUNOL, V49, P989, DOI 10.1111/j.1348-0421.2005.tb03694.x
   TORRES JF, 1984, J CLIN MICROBIOL, V20, P274, DOI 10.1128/JCM.20.2.274-275.1984
   TULLUS K, 1989, EUR J CLIN MICROBIOL, V8, P390, DOI 10.1007/BF01964052
   Turco R, 2010, ALIMENT PHARM THER, V31, P754, DOI 10.1111/j.1365-2036.2009.04229.x
   UHNOO I, 1986, J INFECTION, V13, P73, DOI 10.1016/S0163-4453(86)92348-0
   Valentini D, 2013, EUR J CLIN MICROBIOL, V32, P909, DOI 10.1007/s10096-013-1825-9
   Vernacchio L, 2006, PEDIATR INFECT DIS J, V25, P2, DOI 10.1097/01.inf.0000195623.57945.87
   VISCIDI R, 1983, J INFECT DIS, V148, P93, DOI 10.1093/infdis/148.1.93
   VISCIDI R, 1981, GASTROENTEROLOGY, V81, P5
   Wilcox MH, 2008, J ANTIMICROB CHEMOTH, V62, P388, DOI 10.1093/jac/dkn163
   WOLFHAGEN MJHM, 1994, GUT, V35, P1608, DOI 10.1136/gut.35.11.1608
NR 109
TC 31
Z9 31
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD JUL
PY 2016
VL 35
IS 7
BP 1047
EP 1057
DI 10.1007/s10096-016-2639-3
PG 11
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA DR7ON
UT WOS:000380089700001
PM 27107991
OA Green Published, Other Gold
DA 2020-12-17
ER

PT J
AU Kumar, N
   Miyajima, F
   He, M
   Roberts, P
   Swale, A
   Ellison, L
   Pickard, D
   Smith, G
   Molyneux, R
   Dougan, G
   Parkhill, J
   Wren, BW
   Parry, CM
   Pirmohamed, M
   Lawley, TD
AF Kumar, Nitin
   Miyajima, Fabio
   He, Miao
   Roberts, Paul
   Swale, Andrew
   Ellison, Louise
   Pickard, Derek
   Smith, Godfrey
   Molyneux, Rebecca
   Dougan, Gordon
   Parkhill, Julian
   Wren, Brendan W.
   Parry, Christopher M.
   Pirmohamed, Munir
   Lawley, Trevor D.
TI Genome-Based Infection Tracking Reveals Dynamics of Clostridium
   difficile Transmission and Disease Recurrence
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE C. difficile 027/ST1; whole-genome sequencing; ward-based transmission;
   highly contagious individuals; recurrence
ID EVOLUTION; EPIDEMIOLOGY; STRAINS; SPREAD
AB Background. Accurate tracking of Clostridium difficile transmission within healthcare settings is key to its containment but is hindered by the lack of discriminatory power of standard genotyping methods. We describe a whole-genome phylogenetic-based method to track the transmission of individual clones in infected hospital patients from the epidemic C. difficile 027/ST1 lineage, and to distinguish between the 2 causes of recurrent disease, relapse (same strain), or reinfection (different strain).
   Methods. We monitored patients with C. difficile infection in a UK hospital over a 2-year period. We performed whole-genome sequencing and phylogenetic analysis of 108 strains isolated from symptomatic patients. High-resolution phylogeny was integrated with in-hospital transfers and contact data to create an infection network linking individual patients and specific hospital wards.
   Results. Epidemic C. difficile 027/ST1 caused the majority of infections during our sampling period. Integration of whole-genome single nucleotide polymorphism (SNP) phylogenetic analysis, which accurately discriminated between 27 distinct SNP genotypes, with patient movement and contact data identified 32 plausible transmission events, including ward-based contamination (66%) or direct donor-recipient contact (34%). Highly contagious donors were identified who contributed to the persistence of clones within distinct hospital wards and the spread of clones between wards, especially in areas of intense turnover. Recurrent cases were identified between 4 and 26 weeks, highlighting the limitation of the standard < 8-week cutoff used for patient diagnosis and management.
   Conclusions. Genome-based infection tracking to monitor the persistence and spread of C. difficile within healthcare facilities could inform infection control and patient management.
C1 [Kumar, Nitin; He, Miao; Ellison, Louise; Pickard, Derek; Dougan, Gordon; Parkhill, Julian; Lawley, Trevor D.] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
   [Miyajima, Fabio; Swale, Andrew; Pirmohamed, Munir] Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
   [Roberts, Paul; Smith, Godfrey; Molyneux, Rebecca] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England.
   [Wren, Brendan W.; Parry, Christopher M.] London Sch Hyg & Trop Med, London, England.
RP Lawley, TD (corresponding author), Wellcome Trust Sanger Inst, Host Microbiota Interact Lab, Hinxton CB10 1SA, Cambs, England.
EM tl2@sanger.ac.uk
RI Pirmohamed, Munir/H-6004-2011; Parkhill, Julian/G-4703-2011; Miyajima,
   Fabio/K-6587-2012
OI Pirmohamed, Munir/0000-0002-7534-7266; Parkhill,
   Julian/0000-0002-7069-5958; Miyajima, Fabio/0000-0002-1347-4825
FU Wellcome TrustWellcome Trust [098051]; Medical Research Council
   UKMedical Research Council UK (MRC) [PF451]; Medical Research
   CouncilMedical Research Council UK (MRC) [MR/K000551/1, MR/L006758/1,
   G0700654] Funding Source: researchfish; National Institute for Health
   ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10064]
   Funding Source: researchfish
FX This work was supported by the Wellcome Trust (grant number 098051) and
   Medical Research Council UK (grant number PF451).
CR Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4
   Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706
   Colijn Caroline, 2014, Evolution Medicine and Public Health, P96, DOI 10.1093/emph/eou018
   Donskey CJ, 2010, CLIN INFECT DIS, V50, P1458, DOI 10.1086/652649
   Dubberke ER, 2014, INFECT CONT HOSP EP, V35, P628, DOI [10.1086/676023, 10.1017/S0899823X00193857]
   Eyre DW, 2013, J CLIN MICROBIOL, V51, P4141, DOI 10.1128/JCM.01095-13
   Eyre DW, 2014, J INFECT DIS, V209, P1446, DOI 10.1093/infdis/jit598
   Eyre DW, 2013, NEW ENGL J MED, V369, P1195, DOI 10.1056/NEJMoa1216064
   Eyre DW, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001124
   Eyre DW, 2012, J CLIN MICROBIOL, V50, P142, DOI 10.1128/JCM.05177-11
   Gardy JL, 2011, NEW ENGL J MED, V364, P730, DOI 10.1056/NEJMoa1003176
   Gerding DN, 2015, JAMA-J AM MED ASSOC, V313, P1719, DOI 10.1001/jama.2015.3725
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Griffiths D, 2010, J CLIN MICROBIOL, V48, P770, DOI 10.1128/JCM.01796-09
   GURTLER V, 1993, J GEN MICROBIOL, V139, P3089, DOI 10.1099/00221287-139-12-3089
   Harris SR, 2010, SCIENCE, V327, P469, DOI 10.1126/science.1182395
   He M, 2013, NAT GENET, V45, P109, DOI 10.1038/ng.2478
   Kelly Ciaran P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500
   Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639
   Marsh JW, 2006, J CLIN MICROBIOL, V44, P2558, DOI 10.1128/JCM.02364-05
   McDonald LC, 2007, INFECT CONT HOSP EP, V28, P140, DOI 10.1086/511798
   McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590
   Paradis E, 2004, BIOINFORMATICS, V20, P289, DOI 10.1093/bioinformatics/btg412
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Rupnik M, 1998, J CLIN MICROBIOL, V36, P2240, DOI 10.1128/JCM.36.8.2240-2247.1998
   Rupnik M, 2009, NAT REV MICROBIOL, V7, P526, DOI 10.1038/nrmicro2164
   Stabler RA, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r102
   UK Health Protection Agency, 2009, CLOSTR DIFF INF DEAL, P1
   Vonberg RP, 2008, CLIN MICROBIOL INFEC, V14, P2, DOI 10.1111/j.1469-0691.2008.01992.x
   Walker AS, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001172
   Walker TM, 2013, LANCET INFECT DIS, V13, P137, DOI 10.1016/S1473-3099(12)70277-3
NR 31
TC 41
Z9 42
U1 1
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2016
VL 62
IS 6
BP 746
EP 752
DI 10.1093/cid/civ1031
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DF9XU
UT WOS:000371716700010
PM 26683317
OA Green Accepted, Other Gold, Green Published
DA 2020-12-17
ER

PT J
AU Warburton, A
   Miyajima, F
   Shazadi, K
   Crossley, J
   Johnson, MR
   Marson, AG
   Baker, GA
   Quinn, JP
   Sills, GJ
AF Warburton, Alix
   Miyajima, Fabio
   Shazadi, Kanvel
   Crossley, Joanne
   Johnson, Michael R.
   Marson, Anthony G.
   Baker, Gus A.
   Quinn, John P.
   Sills, Graeme J.
TI NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in
   adults with newly diagnosed epilepsy
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE BDNF; Cognition; Epilepsy; NRSF/REST; Biomarkers
ID TEMPORAL-LOBE EPILEPSY; RESTRICTIVE SILENCER FACTOR; NEUROTROPHIC FACTOR
   GENE; TRKB MESSENGER-RNA; FOLLOW-UP; VAL66MET POLYMORPHISM;
   ALZHEIMERS-DISEASE; VERBAL MEMORY; BRAIN; EXPRESSION
AB Cognitive dysfunction is a common comorbidity in people with epilepsy, but its causes remain unclear. It may be related to the etiology of the disorder, the consequences of seizures, or the effects of antiepileptic drug treatment. Genetics may also play a contributory role. We investigated the influence of variants in the genes encoding neuron-restrictive silencer factor (NRSF) and brain-derived neurotrophic factor (BDNF), proteins previously associated with cognition and epilepsy, on cognitive function in people with newly diagnosed epilepsy. A total of 82 patients who had previously undergone detailed neuropsychological assessment were genotyped for single nucleotide polymorphisms (SNPs) across the NRSF and BDNF genes. Putatively functional SNPs were included in a genetic association analysis with specific cognitive domains, including memory, psychomotor speed, and information processing. Cross-sectional and longitudinal designs were used to explore genetic influences on baseline cognition at diagnosis and change from baseline over the first year since diagnosis, respectively. We found a statistically significant association between genotypic variation and memory function at both baseline (NRSF: rs1105434, rs2227902 and BDNF: rs1491850, rs2030324, rs11030094) and in our longitudinal analysis (NRSF: rs2227902 and BDNF: rs12273363). Psychomotor speed was also associated with genotype (NRSF rs3796529) in the longitudinal assessment. In line with our previous work on general cognitive function in the healthy aging population, we observed an additive interaction between risk alleles for the NRSF rs2227902 (G) and BDNF rs6265 (A) polymorphismswhichwas again consistent with a significantly greater decline in delayed recall over the first year since diagnosis. These findings support a role for the NRSF-BDNF pathway in the modulation of cognitive function in patients with newly diagnosed epilepsy. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Warburton, Alix; Miyajima, Fabio; Shazadi, Kanvel; Crossley, Joanne; Marson, Anthony G.; Baker, Gus A.; Quinn, John P.; Sills, Graeme J.] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool L69 3GL, Merseyside, England.
   [Johnson, Michael R.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England.
RP Sills, GJ (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Wolfson Ctr Personalised Med, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
EM g.sills@liv.ac.uk
RI Miyajima, Fabio/K-6587-2012; Marson, Anthony/AAW-9776-2020; Quinn,
   John/A-2972-2010
OI Miyajima, Fabio/0000-0002-1347-4825; Marson,
   Anthony/0000-0002-6861-8806; Quinn, John/0000-0003-3551-7803; Sills,
   Graeme/0000-0002-3389-8713
FU UK Biotechnology and Biological Sciences Research Council
   (BBSRC)Biotechnology and Biological Sciences Research Council (BBSRC)
   [BB/F016905/1]; Biotechnology and Biological Sciences Research
   CouncilBiotechnology and Biological Sciences Research Council (BBSRC)
   [976606] Funding Source: researchfish
FX This study was supported by the UK Biotechnology and Biological Sciences
   Research Council (BBSRC) in the form of studentship funding to AW (ref.
   BB/F016905/1). The funder had no involvement in study design,
   collection, analysis or interpretation of data, writing the article, or
   in the decision to submit the article for publication.
CR Abuhatzira L, 2007, EPIGENETICS-US, V2, P214, DOI 10.4161/epi.2.4.5212
   Aikia M, 1999, EPILEPSIA, V40, P100
   Aikia M, 2001, EPILEPSY BEHAV, V2, P20, DOI 10.1006/ebeh.2000.0140
   Andersson-Roswall L, 2004, EPILEPSY BEHAV, V5, P677, DOI 10.1016/j.yebeh.2004.05.012
   Baker GA, 2011, EPILEPSIA, V52, P1084, DOI 10.1111/j.1528-1167.2011.03043.x
   BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N
   Bassuk AG, 2008, AM J HUM GENET, V83, P572, DOI 10.1016/j.ajhg.2008.10.003
   Berg AT, 2011, EPILEPSIA, V52, P7, DOI 10.1111/j.1528-1167.2010.02905.x
   Bhandare R, 2010, GENOME RES, V20, P428, DOI 10.1101/gr.102038.109
   Bruce AW, 2006, J NEUROCHEM, V98, P1828, DOI 10.1111/j.1471-4159.2006.04010.x
   Calderone A, 2003, J NEUROSCI, V23, P2112
   Cheah SY, 2014, ALCOHOL ALCOHOLISM, V49, P491, DOI 10.1093/alcalc/agu040
   Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   DODRILL CB, 1992, EPILEPSIA, V33, P327, DOI 10.1111/j.1528-1157.1992.tb02323.x
   Dunham JS, 2009, J PSYCHIATR RES, V43, P1175, DOI 10.1016/j.jpsychires.2009.03.008
   Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804
   Edenberg HJ, 2009, COLD SPRING HARB PRO, V2009
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791
   Gerasimova A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054359
   Gillies S, 2009, NEUROPEPTIDES, V43, P333, DOI 10.1016/j.npep.2009.05.004
   Gillies SG, 2011, J MOL NEUROSCI, V44, P77, DOI 10.1007/s12031-010-9420-3
   Graff J, 2012, NATURE, V483, P222, DOI 10.1038/nature10849
   Gratacos M, 2008, PHARMACOGENOMICS J, V8, P101, DOI 10.1038/sj.tpj.6500460
   Guan JS, 2009, NATURE, V459, P55, DOI 10.1038/nature07925
   Hall D, 2003, AM J HUM GENET, V73, P370, DOI 10.1086/377003
   Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003
   Helmstaedter C, 2000, NERVENARZT, V71, P629, DOI 10.1007/s001150050639
   Helmstaedter C, 2003, ANN NEUROL, V54, P425, DOI 10.1002/ana.10692
   Helmstaedter C, 2009, BRAIN, V132, P2822, DOI 10.1093/brain/awp182
   HENDERSON CR, 1986, J ANIM SCI, V63, P208
   Hermann B, 2006, BRAIN, V129, P2609, DOI 10.1093/brain/awl196
   Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872
   Hing B, 2012, BIOL PSYCHIAT, V71, P618, DOI 10.1016/j.biopsych.2011.11.030
   Holmes MD, 1998, EPILEPSIA, V39, P1189, DOI 10.1111/j.1528-1157.1998.tb01310.x
   Honea RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076001
   Hu XL, 2011, CEREB CORTEX, V21, P2158, DOI 10.1093/cercor/bhq284
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Jiang XY, 2005, NEUROPSYCHOPHARMACOL, V30, P1353, DOI 10.1038/sj.npp.1300703
   Jokeit H, 1999, J NEUROL NEUROSUR PS, V67, P44, DOI 10.1136/jnnp.67.1.44
   Kahrizi K, 2009, EUR J HUM GENET, V17, P125, DOI 10.1038/ejhg.2008.159
   Kent GP, 2006, EPILEPSY BEHAV, V9, P469, DOI 10.1016/j.yebeh.2006.07.005
   Kocabas NA, 2011, INT CLIN PSYCHOPHARM, V26, P1, DOI 10.1097/YIC.0b013e32833d18f8
   Lang UE, 2005, PSYCHOPHARMACOLOGY, V180, P95, DOI 10.1007/s00213-004-2137-7
   Laske C, 2011, INT J NEUROPSYCHOPH, V14, P399, DOI 10.1017/S1461145710001008
   Laumet G, 2010, J ALZHEIMERS DIS, V20, P1181, DOI 10.3233/JAD-2010-100126
   LEWONTIN RC, 1964, GENETICS, V49, P49
   Lim YY, 2015, MOL PSYCHIATR, V20, P1322, DOI 10.1038/mp.2014.123
   Lin Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094961
   Liu LX, 2008, PSYCHIAT GENET, V18, P267, DOI 10.1097/YPG.0b013e3283060f59
   Liu M, 2012, ACTA BIOCH BIOPH SIN, V44, P476, DOI 10.1093/abbs/gms023
   Lu T, 2014, NATURE, V507, P448, DOI 10.1038/nature13163
   Marson AG, 2007, LANCET, V369, P1016, DOI 10.1016/S0140-6736(07)60461-9
   Marson AG, 2007, LANCET, V369, P1000, DOI 10.1016/S0140-6736(07)60460-7
   McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295
   Meador KJ, 2002, NEUROLOGY, V58, pS21, DOI 10.1212/WNL.58.8_suppl_5.S21
   Mercader JM, 2007, GENES BRAIN BEHAV, V6, P706, DOI 10.1111/j.1601-183X.2007.00301.x
   Miyajima F, 2008, GENES BRAIN BEHAV, V7, P714, DOI 10.1111/j.1601-183X.2008.00409.x
   Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x
   Motamedi G, 2003, EPILEPSY BEHAV, V4, pS25, DOI 10.1016/j.yebeh.2003.07.004
   NIBUYA M, 1995, J NEUROSCI, V15, P7539
   Nishimura K, 2007, BIOCHEM BIOPH RES CO, V356, P200, DOI 10.1016/j.bbrc.2007.02.135
   Paller KA, 1997, J COGNITIVE NEUROSCI, V9, P277, DOI 10.1162/jocn.1997.9.2.277
   Palm K, 1998, J NEUROSCI, V18, P1280
   Park SP, 2008, J CLIN NEUROL, V4, P99, DOI 10.3988/jcn.2008.4.3.99
   PATTERSON HD, 1971, BIOMETRIKA, V58, P545, DOI 10.1093/biomet/58.3.545
   Pencea V, 2001, J NEUROSCI, V21, P6706
   Piazzini A, 2006, EPILEPSY RES, V72, P89, DOI 10.1016/j.eplepsyres.2006.04.004
   Pruunsild P, 2011, J NEUROSCI, V31, P3295, DOI 10.1523/JNEUROSCI.4540-10.2011
   Quinn JP, 2002, REGUL PEPTIDES, V108, P135, DOI 10.1016/S0167-0115(02)00103-9
   Ray MT, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.26
   Rhie SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063925
   Roopra A, 2001, Mol Interv, V1, P219
   Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016
   SEARLE SR, 1989, J ANIM BREED GENET, V106, P1, DOI 10.1111/j.1439-0388.1989.tb00209.x
   Shimojo M, 2006, J NEUROCHEM, V96, P1130, DOI 10.1111/j.1471-4159.2005.03608.x
   Spencer EM, 2006, NEUROBIOL DIS, V24, P41, DOI 10.1016/j.nbd.2006.04.020
   Tateno M, 2008, PSYCHIAT INVEST, V5, P21, DOI 10.4306/pi.2008.5.1.21
   Taylor J, 2010, EPILEPSY BEHAV, V18, P397, DOI 10.1016/j.yebeh.2010.05.007
   Taylor J, 2010, EPILEPSIA, V51, P48, DOI 10.1111/j.1528-1167.2009.02195.x
   Tellez-Zenteno JF, 2007, EPILEPSIA, V48, P2336
   Thompson M, 2011, J PSYCHIATR NEUROSCI, V36, P195, DOI 10.1503/jpn.100048
   Thompson PJ, 2005, EPILEPSIA, V46, P1780, DOI 10.1111/j.1528-1167.2005.00279.x
   Tsolaki M, 2014, EUR J CLIN NUTR, V68, P1186, DOI 10.1038/ejcn.2014.189
   Tzschach A, 2006, HUM MUTAT, V27, P389, DOI 10.1002/humu.9420
   Voineskos AN, 2011, ARCH GEN PSYCHIAT, V68, P198, DOI 10.1001/archgenpsychiatry.2010.194
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Weinstock-Guttman Bianca, 2011, Pathophysiology, V18, P43, DOI 10.1016/j.pathophys.2010.04.005
   Zai CC, 2010, PROG NEURO-PSYCHOPH, V34, P1412, DOI 10.1016/j.pnpbp.2010.07.019
   Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219
NR 93
TC 8
Z9 8
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD JAN
PY 2016
VL 54
BP 117
EP 127
DI 10.1016/j.yebeh.2015.11.013
PG 11
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA DB3PZ
UT WOS:000368425000020
PM 26708060
OA Green Published, Green Accepted, Other Gold
DA 2020-12-17
ER

PT J
AU Nakamura, CA
   Roberts, P
   Beadsworth, M
   O'Brien, S
   Pirmohamed, M
   Hughes, D
   Miyajima, F
AF Nakamura, C. A.
   Roberts, P.
   Beadsworth, M.
   O'Brien, S.
   Pirmohamed, M.
   Hughes, D.
   Miyajima, F.
TI HEALTH-ECONOMIC EVALUATION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) AND
   EPIDEMIOLOGY IN ENGLAND AND MERSEYSIDE
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Nakamura, C. A.; O'Brien, S.; Pirmohamed, M.; Miyajima, F.] Univ Liverpool, Liverpool, Merseyside, England.
   [Roberts, P.; Beadsworth, M.] Royal Liverpool & Broadgreen Univ Hosp Trust, Liverpool, Merseyside, England.
   [Hughes, D.] Bangor Univ, Bangor, Gwynedd, Wales.
RI Pirmohamed, Munir/H-6004-2011; Miyajima, Fabio/K-6587-2012; Hughes,
   Dyfrig/H-5252-2012
OI Pirmohamed, Munir/0000-0002-7534-7266; Miyajima,
   Fabio/0000-0002-1347-4825; Hughes, Dyfrig/0000-0001-8247-7459
FU Medical Research CouncilMedical Research Council UK (MRC) [G0700654,
   MR/K000551/1, MR/L006758/1] Funding Source: Medline; National Institute
   for Health ResearchNational Institute for Health Research (NIHR)
   [NF-SI-0512-10064] Funding Source: researchfish
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD NOV
PY 2015
VL 18
IS 7
MA PIN37
BP A582
EP A582
DI 10.1016/j.jval.2015.09.1947
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA V46CC
UT WOS:000209861300430
PM 26533270
OA Bronze
DA 2020-12-17
ER

PT J
AU Senoh, M
   Kato, H
   Fukuda, T
   Niikawa, A
   Hori, Y
   Hagiya, H
   Ito, Y
   Miki, H
   Abe, Y
   Furuta, K
   Takeuchi, H
   Tajima, H
   Tominaga, H
   Satomura, H
   Kato, H
   Morita, S
   Tanada, A
   Hara, T
   Kawada, M
   Sato, Y
   Takahashi, M
   Higuchi, A
   Nakajima, T
   Wakamatsu, Y
   Toyokawa, M
   Ueda, A
   Roberts, P
   Miyajima, F
   Shibayamal, K
AF Senoh, Mitsutoshi
   Kato, Haru
   Fukuda, Tadashi
   Niikawa, Akiko
   Hori, Yoshiko
   Hagiya, Hideharu
   Ito, Yoichiro
   Miki, Hiroshi
   Abe, Yoshifumi
   Furuta, Kiyoshi
   Takeuchi, Hideki
   Tajima, Hirokazu
   Tominaga, Harumi
   Satomura, Hideyuki
   Kato, Hideaki
   Morita, Sayuri
   Tanada, Ai
   Hara, Toshinori
   Kawada, Miki
   Sato, Yuka
   Takahashi, Masahiko
   Higuchi, Akiko
   Nakajima, Tomoko
   Wakamatsu, Yukiko
   Toyokawa, Masahiro
   Ueda, Akiko
   Roberts, Paul
   Miyajima, Fabio
   Shibayamal, Keigo
TI Predominance of PCR-ribotypes, 018 (smz) and 369 (trf) of Clostridium
   difficile in Japan: a potential relationship with other global
   circulating strains?
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID ANTIMICROBIAL RESISTANCE; CLOSTFIDIUM-DIFFICILE; INFECTION;
   EPIDEMIOLOGY; EMERGENCE; TOXIN; MULTICENTER; HOSPITALS; DIARRHEA; GENE
AB Global spread and evolutionary links of an epidemic Clostridium difficile strain (PCR-ribotype 027) have been noted in recent decades. However, in Japan, no outbreaks caused by type 027 have been reported to date. A total of 120 C. difficile isolates from patients at 15 hospitals during non-outbreak seasons between 2011 and 2013 as well as 18 and 21 isolates collected from two hospitals in 2010 and 2009, respectively, in outbreak periods in Japan, were examined. Among these 120 isolates, Japan-ribotypes smz and ysmz (subtype variant of smz) were the most predominant (39.2 %) followed by Japan-ribotype trf (15.8 %). Types smz/ysmz and trf were also concurrently predominant at two hospitals in the outbreak settings. Out of the five binary toxin-positive isolates observed, only one was PCR-ribotype 027 and another PCR-ribotype 078. Type smz was later found to correspond to PCR-ribotype 018. High rates of resistance against gatifloxacin, moxifloxacin, erythromycin and clindamycin were observed in the PCR-ribotype 018 isolates. Interestingly, all trf isolates were toxin A-negative, toxin B-positive, but they did not correspond to PCR-ribotype 017, thus being assigned a new ribotype (PCR-ribotype 369). In conclusion, PCR-ribotypes 018 (smz) and 369 (trf) were identified as major circulating strains in both outbreak and non-outbreak settings in Japan. Given their epidemiological relevance, molecular investigations are warranted to clarify potential evolutionary links with related strains found elsewhere, such as PCR-ribotypes 018 and 017 from Europe and North America.
C1 [Senoh, Mitsutoshi; Kato, Haru; Fukuda, Tadashi; Shibayamal, Keigo] Natl Inst Infect Dis, Dept Bacteriol 2, Tokyo, Japan.
   [Niikawa, Akiko] Ishikawa Prefectural Cent Hosp, Ishikawa, Japan.
   [Hori, Yoshiko] Okayama Saiseikai Gen Hosp, Okayama, Japan.
   [Hagiya, Hideharu] Tsuyama Chuo Hosp, Okayama, Japan.
   [Ito, Yoichiro] Japanese Red Cross Gifu Hosp, Gifu, Japan.
   [Miki, Hiroshi; Abe, Yoshifumi] NHO Sendai Med Ctr, Miyagi, Japan.
   [Furuta, Kiyoshi; Takeuchi, Hideki] NHO Matsumoto Med Ctr, Nagano, Japan.
   [Tajima, Hirokazu] Aichi Canc Ctr Hosp, Aichi, Japan.
   [Tominaga, Harumi] NHO Kure Med Ctr, Hiroshima, Japan.
   [Satomura, Hideyuki] Chiba Canc Ctr, Chiba 2608717, Japan.
   [Kato, Hideaki; Morita, Sayuri; Tanada, Ai] Toyokawa City Hosp, Aichi, Japan.
   [Hara, Toshinori] Hiroshima Univ Hosp, Hiroshima, Japan.
   [Kawada, Miki] Saitama City Hosp, Saitama, Japan.
   [Takahashi, Masahiko; Higuchi, Akiko] NHO Tokyo Med Ctr, Tokyo, Japan.
   [Nakajima, Tomoko; Wakamatsu, Yukiko] Tsuruoka Municipal Shonai Hosp, Yamagata, Japan.
   [Toyokawa, Masahiro; Ueda, Akiko] Osaka Univ Hosp, Osaka 553, Japan.
RP Kato, H (corresponding author), Natl Inst Infect Dis, Dept Bacteriol 2, Tokyo, Japan.
EM cato@nih.go.jp
RI Miyajima, Fabio/K-6587-2012
OI Miyajima, Fabio/0000-0002-1347-4825
FU Japan Agency for Medical Research and Development, AMEDJapan Agency for
   Medical Research and Development (AMED); Medical Research CouncilMedical
   Research Council UK (MRC) [MR/K000551/1] Funding Source: researchfish
FX We thank Dr V. Hall (Public Health Wales, Cardiff, UK) for analysing
   ribotype 369 (trf) isolate and Dr S. Suzuki (National Institute of
   Infectious Diseases, Tokyo, Japan) for her helpful comments. The
   technical assistance of S. Yonamine, K. Kai, Y. Taki and Y. Yoshimura is
   gratefully acknowledged. This work was supported by a grant (Research
   Program on Emerging and Re-emerging Infectious Diseases) from the Japan
   Agency for Medical Research and Development, AMED. The authors declare
   no conflicts of interest.
CR Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4
   Cheng VCC, 2011, EUR J CLIN MICROBIOL, V30, P1371, DOI 10.1007/s10096-011-1231-0
   Clinical and Laboratory Standards Institute (CLSI), 2014, M100S24 CLSI
   Davies KA, 2014, LANCET INFECT DIS, V14, P1208, DOI 10.1016/S1473-3099(14)70991-0
   Drudy D, 2007, CLIN MICROBIOL INFEC, V13, P298, DOI 10.1111/j.1469-0691.2006.01634.x
   Freeman J, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2014.09.017
   Goorhuis A, 2009, CLIN MICROBIOL INFEC, V15, P1080, DOI 10.1111/j.1469-0691.2009.02759.x
   Goorhuis A, 2008, CLIN INFECT DIS, V47, P1162, DOI 10.1086/592257
   Han SH, 2014, J MED MICROBIOL, V63, P1542, DOI 10.1099/jmm.0.070672-0
   Hawkey PM, 2013, J CLIN MICROBIOL, V51, P3308, DOI 10.1128/JCM.00587-13
   He M, 2013, NAT GENET, V45, P109, DOI 10.1038/ng.2478
   Iwashima Y, 2010, J INFECT CHEMOTHER, V16, P329, DOI 10.1007/s10156-010-0066-4
   Janezic S, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-173
   Kato H, 2005, J CLIN MICROBIOL, V43, P6108, DOI 10.1128/JCM.43.12.6108-6112.2005
   Kato H, 2001, J MED MICROBIOL, V50, P720, DOI 10.1099/0022-1317-50-8-720
   Kato H, 2001, J CLIN MICROBIOL, V39, P1391, DOI 10.1128/JCM.39.4.1391-1395.2001
   KATO H, 2007, EUROSURVEILLANCE, V12, P70113
   Kato H, 2010, J MED MICROBIOL, V59, P556, DOI 10.1099/jmm.0.016147-0
   Killgore G, 2008, J CLIN MICROBIOL, V46, P431, DOI 10.1128/JCM.01484-07
   Komatsu M, 2003, EUR J CLIN MICROBIOL, V22, P525, DOI 10.1007/s10096-003-0992-5
   Lee JH, 2014, J MED MICROBIOL, V63, P819, DOI 10.1099/jmm.0.072082-0
   Louie TJ, 2011, NEW ENGL J MED, V364, P422, DOI 10.1056/NEJMoa0910812
   Miller M, 2010, CLIN INFECT DIS, V50, P194, DOI 10.1086/649213
   Nishimura S, 2014, J INFECT CHEMOTHER, V20, P729, DOI 10.1016/j.jiac.2014.07.004
   Niwa H, 2013, VET REC, V173, P607, DOI 10.1136/vr.101960
   Pasquale V, 2012, FOOD MICROBIOL, V31, P309, DOI 10.1016/j.fm.2012.03.001
   Pituch H, 2011, J MED MICROBIOL, V60, P1200, DOI 10.1099/jmm.0.029801-0
   Sato Hiroko, 2004, Kansenshogaku Zasshi, V78, P312
   Sawabe E, 2007, EUR J CLIN MICROBIOL, V26, P695, DOI 10.1007/s10096-007-0355-8
   Shin BM, 2008, J MED MICROBIOL, V57, P697, DOI 10.1099/jmm.0.47771-0
   Spigaglia P, 2011, J ANTIMICROB CHEMOTH, V66, P2227, DOI 10.1093/jac/dkr292
   Spigaglia P, 2010, J CLIN MICROBIOL, V48, P2892, DOI 10.1128/JCM.02482-09
   Stubbs S, 2000, FEMS MICROBIOL LETT, V186, P307, DOI 10.1111/j.1574-6968.2000.tb09122.x
   Stubbs SLJ, 1999, J CLIN MICROBIOL, V37, P461, DOI 10.1128/JCM.37.2.461-463.1999
   Tenover FC, 2010, J CLIN MICROBIOL, V48, P3719, DOI 10.1128/JCM.00427-10
   Tickler IA, 2014, ANTIMICROB AGENTS CH, V58, P4214, DOI 10.1128/AAC.02775-13
   Usui M, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00513
   Walker AS, 2013, CLIN INFECT DIS, V56, P1589, DOI 10.1093/cid/cit127
   Wilcox MH, 2012, CLIN INFECT DIS, V55, P1056, DOI 10.1093/cid/cis614
NR 39
TC 33
Z9 34
U1 0
U2 6
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-2615
EI 1473-5644
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD OCT
PY 2015
VL 64
BP 1226
EP 1236
DI 10.1099/jmm.0.000149
PN 10
PG 11
WC Microbiology
SC Microbiology
GA CX1MS
UT WOS:000365460900015
PM 26238868
OA Bronze
DA 2020-12-17
ER

PT J
AU Mirza, N
   Appleton, R
   Burn, S
   Carr, D
   Crooks, D
   du Plessis, D
   Duncan, R
   Farah, JO
   Josan, V
   Miyajima, F
   Mohanraj, R
   Shukralla, A
   Sills, GJ
   Marson, AG
   Pirmohamed, M
AF Mirza, Nasir
   Appleton, Richard
   Burn, Sasha
   Carr, Daniel
   Crooks, Daniel
   du Plessis, Daniel
   Duncan, Roderick
   Farah, Jibril Osman
   Josan, Vivek
   Miyajima, Fabio
   Mohanraj, Rajiv
   Shukralla, Arif
   Sills, Graeme J.
   Marson, Anthony G.
   Pirmohamed, Munir
TI Identifying the biological pathways underlying human focal epilepsy:
   from complexity to coherence to centrality
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID TEMPORAL-LOBE EPILEPSY; KAPPA-OPIOID RECEPTORS; GENOME-WIDE ASSOCIATION;
   GENE-EXPRESSION; TRANSCRIPTOMIC ANALYSIS; DRUG DISCOVERY; BRAIN-TISSUE;
   NETWORK; SEIZURES; ANTICONVULSANT
AB Numerous diverse biological pathways are dysregulated in the epileptic focus. Which of these pathways are most critical in producing the biological abnormalities that lead to epilepsy? Answering this question is key to identifying the primary causes of epilepsy and for discovering new therapeutic strategies with greater efficacy than currently available antiepileptics (AEDs). We have performed the largest genome-wide transcriptomic analysis to date comparing epileptic with normal human hippocampi. We have identified 118 differentially expressed and, for the first time, differentially connected pathways in the epileptic focus. Using network mapping techniques, we have shown that these dysregulated pathways, though seemingly disparate, form a coherent interconnected central network. Using closeness centrality analysis, we have identified that the most influential hub pathways in this network are signalling through G protein-coupled receptors, in particular opioid receptors, and their downstream effectors PKA/CREB and DAG/IP3. Next, we have objectively demonstrated that genetic association of gene sets in independent genome-wide association studies(GWASs) can be used to identify causally relevant gene sets: we show that proven causal epilepsy genes, which cause familial Mendelian epilepsy syndromes, are associated in published sporadic epilepsy GWAS results. Using the same technique, we have shown that central pathways identified (opioid receptor and PKA/CREB and DAG/IP3 signalling pathways) are genetically associated with focal epilepsy and, hence, likely causal. Published functional studies in animal models provide evidence of a role for these pathways in epilepsy. Our work shows that these pathways play a central role in human focal epilepsy and that they are important currently unexploited antiepileptic drug targets.
C1 [Mirza, Nasir; Carr, Daniel; Miyajima, Fabio; Sills, Graeme J.; Marson, Anthony G.; Pirmohamed, Munir] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GL, Merseyside, England.
   [Appleton, Richard] Alder Hey Childrens NHS Fdn Trust, Paediat Neurosci Fdn, Roald Dahl EEG Unit, Liverpool L12 2AP, Merseyside, England.
   [Burn, Sasha] Alder Hey Childrens NHS Fdn Trust, Dept Neurosurg, Liverpool L12 2AP, Merseyside, England.
   [Crooks, Daniel] Walton Ctr NHS Fdn Trust, Dept Neuropathol, Liverpool L9 7LJ, Merseyside, England.
   [du Plessis, Daniel] Salford Royal NHS Fdn Trust, Dept Cellular Pathol, Salford M6 8HD, Lancs, England.
   [Duncan, Roderick] Christchurch Hosp, Dept Neurol, Christchurch 8140, New Zealand.
   [Farah, Jibril Osman] Walton Ctr NHS Fdn Trust, Dept Neurosurg, Liverpool L9 7LJ, Merseyside, England.
   [Josan, Vivek] Salford Royal NHS Fdn Trust, Dept Neurosurg, Salford M6 8HD, Lancs, England.
   [Mohanraj, Rajiv; Shukralla, Arif] Salford Royal NHS Fdn Trust, Dept Neurol, Salford M6 8HD, Lancs, England.
RP Mirza, N (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
EM nasir.mirza@liv.ac.uk
RI Marson, Anthony/AAW-9776-2020; Miyajima, Fabio/K-6587-2012; Pirmohamed,
   Munir/H-6004-2011
OI Marson, Anthony/0000-0002-6861-8806; Miyajima,
   Fabio/0000-0002-1347-4825; Pirmohamed, Munir/0000-0002-7534-7266; Sills,
   Graeme/0000-0002-3389-8713; Carr, Daniel/0000-0001-8028-4282; Mohanraj,
   Rajiv/0000-0002-2559-148X
FU Medical Research CouncilMedical Research Council UK (MRC); NHS Chair of
   Pharmacogenetics; MRC Centre for Drug Safety Science; Medical Research
   CouncilMedical Research Council UK (MRC) [G0900385, MR/L006758/1]
   Funding Source: researchfish; National Institute for Health
   ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10064]
   Funding Source: researchfish
FX N.M. was funded by a Medical Research Council Research Training
   Fellowship. M.P. is an NIHR Senior Investigator and acknowledges the
   support from the NHS Chair of Pharmacogenetics and the MRC Centre for
   Drug Safety Science.
CR Amar D, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002955
   Anney RJL, 2014, LANCET NEUROL, V13, P893, DOI 10.1016/S1474-4422(14)70171-1
   Arion D, 2006, NEUROBIOL DIS, V22, P374, DOI 10.1016/j.nbd.2005.12.012
   Becker AJ, 2003, EUR J NEUROSCI, V18, P2792, DOI 10.1111/j.1460-9568.2003.02993.x
   Becker AJ, 2002, NEUROREPORT, V13, P1327, DOI 10.1097/00001756-200207190-00023
   Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x
   Choi Y, 2009, BIOINFORMATICS, V25, P2780, DOI 10.1093/bioinformatics/btp502
   Cuellar-Herrera M, 2012, HIPPOCAMPUS, V22, P122, DOI 10.1002/hipo.20891
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Eishingdrelo Haifeng, 2013, Curr Chem Genom Transl Med, V7, P9, DOI 10.2174/2213988501307010009
   Emery AC, 2013, ADV PHARMACOL, V68, P335, DOI 10.1016/B978-0-12-411512-5.00016-6
   Fang Ye, 2004, Drug Discov Today, V9, pS61
   Fichna J, 2013, PROG NEURO-PSYCHOPH, V40, P126, DOI 10.1016/j.pnpbp.2012.07.020
   Flight RM, 2010, OMICS, V14, P99, DOI 10.1089/omi.2009.0096
   FREEMAN LC, 1979, SOC NETWORKS, V1, P215, DOI 10.1016/0378-8733(78)90021-7
   Gao WJ, 2006, EXP NEUROL, V197, P495, DOI 10.1016/j.expneurol.2005.05.018
   Hammers A, 2007, BRAIN, V130, P1009, DOI 10.1093/brain/awm012
   Heinig M, 2010, NATURE, V467, P460, DOI 10.1038/nature09386
   Huang L, 2014, BIOINFORMATICS, V30, P228, DOI 10.1093/bioinformatics/btu278
   Jamali S, 2006, BRAIN, V129, P625, DOI 10.1093/brain/awl001
   Jassal B, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq018
   Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138
   Johnson MR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7031
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kai T, 1998, NEUROCHEM RES, V23, P163, DOI 10.1023/A:1022424707543
   Kaminski RM, 2007, NEUROPHARMACOLOGY, V52, P895, DOI 10.1016/j.neuropharm.2006.10.007
   Kasperaviciute D, 2010, BRAIN, V133, P2136, DOI 10.1093/brain/awq130
   Kelder T, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-127
   Leach NT, 2007, AM J HUM GENET, V80, P792, DOI 10.1086/513019
   LEE RJ, 1984, NEUROPHARMACOLOGY, V23, P517, DOI 10.1016/0028-3908(84)90024-8
   LEE RJ, 1987, BRAIN RES, V401, P353, DOI 10.1016/0006-8993(87)91420-X
   Lee TS, 2007, MOL MED, V13, P1, DOI 10.2119/2006-00079.Lee
   Li Y, 2008, BIOINFORMATICS, V24, P1442, DOI 10.1093/bioinformatics/btn200
   Liang WS, 2008, PHYSIOL GENOMICS, V33, P240, DOI 10.1152/physiolgenomics.00242.2007
   Loacker S, 2007, BRAIN, V130, P1017, DOI 10.1093/brain/awl384
   Lundstrom K, 2009, METHODS MOL BIOL, V552, P51, DOI 10.1007/978-1-60327-317-6_4
   Matsumoto M, 1999, J MOL MED, V77, P406, DOI 10.1007/s001090050370
   Mazarati A, 1999, NEUROSCIENCE, V89, P167, DOI 10.1016/S0306-4522(98)00320-0
   McDermott CM, 2011, J PHYSIOL-LONDON, V589, P3517, DOI 10.1113/jphysiol.2011.211623
   Mentzen WI, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-601
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mirza N, 2011, HUM MOL GENET, V20, P4381, DOI 10.1093/hmg/ddr365
   Nam D, 2010, NUCLEIC ACIDS RES, V38, pW749, DOI 10.1093/nar/gkq428
   Ozgur A, 2008, BIOINFORMATICS, V24, pI277, DOI 10.1093/bioinformatics/btn182
   Ozbas-Gerceker F, 2006, NEUROSCIENCE, V138, P457, DOI 10.1016/j.neuroscience.2005.11.043
   Parikshak NN, 2013, CELL, V155, P1008, DOI 10.1016/j.cell.2013.10.031
   Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908
   PRZEWLOCKA B, 1995, NEUROSCI LETT, V186, P131, DOI 10.1016/0304-3940(95)11303-E
   Rogawski Michael A, 2008, Epilepsy Curr, V8, P127, DOI 10.1111/j.1535-7511.2008.00272.x
   Roussos P, 2012, ARCH GEN PSYCHIAT, V69, P1205, DOI 10.1001/archgenpsychiatry.2012.704
   SANDER JW, 2003, EPILEPSIA S1, V44, P17
   Schmidt D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g254
   Schunk E, 2011, HIPPOCAMPUS, V21, P1010, DOI 10.1002/hipo.20813
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Spataro N, 2015, HUM MOL GENET, V24, P2023, DOI 10.1093/hmg/ddu616
   Speed D, 2014, BRAIN, V137, P2680, DOI 10.1093/brain/awu206
   Tellez-Zenteno JF, 2014, EPILEPSIA, V55, P829, DOI 10.1111/epi.12633
   Teschendorff AE, 2011, BIOINFORMATICS, V27, P1496, DOI 10.1093/bioinformatics/btr171
   van Gassen KLI, 2008, EPILEPSIA, V49, P1055, DOI 10.1111/j.1528-1167.2007.01470.x
   Venugopal AK, 2012, J PROTEOM BIOINFORM, V5, DOI [10.4172/jpb.1000210, DOI 10.4172/JPB.1000210]
   Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110
   Xiao F, 2008, BRAIN RES, V1233, P168, DOI 10.1016/j.brainres.2008.07.101
   Yang Q, 2012, J SURG RES, V176, P549, DOI 10.1016/j.jss.2011.09.052
   Yang S, 2006, CANCER INFORM, V2, P351
   Yang Xinan, 2006, Journal of Bioinformatics and Computational Biology, V4, P693, DOI 10.1142/S0219720006002120
   Zhu XJ, 2012, NEUROBIOL DIS, V45, P253, DOI 10.1016/j.nbd.2011.08.009
NR 66
TC 13
Z9 13
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2015
VL 24
IS 15
BP 4306
EP 4316
DI 10.1093/hmg/ddv163
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CR4OK
UT WOS:000361314100011
PM 25941323
OA Bronze
DA 2020-12-17
ER

PT J
AU Lemos, L
   Miyajima, F
   Martins, DTD
   Pritchard, DM
   Burkitt, MD
AF Lemos, L.
   Miyajima, F.
   Tabajara de Oliveira Martins, D.
   Pritchard, D. M.
   Burkitt, M. D.
TI HEXANE EXTRACTS OF CALOPHYLLUM BRASILIENSE INHIBIT THE DEVELOPMENT OF
   GASTRIC PRENEOPLASIA IN HELICOBACTER FELIS INFECTED INS-GAS MICE
SO GUT
LA English
DT Meeting Abstract
CT 2nd Digestive-Disorders-Federation Conference
CY JUN 22-25, 2015
CL London, ENGLAND
SP Digest Disorders Federat
C1 [Lemos, L.; Tabajara de Oliveira Martins, D.] Univ Fed Mato Grosso, Dept Biol Basic Sci, Mato Grosso, Brazil.
   [Lemos, L.; Pritchard, D. M.; Burkitt, M. D.] Univ Liverpool, Dept Mol & Cellular Physiol, Gastroenterol Res Unit, Liverpool L69 3BX, Merseyside, England.
   [Miyajima, F.] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England.
RI Lemos, Larissa/AAM-7217-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2015
VL 64
SU 1
MA PTH-165
BP A481
EP A481
DI 10.1136/gutjnl-2015-309861.1053
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CS3EH
UT WOS:000361954002041
DA 2020-12-17
ER

PT J
AU Queiroz, CJD
   Ydy, LRA
   Miyajima, F
   Jenkins, J
AF dos Santos Queiroz, Cleberson Jean
   Ydy, Lenuce Ribeiro Aziz
   Miyajima, Fabio
   Jenkins, John
TI Immunohistochemical validation of novel candidate biomarkers for
   colorectal cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Liverpool, Inst Translat Med, Liverpool L69 3BX, Merseyside, England.
   Univ Fed Mato Grosso, Cuiaba, Brazil.
   Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England.
   Univ Liverpool, Dept Gastroenterol, Liverpool L69 3BX, Merseyside, England.
RI Miyajima, Fabio/K-6587-2012
OI Miyajima, Fabio/0000-0002-1347-4825
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e22251
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904617
DA 2020-12-17
ER

PT J
AU Swale, A
   Miyajima, F
   Kolamunnage-Dona, R
   Roberts, P
   Little, M
   Beeching, NJ
   Beadsworth, MBJ
   Liloglou, T
   Pirmohamed, M
AF Swale, Andrew
   Miyajima, Fabio
   Kolamunnage-Dona, Ruwanthi
   Roberts, Paul
   Little, Margaret
   Beeching, Nicholas J.
   Beadsworth, Mike B. J.
   Liloglou, Triantafillos
   Pirmohamed, Munir
TI Serum Mannose-Binding Lectin Concentration, but Not Genotype, Is
   Associated With Clostridium difficile Infection Recurrence: A
   Prospective Cohort Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Clostridium difficile; CDI; MBL; disease recurrence
ID PROTEIN; GENE; VARIANTS; PROMOTER; MBL2; INFLAMMATION; PREDICTORS;
   DEFICIENCY; INCREASES; SEVERITY
AB Background. Mannose-binding lectin (MBL) plays a key role in the activation of the lectin-complement pathway of innate immunity, and its deficiency has been linked with several acute infections. However, its role in predisposing to, or modulating disease severity in, Clostridium difficile infection (CDI) has not been investigated.
   Methods. We prospectively recruited 308 CDI case patients and 145 control patients with antibiotic-associated diarrhea (AAD). CDI outcome measures were disease severity, duration of symptoms, 30-day mortality, and 90-day recurrence. Serum concentrations of MBL were determined using a commercial enzyme-linked immunosorbent assay transferred to an electrochemiluminescence-based platform. MBL2 polymorphisms were typed using a combination of pyrosequencing and TaqMan genotyping assays.
   Results. The frequency of the MBL2 genetic variants was similar to that reported in other white populations. MBL serum concentrations in CDI and AAD subjects were determined by MBL2 exonic variants B, C, and D and the haplotypes (LYPB, LYQC, and HYPD). There was no difference in either MBL concentrations or genotypes between cases and controls. MBL concentration, but not genotype, was a determinant of CDI recurrence (odds ratios, 3.18 [95% confidence interval {CI}, 1.40-7.24] and 2.61 [95% CI, 1.35-5.04] at the <50 ng/mL and <100 ng/mL cutoff points, respectively; P<.001). However, neither MBL concentration nor MBL2 genotype was linked with the other CDI outcomes.
   Conclusions. Serum MBL concentration did not differentiate between CDI cases and AAD controls, but among CDI cases, MBL concentration, but not genotype, was associated with CDI recurrence, indicating that MBL acts as a modulator of disease, rather than a predisposing factor.
C1 [Swale, Andrew; Miyajima, Fabio; Little, Margaret; Pirmohamed, Munir] Univ Liverpool, Wolfson Ctr Personalised Med, Liverpool L69 3GL, Merseyside, England.
   [Swale, Andrew; Miyajima, Fabio; Roberts, Paul; Little, Margaret; Beeching, Nicholas J.; Beadsworth, Mike B. J.; Pirmohamed, Munir] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England.
   [Kolamunnage-Dona, Ruwanthi] Univ Liverpool, Dept Biostat, Liverpool L69 3GL, Merseyside, England.
   [Beeching, Nicholas J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L69 3GL, Merseyside, England.
   [Beeching, Nicholas J.] Univ Liverpool, Hlth Protect Unit Gastrointestinal Infect, Natl Inst Hlth Res, Liverpool L69 3GL, Merseyside, England.
   [Liloglou, Triantafillos] Univ Liverpool, Canc Res Ctr, Liverpool L69 3GL, Merseyside, England.
RP Miyajima, F (corresponding author), Univ Liverpool, Wolfson Ctr Personalised Med, 1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
EM fabio@liv.ac.uk
RI Kolamunnage-Dona, Ruwanthi/W-7979-2019; Beeching, Nicholas
   J/L-5363-2017; Miyajima, Fabio/K-6587-2012; Pirmohamed,
   Munir/H-6004-2011
OI Kolamunnage-Dona, Ruwanthi/0000-0003-3886-6208; Miyajima,
   Fabio/0000-0002-1347-4825; Pirmohamed, Munir/0000-0002-7534-7266;
   Beeching, Nicholas/0000-0002-7019-8791
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   in microbial diseases in Liverpool; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/K000551/1]; NIHRNational Institute for
   Health Research (NIHR) [BRF-2011-028]; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/L006758/1] Funding Source: researchfish;
   National Institute for Health ResearchNational Institute for Health
   Research (NIHR) [NF-SI-0512-10064, BRF-2011-028] Funding Source:
   researchfish
FX This work was funded by the National Institute for Health Research
   (NIHR) Biomedical Research Centre in microbial diseases in Liverpool,
   and by the Medical Research Council (MR/K000551/1). We would also like
   to thank the NIHR for PhD student funding for Andrew Swale
   (BRF-2011-028). M. P. is an NIHR Senior Investigator.
CR Adamek M, 2013, TISSUE ANTIGENS, V82, P410, DOI 10.1111/tan.12232
   Bernig T, 2004, GENES IMMUN, V5, P461, DOI 10.1038/sj.gene.6364116
   Buonomo EL, 2013, J INFECT DIS, V208, P917, DOI 10.1093/infdis/jit277
   Butt E, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-316
   Chalmers JD, 2013, LANCET RESP MED, V1, P224, DOI 10.1016/S2213-2600(13)70001-8
   Dean MM, 2005, J CLIN IMMUNOL, V25, P346, DOI 10.1007/s10875-005-4702-1
   Dommett RM, 2006, TISSUE ANTIGENS, V68, P193, DOI 10.1111/j.1399-0039.2006.00649.x
   Eisen DP, 2008, CLIN INFECT DIS, V47, P510, DOI 10.1086/590006
   El Feghaly RE, 2013, CLIN INFECT DIS, V56, P1713, DOI 10.1093/cid/cit147
   Eyre DW, 2012, CLIN INFECT DIS, V55, pS77, DOI 10.1093/cid/cis356
   Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283
   Garred P, 2002, PEDIATR PULM, V33, P201, DOI 10.1002/ppul.10064
   Grondahl-Yli-Hannuksela K, 2013, APMIS, V121, P311, DOI 10.1111/apm.12000
   Guo N, 1998, MAMM GENOME, V9, P246, DOI 10.1007/s003359900735
   Harrison E, 2012, INT J IMMUNOGENET, V39, P224, DOI 10.1111/j.1744-313X.2011.01078.x
   Hensgens MPM, 2014, CLIN MICROBIOL INFEC, V20, pO301, DOI 10.1111/1469-0691.12391
   Hirota SA, 2012, INFECT IMMUN, V80, P4474, DOI 10.1128/IAI.00933-12
   Hu MY, 2009, GASTROENTEROLOGY, V136, P1206, DOI 10.1053/j.gastro.2008.12.038
   Ip WKE, 2009, IMMUNOL REV, V230, P9, DOI 10.1111/j.1600-065X.2009.00789.x
   Jack DL, 2001, J INFECT DIS, V184, P1152, DOI 10.1086/323803
   Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x
   Khanafer N, 2013, WORLD J GASTROENTERO, V19, P8034, DOI 10.3748/wjg.v19.i44.8034
   Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316
   Madsen HO, 1998, J IMMUNOL, V161, P3169
   MADSEN HO, 1995, J IMMUNOL, V155, P3013
   Miyajima F, 2014, CLIN INFECT DIS, V58, pE148, DOI 10.1093/cid/ciu152
   Miyajima F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022804
   Moller-Kristensen M, 2006, J IMMUNOL, V176, P1769, DOI 10.4049/jimmunol.176.3.1769
   Osthoff M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/962695
   Public Health England, 2013, UPD GUID MAN TREATM
   Rao K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092578
   Rao K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058265
   Ryan A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002076
   SASTRY R, 1995, MAMM GENOME, V6, P103, DOI 10.1007/BF00303252
   Seibold F, 2004, GASTROENTEROLOGY, V127, P1076, DOI 10.1053/j.gastro.2004.07.056
   Shastri YM, 2008, AM J MED, V121, P1099, DOI 10.1016/j.amjmed.2008.06.034
   Shi L, 2004, J EXP MED, V199, P1379, DOI 10.1084/jem.20032207
   Steffensen R, 2000, J IMMUNOL METHODS, V241, P33, DOI 10.1016/S0022-1759(00)00198-8
   SUPER M, 1989, LANCET, V2, P1236
   Townsend R, 2001, CLIN EXP IMMUNOL, V124, P223, DOI 10.1046/j.1365-2249.2001.01549.x
   Turner MW, 2003, MOL IMMUNOL, V40, P423, DOI 10.1016/S0161-5890(03)00155-X
   Vohra P, 2012, FEMS IMMUNOL MED MIC, V65, P96, DOI 10.1111/j.1574-695X.2012.00952.x
   Wang MY, 2011, CELL MOL IMMUNOL, V8, P265, DOI 10.1038/cmi.2011.1
NR 43
TC 7
Z9 8
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 15
PY 2014
VL 59
IS 10
BP 1429
EP 1436
DI 10.1093/cid/ciu666
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TC
UT WOS:000344646700012
PM 25170052
OA Green Accepted, Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Swale, A
   Miyajima, F
   Roberts, P
   Hall, A
   Little, M
   Beadsworth, MBJ
   Beeching, NJ
   Kolamunnage-Dona, R
   Parry, CM
   Pirmohamed, M
AF Swale, Andrew
   Miyajima, Fabio
   Roberts, Paul
   Hall, Amanda
   Little, Margaret
   Beadsworth, Mike B. J.
   Beeching, Nick J.
   Kolamunnage-Dona, Ruwanthi
   Parry, Chris M.
   Pirmohamed, Munir
TI Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium
   difficile Infection (CDI): A Prospective Cohort Study
SO PLOS ONE
LA English
DT Article
ID INTESTINAL INFLAMMATION; CROHNS-DISEASE; TOXIN-B; BLOOD LEUKOCYTES;
   PSEUDOMEMBRANOUS COLITIS; PROSPECTIVE MULTICENTER; ULCERATIVE-COLITIS;
   ENDOSCOPIC SCORE; ACTIVITY INDEX; DIARRHEA
AB Measurement of both calprotectin and lactoferrin in faeces has successfully been used to discriminate between functional and inflammatory bowel conditions, but evidence is limited for Clostridium difficile infection (CDI). We prospectively recruited a cohort of 164 CDI cases and 52 controls with antibiotic-associated diarrhoea (AAD). Information on disease severity, duration of symptoms, 30-day mortality and 90-day recurrence as markers of complicated CDI were recorded. Specimens were subject to microbiological culture and PCR-ribotyping. Levels of faecal calprotectin (FC) and lactoferrin (FL) were measured by ELISA. Statistical analysis was conducted using percentile categorisation. ROC curve analysis was employed to determine optimal cut-off values. Both markers were highly correlated with each other (r(2) = 0.74) and elevated in cases compared to controls (p < 0.0001; ROC > 0.85), although we observed a large amount of variability across both groups. The optimal case-control cut-off point was 148 mg/kg for FC and 8.1 ng/mu l for FL. Median values for FL in CDI cases were significantly greater in patients suffering from severe disease compared to non-severe disease (104.6 vs. 40.1 ng/mu l, p = 0.02), but were not significant for FC (969.3 vs. 512.7 mg/kg, p = 0.09). Neither marker was associated with 90-day recurrence, prolonged CDI symptoms, positive culture results and colonisation by ribotype 027. Both FC and FL distinguished between CDI cases and AAD controls. Although FL was associated with disease severity in CDI patients, this showed high inter-individual variability and was an isolated finding. Thus, FC and FL are unlikely to be useful as biomarkers of complicated CDI disease.
C1 [Swale, Andrew; Miyajima, Fabio; Little, Margaret; Pirmohamed, Munir] Univ Liverpool, Wolfson Ctr Personalised Med, Liverpool L69 3BX, Merseyside, England.
   [Swale, Andrew; Miyajima, Fabio; Roberts, Paul; Little, Margaret; Beadsworth, Mike B. J.; Beeching, Nick J.; Pirmohamed, Munir] Royal Liverpool & Broadgreen Univ Hosp Trust, Liverpool, Merseyside, England.
   [Hall, Amanda; Parry, Chris M.] Univ Liverpool, Inst Infect & Global Heath, Liverpool L69 3BX, Merseyside, England.
   [Beeching, Nick J.] NIHR Hlth Protect Unit Gastrointestinal Infect, Liverpool, Merseyside, England.
   [Beadsworth, Mike B. J.; Beeching, Nick J.; Parry, Chris M.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Kolamunnage-Dona, Ruwanthi] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England.
RP Pirmohamed, M (corresponding author), Univ Liverpool, Wolfson Ctr Personalised Med, Liverpool L69 3BX, Merseyside, England.
EM munirp@liv.ac.uk
RI Miyajima, Fabio/K-6587-2012; Kolamunnage-Dona, Ruwanthi/W-7979-2019;
   Pirmohamed, Munir/H-6004-2011; Beeching, Nicholas J/L-5363-2017
OI Miyajima, Fabio/0000-0002-1347-4825; Kolamunnage-Dona,
   Ruwanthi/0000-0003-3886-6208; Pirmohamed, Munir/0000-0002-7534-7266;
   Beeching, Nicholas/0000-0002-7019-8791
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   in microbial diseases in Liverpool; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/K000551/1]; NIHRNational Institute for
   Health Research (NIHR) [BRF-2011-028]; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/L006758/1] Funding Source: researchfish;
   National Institute for Health ResearchNational Institute for Health
   Research (NIHR) [BRF-2011-028, NF-SI-0512-10064] Funding Source:
   researchfish
FX This work was funded by the National Institute for Health Research
   (NIHR) Biomedical Research Centre in microbial diseases in Liverpool,
   and by the Medical Research Council [MR/K000551/1]. The authors would
   also like to thank the NIHR for PhD student funding for Andrew Swale
   [BRF-2011-028]. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Archbald-Pannone L, 2010, J AM MED DIR ASSOC, V11, P263, DOI 10.1016/j.jamda.2009.09.006
   Babcock GJ, 2006, INFECT IMMUN, V74, P6339, DOI 10.1128/IAI.00982-06
   BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003
   Bidet P, 1999, FEMS MICROBIOL LETT, V175, P261, DOI 10.1016/S0378-1097(99)00204-9
   Boone JH, 2013, EUR J CLIN MICROBIOL, V32, P1517, DOI 10.1007/s10096-013-1905-x
   Boone JH, 2012, US: Techlab, Inc. Patent, Patent No. [US20120276060 A1, 20120276060]
   Caplin B, 2011, NEPHROL DIAL TRANSPL, V26, P2656, DOI 10.1093/ndt/gfq763
   Costa F, 2003, DIGEST LIVER DIS, V35, P642, DOI 10.1016/S1590-8658(03)00381-5
   D'Inca R, 2007, INT J COLORECTAL DIS, V22, P429, DOI 10.1007/s00384-006-0159-9
   Daskivich TJ, 2011, CANCER-AM CANCER SOC, V117, P4642, DOI 10.1002/cncr.26104
   Daskivich TJ, 2014, EUR UROL
   El Feghaly RE, 2013, CLIN INFECT DIS, V56, P1713, DOI 10.1093/cid/cit147
   Garcia-Sanchez V, 2010, J CROHNS COLITIS, V4, P144, DOI 10.1016/j.crohns.2009.09.008
   HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990
   Health Protection Agency, CLOSTR DIFF RIB NETW
   Hippenstiel S, 2000, BLOOD, V95, P3044
   Hurley BW, 2002, ARCH INTERN MED, V162, P2177, DOI 10.1001/archinte.162.19.2177
   Ishida Y, 2004, J IMMUNOL, V172, P3018, DOI 10.4049/jimmunol.172.5.3018
   JONES JR, 2008, CONSUM REP, V73, P6
   Kelly CP, 2011, J MED MICROBIOL, V60, P1070, DOI 10.1099/jmm.0.030015-0
   KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406
   Kopylov U, 2014, INFLAMM BOWEL DIS
   Langhorst J, 2005, INFLAMM BOWEL DIS, V11, P1085, DOI 10.1097/01.MIB.0000187980.08686.18
   Langhorst J, 2008, AM J GASTROENTEROL, V103, P162, DOI 10.1111/j.1572-0241.2007.01556.x
   LaSala PR, 2013, J CLIN MICROBIOL, V51, P311, DOI 10.1128/JCM.02735-12
   Lemee L, 2004, J CLIN MICROBIOL, V42, P5710, DOI 10.1128/JCM.42.12.5710-5714.2004
   Lyras D, 2009, NATURE, V458, P1176, DOI 10.1038/nature07822
   National Institute for Health and Care Excellence, FAEC CALPR DIAGN TES
   Pawlowski SW, 2009, J HOSP INFECT, V73, P185, DOI 10.1016/j.jhin.2009.05.013
   Planche TD, 2013, LANCET INFECT DIS, V13, P936, DOI 10.1016/S1473-3099(13)70200-7
   PRICE AB, 1977, J CLIN PATHOL, V30, P1, DOI 10.1136/jcp.30.1.1
   Public Health England, 2013, UPD GUID MAN TREATM
   Savidge TC, 2003, GASTROENTEROLOGY, V125, P413, DOI 10.1016/S0016-5085(03)00902-8
   Schoepfer AM, 2008, INFLAMM BOWEL DIS, V14, P32, DOI 10.1002/ibd.20275
   Schoepfer AM, 2010, AM J GASTROENTEROL, V105, P162, DOI 10.1038/ajg.2009.545
   Schoepfer AM, 2009, INFLAMM BOWEL DIS, V15, P1851, DOI 10.1002/ibd.20986
   Shastri YM, 2008, AM J MED, V121, P1099, DOI 10.1016/j.amjmed.2008.06.034
   Sipponen T, 2008, ALIMENT PHARM THER, V28, P1221, DOI 10.1111/j.1365-2036.2008.03835.x
   Sipponen T, 2008, INFLAMM BOWEL DIS, V14, P1392, DOI 10.1002/ibd.20490
   Sipponen T, 2008, INFLAMM BOWEL DIS, V14, P40, DOI 10.1002/ibd.20312
   Steiner TS, 1997, CLIN DIAGN LAB IMMUN, V4, P719, DOI 10.1128/CDLI.4.6.719-722.1997
   Summerton CB, 2002, EUR J GASTROEN HEPAT, V14, P841, DOI 10.1097/00042737-200208000-00005
   Tibble J, 2000, GUT, V47, P506, DOI 10.1136/gut.47.4.506
   Vaishnavi C, 2000, MICROBES INFECT, V2, P1827, DOI 10.1016/S1286-4579(00)01343-5
   van Langenberg DR, 2010, INTERN MED J, V40, P819, DOI 10.1111/j.1445-5994.2009.02102.x
   Whitehead SJ, 2014, J MED MICROBIOL
NR 46
TC 19
Z9 21
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2014
VL 9
IS 8
AR e106118
DI 10.1371/journal.pone.0106118
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO2EE
UT WOS:000341127500108
PM 25170963
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Swale, A
   Zhang, JE
   Alfirevic, A
   Little, M
   Beeching, NJ
   Smith, G
   Kolamunnage-Dona, R
   Pirmohamed, M
AF Miyajima, Fabio
   Swale, Andrew
   Zhang, J. Eunice
   Alfirevic, Ana
   Little, Margaret
   Beeching, Nicholas J.
   Smith, Godfrey
   Kolamunnage-Dona, Ruwanthi
   Pirmohamed, Munir
TI Is the Interleukin 8 Promoter Polymorphism rs4073/-251T > A Associated
   With Clostridium difficile Infection?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Clostridium difficile; genetic predisposition; interleukin 8; host
   response; meta-analysis
ID COMMON POLYMORPHISM; GENE PROMOTER; DIARRHEA; PATHOGENICITY;
   INFLAMMATION; COLITIS
AB The interleukin 8 gene single-nucleotide polymorphism rs4073/-251T >A predisposes to Clostridium difficile infection (CDI), but this association has not been independently validated. In this study, we were unable to replicate this association in either a white cohort or by meta-analysis, suggesting that rs4073/-251T >A is unlikely to constitute a major risk factor for CDI.
C1 [Miyajima, Fabio; Swale, Andrew; Zhang, J. Eunice; Alfirevic, Ana; Little, Margaret; Pirmohamed, Munir] Univ Liverpool, Wolfson Ctr Personalised Med, Liverpool L69 3GL, Merseyside, England.
   [Miyajima, Fabio; Swale, Andrew; Little, Margaret; Beeching, Nicholas J.; Smith, Godfrey; Pirmohamed, Munir] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England.
   [Beeching, Nicholas J.] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.
   [Kolamunnage-Dona, Ruwanthi] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England.
RP Miyajima, F (corresponding author), Univ Liverpool, Wolfson Ctr Personalised Med, Liverpool L69 3GL, Merseyside, England.
EM fabio@liv.ac.uk
RI Beeching, Nicholas J/L-5363-2017; Miyajima, Fabio/K-6587-2012;
   Pirmohamed, Munir/H-6004-2011; Kolamunnage-Dona, Ruwanthi/W-7979-2019
OI Miyajima, Fabio/0000-0002-1347-4825; Pirmohamed,
   Munir/0000-0002-7534-7266; Kolamunnage-Dona,
   Ruwanthi/0000-0003-3886-6208; Beeching, Nicholas/0000-0002-7019-8791
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   in microbial diseases in Liverpool; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/K000551/1]; NIHRNational Institute for
   Health Research (NIHR) [BRF-2011-028]; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/L006758/1] Funding Source: researchfish;
   National Institute for Health ResearchNational Institute for Health
   Research (NIHR) [BRF-2011-028, NF-SI-0512-10064] Funding Source:
   researchfish
FX Financial support. This work was supported by the National Institute for
   Health Research (NIHR) Biomedical Research Centre in microbial diseases
   in Liverpool, and by the Medical Research Council (MR/K000551/1). We
   also thank the NIHR for PhD student funding for A. S. (BRF-2011-028). M.
   P. is a NIHR Senior Investigator.
CR Bobo LD, 2013, INFECT IMMUN, V81, P713, DOI 10.1128/IAI.00186-12
   Flores J, 2009, CURR OPIN INFECT DIS, V22, P471, DOI 10.1097/QCO.0b013e3283304eb6
   Garey KW, 2010, CLIN INFECT DIS, V51, P1406, DOI 10.1086/657398
   Greenberg DE, 2002, J INFECT DIS, V185, P944, DOI 10.1086/339617
   Hansen J, 2010, CURR OPIN GASTROEN, V26, P564, DOI 10.1097/MOG.0b013e32833f1195
   Health UDo Services H. National cancer Institute, 2009, COMPL FIX TESTS, P1
   Jiang ZD, 2006, AM J GASTROENTEROL, V101, P1112, DOI 10.1111/j.1572-0241.2006.00482.x
   Jiang ZD, 2007, CLIN GASTROENTEROL H, V5, P964, DOI 10.1016/j.cgh.2007.04.018
   KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406
   McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590
   Poxton IR, 2001, CLIN MICROBIOL INFEC, V7, P421, DOI 10.1046/j.1198-743x.2001.00287.x
   Steiner TS, 1997, CLIN DIAGN LAB IMMUN, V4, P719, DOI 10.1128/CDLI.4.6.719-722.1997
NR 12
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2014
VL 58
IS 12
BP E148
EP E151
DI 10.1093/cid/ciu152
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AI7AO
UT WOS:000337031700001
PM 24633688
OA Bronze
DA 2020-12-17
ER

PT J
AU Alfirevic, A
   Carr, DF
   Miyajima, F
   Pushpakom, S
   Sutton, L
   Jorgensen, AL
   Pirmohamed, M
AF Alfirevic, Ana
   Carr, Daniel F.
   Miyajima, Fabio
   Pushpakom, Sudeep
   Sutton, Laura
   Jorgensen, Andrea L.
   Pirmohamed, Munir
TI The Wolfson Centre for Personalised Medicine, University of Liverpool,
   Liverpool, UK
SO PHARMACOGENOMICS
LA English
DT Article
ID PHENOTYPE STANDARDIZATION; HYPERSENSITIVITY; INJURY; ISSUES
AB The Wolfson Centre for Personalised Medicine is part of the Institute of Translational Medicine at the University of Liverpool (Liverpool, UK). It houses a multidisciplinary team of personalized medicine researchers engaged in collaborative research with partners across the globe. The primary focus of the centre is the identification of predictive biomarkers of drug safety and efficacy with the aim of translation from 'bench-to-bedside'. Studies utilizing the latest genotyping and phenotyping, and point-of-care technologies, are undertaken with the ultimate aim of developing easy access for patients to truly personalized medicine. In addition to translation into clinical practice, the Centre puts significant emphasis into education of clinicians and scientists alike, as well as public engagement activities to promote personalized medicine.
C1 [Alfirevic, Ana; Carr, Daniel F.; Miyajima, Fabio; Pushpakom, Sudeep; Pirmohamed, Munir] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GL, Merseyside, England.
   [Sutton, Laura; Jorgensen, Andrea L.] Univ Liverpool, Dept Biostat, Liverpool L69 3GS, Merseyside, England.
RP Pirmohamed, M (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Block A Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England.
EM munirp@liv.ac.uk
RI Pirmohamed, Munir/H-6004-2011; Miyajima, Fabio/K-6587-2012; Pushpakom,
   Sudeep/AAK-3281-2020
OI Pirmohamed, Munir/0000-0002-7534-7266; Miyajima,
   Fabio/0000-0002-1347-4825; Carr, Daniel/0000-0001-8028-4282; Sutton,
   Laura/0000-0003-3327-5927
FU Medical Research CouncilMedical Research Council UK (MRC) [G0700654B]
   Funding Source: researchfish; National Institute for Health
   ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10064]
   Funding Source: researchfish
CR [Anonymous], 2008, LANCET, V372, P2152
   Behr ER, 2013, EUR HEART J, V34, P1958, DOI 10.1093/eurheartj/ehs172
   Carr DF, 2013, CLIN INFECT DIS, V56, P1330, DOI 10.1093/cid/cit021
   Freidlin B, 2010, J NATL CANCER I, V102, P152, DOI 10.1093/jnci/djp477
   Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334
   He M, 2013, NAT GENET, V45, P109, DOI 10.1038/ng.2478
   Jorgensen AL, 2008, STAT MED, V27, P6547, DOI 10.1002/sim.3420
   Klein TE, 2009, NEW ENGL J MED, V360, P753, DOI 10.1056/NEJMoa0809329
   McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297
   Monshi MM, 2013, HEPATOLOGY, V57, P727, DOI 10.1002/hep.26077
   Pirmohamed M, 2011, CLIN PHARMACOL THER, V89, P784, DOI 10.1038/clpt.2011.30
   Pirmohamed M, 2011, CLIN PHARMACOL THER, V89, P896, DOI 10.1038/clpt.2011.79
   Pirmohamed M, 2010, CLIN PHARMACOL THER, V88, P862, DOI 10.1038/clpt.2010.245
   Pirmohamed M, 2013, NAT REV DRUG DISCOV, V12, P3, DOI 10.1038/nrd3921
   Rawlins M, 2008, LANCET, V372, P2152, DOI 10.1016/S0140-6736(08)61930-3
NR 15
TC 0
Z9 0
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD JUN
PY 2013
VL 14
IS 8
BP 861
EP 867
DI 10.2217/PGS.13.73
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 164SL
UT WOS:000320429700011
PM 23746181
DA 2020-12-17
ER

PT J
AU He, M
   Miyajima, F
   Roberts, P
   Ellison, L
   Pickard, DJ
   Martin, MJ
   Connor, TR
   Harris, SR
   Fairley, D
   Bamford, KB
   D'Arc, S
   Brazier, J
   Brown, D
   Coia, JE
   Douce, G
   Gerding, D
   Kim, HJ
   Koh, TH
   Kato, H
   Senoh, M
   Louie, T
   Michell, S
   Butt, E
   Peacock, SJ
   Brown, NM
   Riley, T
   Songer, G
   Wilcox, M
   Pirmohamed, M
   Kuijper, E
   Hawkey, P
   Wren, BW
   Dougan, G
   Parkhill, J
   Lawley, TD
AF He, Miao
   Miyajima, Fabio
   Roberts, Paul
   Ellison, Louise
   Pickard, Derek J.
   Martin, Melissa J.
   Connor, Thomas R.
   Harris, Simon R.
   Fairley, Derek
   Bamford, Kathleen B.
   D'Arc, Stephanie
   Brazier, Jon
   Brown, Derek
   Coia, John E.
   Douce, Gill
   Gerding, Dale
   Kim, Hee Jung
   Koh, Tse Hsien
   Kato, Haru
   Senoh, Mitsutoshi
   Louie, Tom
   Michell, Stephen
   Butt, Emma
   Peacock, Sharon J.
   Brown, Nick M.
   Riley, Tom
   Songer, Glen
   Wilcox, Mark
   Pirmohamed, Munir
   Kuijper, Ed
   Hawkey, Peter
   Wren, Brendan W.
   Dougan, Gordon
   Parkhill, Julian
   Lawley, Trevor D.
TI Emergence and global spread of epidemic healthcare-associated
   Clostridium difficile
SO NATURE GENETICS
LA English
DT Article
ID RIBOTYPE 027; NORTH-AMERICA; GENOME; DISEASE; STRAIN; EVOLUTIONARY;
   OUTBREAK; TRANSMISSION; MORTALITY; INFECTION
AB Epidemic C. difficile (027/BI/NAP1) has rapidly emerged in the past decade as the leading cause of antibiotic-associated diarrhea worldwide. However, the key events in evolutionary history leading to its emergence and the subsequent patterns of global spread remain unknown. Here, we define the global population structure of C. difficile 027/BI/NAP1 using whole-genome sequencing and phylogenetic analysis. We show that two distinct epidemic lineages, FQR1 and FQR2, not one as previously thought, emerged in North America within a relatively short period after acquiring the same fluoroquinolone resistance-conferring mutation and a highly related conjugative transposon. The two epidemic lineages showed distinct patterns of global spread, and the FQR2 lineage spread more widely, leading to healthcare-associated outbreaks in the UK, continental Europe and Australia. Our analysis identifies key genetic changes linked to the rapid transcontinental dissemination of epidemic C. difficile 027/BI/NAP1 and highlights the routes by which it spreads through the global healthcare system.
C1 [He, Miao; Ellison, Louise; Pickard, Derek J.; Connor, Thomas R.; Harris, Simon R.; Dougan, Gordon; Parkhill, Julian; Lawley, Trevor D.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Miyajima, Fabio; Roberts, Paul] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England.
   [Miyajima, Fabio; Roberts, Paul; Pirmohamed, Munir] Royal Liverpool & Broadgreen Univ Hosp Natl Hlth, Liverpool, Merseyside, England.
   [Miyajima, Fabio; Roberts, Paul; Pirmohamed, Munir] Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
   [Martin, Melissa J.; Wren, Brendan W.] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1, England.
   [Fairley, Derek] Belfast Hlth & Social Trust, Belfast, Antrim, North Ireland.
   [Bamford, Kathleen B.; D'Arc, Stephanie] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, London, England.
   [Bamford, Kathleen B.; D'Arc, Stephanie] Imperial Coll Healthcare NHS Trust, Dept Bacteriol, London, England.
   [Brazier, Jon] Anaerob Reference Lab, Cardiff, S Glam, Wales.
   [Brown, Derek; Coia, John E.; Douce, Gill] Scottish Salmonella Shigella & Clostridium Diffic, Glasgow, Lanark, Scotland.
   [Gerding, Dale] Hines VA Hosp, Hines, IL USA.
   [Kim, Hee Jung] Yonsei Univ, Coll Med, Seoul, South Korea.
   [Koh, Tse Hsien] Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore.
   [Kato, Haru; Senoh, Mitsutoshi] Natl Inst Infect Dis, Dept Bacteriol, Tokyo, Japan.
   [Louie, Tom] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.
   [Michell, Stephen; Butt, Emma] Univ Exeter, Coll Life & Environm Sci, Exeter, Devon, England.
   [Peacock, Sharon J.] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England.
   [Peacock, Sharon J.; Brown, Nick M.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.
   [Peacock, Sharon J.; Brown, Nick M.] Hlth Protect Agcy, London, England.
   [Riley, Tom] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia.
   [Songer, Glen] Iowa State Univ, Dept Vet Microbiol & Prevent Med, Ames, IA USA.
   [Wilcox, Mark] Univ Leeds, Healthcare Associate Infect Res Grp, Leeds, W Yorkshire, England.
   [Kuijper, Ed] Leiden Univ, Med Ctr, Dept Expt Microbiol, Leiden, Netherlands.
   [Hawkey, Peter] Univ Birmingham, Sch Immun & Infect, Birmingham, W Midlands, England.
RP Lawley, TD (corresponding author), Wellcome Trust Sanger Inst, Cambridge, England.
EM parkhill@sanger.ac.uk; tl2@sanger.ac.uk
RI Pirmohamed, Munir/H-6004-2011; Peacock, Sharon J/ABE-6331-2020; Harris,
   Simon R/K-1318-2013; Parkhill, Julian/G-4703-2011; Miyajima,
   Fabio/K-6587-2012; Connor, Thomas/ABE-5989-2020; Roberts,
   Peter/J-8535-2016; Coia, John/AAP-5379-2020; Brown, Derek/AAE-5597-2020
OI Pirmohamed, Munir/0000-0002-7534-7266; Harris, Simon
   R/0000-0003-1512-6194; Parkhill, Julian/0000-0002-7069-5958; Miyajima,
   Fabio/0000-0002-1347-4825; Connor, Thomas/0000-0003-2394-6504; Coia,
   John/0000-0002-4966-8453; Brown, Derek/0000-0003-3742-8257; Douce,
   Gillian/0000-0002-6654-7346; Brazier, John/0000-0001-8645-4780; Kim,
   Heejung/0000-0002-0190-703X; Kuijper, Ed/0000-0001-5726-2405; Butt,
   Emma/0000-0003-3972-1246
FU Wellcome TrustWellcome Trust [098051, 086418]; Medical Research
   CouncilMedical Research Council UK (MRC) [93614]; Scottish Infection
   Research Network; National Institute for Health Research (NIHR)
   Biomedical Research Centre in Liverpool; Liverpool BRC (Biomedical
   Research Centre); Medical Research CouncilMedical Research Council UK
   (MRC) [G0901743, G1000214, MR/K000551/1] Funding Source: researchfish;
   National Institute for Health ResearchNational Institute for Health
   Research (NIHR) [NF-SI-0512-10064] Funding Source: researchfish
FX We are grateful to members of the European Study Group of Clostridium
   difficile (ESGCD), a working group of ESCMID (European Society of
   Clinical Microbiology and Infectious Diseases), including F. Barbut, T.
   Eckmanns, M. L. Lambert, F. Fitzpatrick, C. Wiuff, H. Pituch, P.
   Reichert, A. F. Widmer, F. Allerberger, D. W. Notermans, M. Delmee, R.
   Frei, O. Lyytikainen, A. Ingebretsen and I. R. Poxton. We thank the
   Wellcome Trust Sanger Institute sequencing and informatics teams. This
   project was funded by the Wellcome Trust (grants 098051 and 086418), a
   Medical Research Council New Investigator Research Grant (T. D. L.;
   grant 93614) and the Scottish Infection Research Network. We acknowledge
   funding from the National Institute for Health Research (NIHR)
   Biomedical Research Centre in Liverpool. Both F. M. and P. R. were
   supported by the Liverpool BRC (Biomedical Research Centre). M. P. is an
   NIHR Senior Investigator.
CR Bartlett JG, 2010, ANN NY ACAD SCI, V1213, P62, DOI 10.1111/j.1749-6632.2010.05863.x
   Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4
   Brazier J.S., 2008, EURO SURVEILL, V13
   Brazier JS, 2012, ANAEROBE, V18, P197, DOI 10.1016/j.anaerobe.2011.12.021
   Brouwer MSM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023014
   Carter GP, 2011, FUTURE MICROBIOL, V6, P121, DOI 10.2217/fmb.10.169
   Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553
   Clements ACA, 2010, LANCET INFECT DIS, V10, P395, DOI 10.1016/S1473-3099(10)70080-3
   Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545
   Dallal RM, 2002, ANN SURG, V235, P363, DOI 10.1097/00000658-200203000-00008
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Harris SR, 2010, SCIENCE, V327, P469, DOI 10.1126/science.1182395
   He M, 2010, P NATL ACAD SCI USA, V107, P7527, DOI 10.1073/pnas.0914322107
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Kelly Ciaran P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500
   Kim H, 2011, KOREAN J LAB MED, V31, P191, DOI 10.3343/kjlm.2011.31.3.191
   Koser CU, 2012, NEW ENGL J MED, V366, P2267, DOI 10.1056/NEJMoa1109910
   Kuijper EJ, 2006, CLIN MICROBIOL INFEC, V12, P2, DOI 10.1111/j.1469-0691.2006.01580.x
   KUIJPER EJ, 2008, EURO SURVEILL, V13
   Kurtz S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r12
   Kurtz S, 2001, NUCLEIC ACIDS RES, V29, P4633, DOI 10.1093/nar/29.22.4633
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Linder JA, 2005, AM J MED, V118, P259, DOI 10.1016/j.amjmed.2004.09.015
   Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639
   MacCannell DR, 2006, J CLIN MICROBIOL, V44, P2147, DOI 10.1128/JCM.02563-05
   McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590
   Morelli G, 2010, NAT GENET, V42, P1140, DOI 10.1038/ng.705
   Muto CA, 2005, INFECT CONT HOSP EP, V26, P273, DOI 10.1086/502539
   Nyc O, 2011, LANCET, V377, P1407, DOI 10.1016/S0140-6736(11)60575-8
   O'Connor JR, 2009, GASTROENTEROLOGY, V136, P1913, DOI 10.1053/j.gastro.2009.02.073
   Pearson T, 2004, P NATL ACAD SCI USA, V101, P13536, DOI 10.1073/pnas.0403844101
   Pepin J, 2005, CAN MED ASSOC J, V173, P1037, DOI 10.1503/cmaj.050978
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Richards M, 2011, MED J AUSTRALIA, V194, P369, DOI 10.5694/j.1326-5377.2011.tb03012.x
   Riggs MM, 2007, CLIN INFECT DIS, V45, P992, DOI 10.1086/521854
   Sebaihia M, 2006, NAT GENET, V38, P779, DOI 10.1038/ng1830
   Spigaglia P, 2010, MOL CELL PROBE, V24, P61, DOI 10.1016/j.mcp.2009.10.002
   Stabler RA, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r102
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Warny M, 2005, LANCET, V366, P1079, DOI 10.1016/S0140-6736(05)67420-X
   Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107
NR 45
TC 424
Z9 435
U1 5
U2 110
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JAN
PY 2013
VL 45
IS 1
BP 109
EP U155
DI 10.1038/ng.2478
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 061HJ
UT WOS:000312838800022
PM 23222960
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Roberts, P
   Swale, A
   Price, V
   Jones, M
   Horan, M
   Beeching, N
   Brazier, J
   Parry, C
   Pendleton, N
   Pirmohamed, M
AF Miyajima, Fabio
   Roberts, Paul
   Swale, Andrew
   Price, Valerie
   Jones, Maureen
   Horan, Michael
   Beeching, Nicholas
   Brazier, Jonathan
   Parry, Christopher
   Pendleton, Neil
   Pirmohamed, Munir
TI Characterisation and Carriage Ratio of Clostridium difficile Strains
   Isolated from a Community-Dwelling Elderly Population in the United
   Kingdom
SO PLOS ONE
LA English
DT Article
ID TERM-CARE FACILITIES; INCREASED SPORULATION; TOXIN PRODUCTION;
   COLONIZATION; DIARRHEA; INFECTION; RESIDENTS; RISK; TRANSMISSION;
   EPIDEMIC
AB Background: Community-associated Clostridium difficile infection (CDI) appears to be an increasing problem. Reported carriage rates by C.difficile are debatable with suggestions that primary asymptomatic carriage is associated with decreased risk of subsequent diarrhoea. However, knowledge of potential reservoirs and intestinal carriage rates in the community, particularly in the elderly, the most susceptible group, is limited. We have determined the presence of C.difficile in the faeces of a healthy elderly cohort living outside of long-term care facilities (LCFs) in the United Kingdom.
   Methods: Faecal samples from 149 community-based healthy elderly volunteers (median age 81 years) were screened for C.difficile using direct (Brazier's CCEY) and enrichment (Cooked Meat broth) culture methods and a glutamate dehydrogenase (GDH) immunoassay. Isolates were PCR-ribotyped and analysed for toxin production and the presence of toxin genes.
   Results: Of 149 faecal samples submitted, six (4%) were found to contain C.difficile. One particular sample was positive by both the GDH immunoassay and direct culture, and concurrently produced two distinct strain types: one toxigenic and the other non-toxigenic. The other five samples were only positive by enrichment culture method. Overall, four C.difficile isolates were non-toxigenic (PCR-ribotypes 009, 026 (n = 2) and 039), while three were toxigenic (PCR-ribotypes 003, 005 and 106). All individuals who had a positive culture were symptom-free and none of them had a history of CDI and/or antibiotics use in the 3 month period preceding recruitment.
   Conclusions: To our knowledge, this is the first study of the presence of C.difficile in healthy elderly community-dwelling individuals residing outside of LCFs. The observed carriage rate is lower than that reported for individuals in LCFs and interestingly no individual carried the common epidemic strain PCR-ribotype 027 (NAP1/BI). Further follow-up of asymptomatic carriers in the community, is required to evaluate host susceptibility to CDI and identify dynamic changes in the host and microbial environment that are associated with pathogenicity.
C1 [Miyajima, Fabio; Roberts, Paul; Swale, Andrew; Price, Valerie; Beeching, Nicholas; Parry, Christopher; Pirmohamed, Munir] Royal Liverpool & Broadgreen Univ Hosp Natl Hlth, NIHR, Biomed Res Ctr, Liverpool, Merseyside, England.
   [Miyajima, Fabio; Swale, Andrew; Pirmohamed, Munir] Univ Liverpool, Dept Pharmacol, Wolfson Ctr Personalised Med, Liverpool L69 3BX, Merseyside, England.
   [Roberts, Paul; Price, Valerie] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Directorate Infect & Immun, Liverpool, Merseyside, England.
   [Jones, Maureen; Horan, Michael; Pendleton, Neil] Univ Manchester, Sch Community Based Med, Neurodegenerat Res Grp, Manchester, Lancs, England.
   [Beeching, Nicholas] Univ Liverpool, Liverpool Sch Trop Med, Clin Grp, Liverpool L3 5QA, Merseyside, England.
   [Brazier, Jonathan] Univ Wales Hosp, Publ Hlth Lab, Anaerobe Reference Unit, Cardiff CF4 4XW, S Glam, Wales.
   [Parry, Christopher] Univ Liverpool, Inst Global Hlth, Div Clin Infect Microbiol & Immunol, Liverpool L69 3BX, Merseyside, England.
   [Parry, Christopher] Mahidol Oxford Trop Med Res Unit, Wellcome Trust Major Overseas Programme, Bangkok, Thailand.
RP Miyajima, F (corresponding author), Royal Liverpool & Broadgreen Univ Hosp Natl Hlth, NIHR, Biomed Res Ctr, Liverpool, Merseyside, England.
EM munirp@liv.ac.uk
RI Miyajima, Fabio/K-6587-2012; Pirmohamed, Munir/H-6004-2011; Pendleton,
   Neil/F-2333-2015; Beeching, Nicholas J/L-5363-2017
OI Miyajima, Fabio/0000-0002-1347-4825; Pirmohamed,
   Munir/0000-0002-7534-7266; Pendleton, Neil/0000-0003-0794-2386;
   Beeching, Nicholas/0000-0002-7019-8791
FU Liverpool Biomedical Research Centre (Royal Liverpool University
   Hospital/NHS Trust and the Wolfson Centre for Personalised
   Medicine/University of Liverpool); National Institute for Health
   ResearchNational Institute for Health Research (NIHR); Northwest
   Development Agency
FX This work was supported by the Liverpool Biomedical Research Centre
   (Royal Liverpool University Hospital/NHS Trust and the Wolfson Centre
   for Personalised Medicine/University of Liverpool), the National
   Institute for Health Research and The Northwest Development Agency. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akerlund T, 2008, J CLIN MICROBIOL, V46, P1530, DOI 10.1128/JCM.01964-07
   Bidet P, 1999, FEMS MICROBIOL LETT, V175, P261, DOI 10.1016/S0378-1097(99)00204-9
   Brazier JS, 1999, J HOSP INFECT, V43, P317, DOI 10.1016/S0195-6701(99)90431-0
   BRAZIER JS, 1993, CLIN INFECT DIS, V16, pS228, DOI 10.1093/clinids/16.Supplement_4.S228
   CAMPBELL RR, 1988, AGE AGEING, V17, P333, DOI 10.1093/ageing/17.5.333
   DENEVE C, 2009, INT J ANTIMICROBIAL, V33
   Dial S, 2005, JAMA-J AM MED ASSOC, V294, P2989, DOI 10.1001/jama.294.23.2989
   DONTA ST, 1982, J PEDIATR-US, V100, P431, DOI 10.1016/S0022-3476(82)80454-X
   Eastwood K, 2009, J CLIN MICROBIOL, V47, P3211, DOI 10.1128/JCM.01082-09
   GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95
   Health UDo Services H. National cancer Institute, 2009, COMPL FIX TESTS, P1
   Hookman P, 2009, WORLD J GASTROENTERO, V15, P1554, DOI 10.3748/wjg.15.1554
   Kato H, 2001, J MED MICROBIOL, V50, P720, DOI 10.1099/0022-1317-50-8-720
   Kaur S, 2007, MICROBIOL IMMUNOL, V51, P1209, DOI 10.1111/j.1348-0421.2007.tb04016.x
   Kuijper EJ, 2007, CURR OPIN INFECT DIS, V20, P376
   Kyne L, 2000, NEW ENGL J MED, V342, P390, DOI 10.1056/NEJM200002103420604
   Lemee L, 2004, J CLIN MICROBIOL, V42, P5710, DOI 10.1128/JCM.42.12.5710-5714.2004
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Martinsen TC, 2005, BASIC CLIN PHARMACOL, V96, P94, DOI 10.1111/j.1742-7843.2005.pto960202.x
   Matsuki S, 2005, INT MICROBIOL, V8, P43
   Merrigan M, 2010, J BACTERIOL, V192, P4904, DOI 10.1128/JB.00445-10
   Ozaki E, 2004, J MED MICROBIOL, V53, P167, DOI 10.1099/jmm.0.05376-0
   Rabbitt PMA, 2004, AGING NEUROPSYCHOL C, V11, P245, DOI 10.1080/13825580490511116
   Riggs MM, 2007, CLIN INFECT DIS, V45, P992, DOI 10.1086/521854
   Rivera Emmanuel V, 2003, J Gend Specif Med, V6, P27
   Ryan J, 2010, IRISH J MED SCI, V179, P245, DOI 10.1007/s11845-009-0361-1
   Shim JK, 1998, LANCET, V351, P633, DOI 10.1016/S0140-6736(97)08062-8
   Simor AE, 2002, INFECT CONT HOSP EP, V23, P696, DOI 10.1086/501997
   SIMOR AE, 1993, CLIN INFECT DIS, V17, P672, DOI 10.1093/clinids/17.4.672
   Stabler RA, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r102
   TATAROWICZ W, 2010, 3 INT CLOSTR DIFF S, V44
   WALKER KJ, 1993, J AM GERIATR SOC, V41, P940, DOI 10.1111/j.1532-5415.1993.tb06759.x
   Warny M, 2005, LANCET, V366, P1079, DOI 10.1016/S0140-6736(05)67420-X
NR 33
TC 47
Z9 47
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2011
VL 6
IS 8
AR e22804
DI 10.1371/journal.pone.0022804
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 811YA
UT WOS:000294253500003
PM 21886769
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-17
ER

PT J
AU Carrol, ED
   Payton, A
   Payne, D
   Miyajima, F
   Chaponda, M
   Mankhambo, LA
   Banda, DL
   Molyneux, EM
   Cox, H
   Jacobson, G
   Carr, DF
   Molyneux, ME
   Stewart, JP
   Quinn, JP
   Hart, CA
   Ollier, WE
AF Carrol, Enitan D.
   Payton, Antony
   Payne, Deborah
   Miyajima, Fabio
   Chaponda, Mas
   Mankhambo, Limangeni A.
   Banda, Daniel L.
   Molyneux, Elizabeth M.
   Cox, Helen
   Jacobson, Greg
   Carr, Daniel F.
   Molyneux, Malcolm E.
   Stewart, James P.
   Quinn, John P.
   Hart, C. Anthony
   Ollier, William E.
TI The IL1RN Promoter rs4251961 Correlates with IL-1 Receptor Antagonist
   Concentrations in Human Infection and Is Differentially Regulated by
   GATA-1
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INVASIVE PNEUMOCOCCAL DISEASE; STREPTOCOCCUS-PNEUMONIAE INFECTION;
   DEVELOPING-WORLD; GENE; POLYMORPHISMS; VARIANT; SUSCEPTIBILITY;
   ASSOCIATION; PROTEINS; DEFENSE
AB IL-1R antagonist (IL-1Ra) is required for adequate host defense in invasive pneumococcal disease (IPD). The minor allele of an IL1RN gene (C/T) promoter polymorphism (rs4251961) has been shown to be associated with decreased IL-1Ra production in healthy adults. We genotyped 299 children with IPD, and examined 19 IL1RN haplotype-tagging single-nucleotide polymorphisms. Human embryonic kidney HEK293(T) cells were transfected with the promoter reporter plasmid pGL3p containing either allelic variant C (pGL3pCC) or T (pGL3pTT) with or without cotransfection with an expression construct overexpressing the globin transcription factor GATA-1. Plasma IL-1Ra concentrations were significantly higher in nonsurvivors compared with survivors (p < 0.0005), and the C allele of rs4251961 was associated with a significant increase in plasma IL-1Ra concentrations (p = 0.01) during the acute illness of IPD. These findings were validated in a cohort of 276 treatment-naive HIV-infected adults, with borderline significance (p = 0.058). Functional analyses demonstrated that the activity of the promoter constructs containing the T allele increased similar to 6-fold as compared with basal activity, and that containing the C allele by similar to 9-fold (p < 0.001) in the presence of GATA-1. Our findings suggest that the IL-1Ra single-nucleotide polymorphism rs4251961 plays a key role in the pathophysiology of IPD and in other human infections. The Journal of Immunology, 2011, 186: 2329-2335.
C1 [Carrol, Enitan D.] Univ Liverpool, Div Child Hlth, Alder Hey Childrens NHS Fdn Trust, Liverpool L12 2AP, Merseyside, England.
   [Miyajima, Fabio; Chaponda, Mas; Carr, Daniel F.] Univ Liverpool, Dept Pharmacol, Liverpool L12 2AP, Merseyside, England.
   [Cox, Helen; Stewart, James P.; Hart, C. Anthony] Univ Liverpool, Div Med Microbiol, Liverpool L12 2AP, Merseyside, England.
   [Jacobson, Greg; Quinn, John P.] Univ Liverpool, Sch Biomed Sci, Liverpool L12 2AP, Merseyside, England.
   [Carrol, Enitan D.; Mankhambo, Limangeni A.; Molyneux, Elizabeth M.] Coll Med, Dept Paediat, Blantyre, Malawi.
   [Payton, Antony; Payne, Deborah; Ollier, William E.] Univ Manchester, Ctr Integrated Genom Med Res, Manchester, Lancs, England.
   [Carrol, Enitan D.; Mankhambo, Limangeni A.; Banda, Daniel L.; Molyneux, Malcolm E.] Malawi Liverpool Wellcome Trust, Clin Res Programme, Blantyre, Malawi.
RP Carrol, ED (corresponding author), Univ Liverpool, Div Child Hlth, Alder Hey Childrens NHS Fdn Trust, Eaton Rd, Liverpool L12 2AP, Merseyside, England.
EM edcarrol@liverpool.ac.uk
RI Quinn, John/A-2972-2010; Jacobson, Gregory/F-7734-2011; Jacobson,
   Gregory/AAJ-4670-2020; Stewart, James/A-6034-2012; Miyajima,
   Fabio/K-6587-2012
OI Quinn, John/0000-0003-3551-7803; Jacobson, Gregory/0000-0003-2804-274X;
   Stewart, James/0000-0002-8928-2037; Miyajima, Fabio/0000-0002-1347-4825;
   Carr, Daniel/0000-0001-8028-4282; Carrol, Enitan/0000-0001-8357-7726;
   Payton, Antony/0000-0003-0335-152X
FU Wellcome TrustWellcome Trust [068026, 078857/Z/05/Z]; Alder Hey
   Children's National Health Service Foundation Trust [7565]; National
   Institute of Health Research Liverpool Biomedical Research Centre for
   Microbial Diseases
FX This work was supported by Wellcome Trust Career Development Grant
   068026 (to E.D.C.), Wellcome Trust Training Fellowship Grant
   078857/Z/05/Z (to M.C.), and Alder Hey Children's National Health
   Service Foundation Trust Endowment Grant Ref 7565 (to H.C.). F.M. is
   supported by the National Institute of Health Research Liverpool
   Biomedical Research Centre for Microbial Diseases.
CR Ali FR, 2010, J NEUROCHEM, V112, P296, DOI 10.1111/j.1471-4159.2009.06453.x
   Brotons O., 2010, MOL PSYCHIA IN PRESS
   Carrol ED, 2002, CLIN INFECT DIS, V35, P495, DOI 10.1086/341497
   Chapman SJ, 2007, AM J RESP CRIT CARE, V176, P181, DOI 10.1164/rccm.200702-169OC
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Greenwood B, 1999, PHILOS T R SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Guindalini C, 2006, P NATL ACAD SCI USA, V103, P4552, DOI 10.1073/pnas.0504789103
   Haddley K, 2008, NEUROCHEM RES, V33, P652, DOI 10.1007/s11064-007-9521-8
   Irikura VM, 1999, INFECT IMMUN, V67, P1901
   Kafka D, 2008, INT IMMUNOL, V20, P1139, DOI 10.1093/intimm/dxn071
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   Kronborg G, 2002, J INFECT DIS, V185, P1517, DOI 10.1086/340216
   Menon R, 2010, ANN HUM GENET, V74, P165, DOI 10.1111/j.1469-1809.2010.00562.x
   Monticelli S, 2004, J BIOL CHEM, V279, P36210, DOI 10.1074/jbc.M406354200
   Payton A, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-28
   Rafiq S, 2007, GENES IMMUN, V8, P344, DOI 10.1038/sj.gene.6364393
   Reiner AP, 2008, ARTERIOSCL THROM VAS, V28, P1407, DOI 10.1161/ATVBAHA.108.167437
   Rijneveld AW, 2003, EUR CYTOKINE NETW, V14, P242
   Roy S, 2002, LANCET, V359, P1569, DOI 10.1016/S0140-6736(02)08516-1
   Roy S, 2002, BRIT MED J, V324, P1369, DOI 10.1136/bmj.324.7350.1369
   Schaaf BM, 2003, AM J RESP CRIT CARE, V168, P476, DOI 10.1164/rccm.200210-1164OC
   Scott JAG, 2007, VACCINE, V25, P2398, DOI 10.1016/j.vaccine.2006.09.008
   Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145
   Yuan FF, 2003, IMMUNOL CELL BIOL, V81, P192, DOI 10.1046/j.1440-1711.2003.01158.x
   Zwijnenburg PJG, 2003, J IMMUNOL, V170, P4724, DOI 10.4049/jimmunol.170.9.4724
NR 26
TC 23
Z9 26
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2011
VL 186
IS 4
BP 2329
EP 2335
DI 10.4049/jimmunol.1002402
PG 7
WC Immunology
SC Immunology
GA 715KF
UT WOS:000286882700053
PM 21248262
OA Bronze
DA 2020-12-17
ER

PT J
AU Mekli, K
   Payton, A
   Miyajima, F
   Platt, H
   Thomas, E
   Downey, D
   Lloyd-Williams, K
   Chase, D
   Toth, ZG
   Elliott, R
   Oilier, WE
   Anderson, IM
   Deakin, JFW
   Bagdy, G
   Juhasz, G
AF Mekli, Krisztina
   Payton, Antony
   Miyajima, Fabio
   Platt, Hazel
   Thomas, Emma
   Downey, Darragh
   Lloyd-Williams, Kathryn
   Chase, Diana
   Toth, Zoltan G.
   Elliott, Rebecca
   Oilier, William E.
   Anderson, Ian M.
   Deakin, J. F. William
   Bagdy, Gyorgy
   Juhasz, Gabriella
TI The HTR1A and HTR1B receptor genes influence stress-related information
   processing
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE Stress; HTR1A; HTR1B; Depression; Anxiety
ID SEROTONIN TRANSPORTER GENE; GENERALIZED ANXIETY DISORDER; MAJOR
   DEPRESSIVE DISORDER; NEGATIVE LIFE EVENTS; MICE LACKING; 5-HT1B
   RECEPTOR; SUICIDE ATTEMPTERS; TREATMENT RESPONSE; POLYMORPHISM;
   ASSOCIATION
AB The serotonergic system has been widely implicated in stress related psychiatric disorders such as depression and anxiety. We investigated the possible association between depression and anxiety scores and SNPs within the HTR1A and HTR1B genes in a population sample (n=1387). There was no direct SNP-phenotype association, but in interaction with recent stressful life events rs6295 G, rs878567 T alleles and rs6296 C alleles were associated with significantly higher symptom scores. A subset of control subjects (n=101) took part in a computerised face emotion processing task. Healthy rs6295 GG carriers did not show an affective bias to perceive more negative emotions but reacted more quickly to fearful faces. Thus we conclude that the serotonin-1A receptor conveys vulnerability to these psychiatric disorders by modulating threat-related information processing. Our results extend previous findings of an interaction between stressful life events and the serotonin transporter gene to two other genes in the serotonergic pathway and emphasise the possible role of increased threat-related information processing as an intermediate phenotype. (C) 2010 Elsevier B.V. and ECNP. All rights reserved.
C1 [Mekli, Krisztina; Thomas, Emma; Lloyd-Williams, Kathryn; Chase, Diana; Elliott, Rebecca; Anderson, Ian M.; Deakin, J. F. William; Juhasz, Gabriella] Univ Manchester, Neurosci & Psychiat Unit, Sch Community Based Med, Fac Med & Human Sci, Manchester M13 9PT, Lancs, England.
   [Mekli, Krisztina; Payton, Antony; Miyajima, Fabio; Platt, Hazel; Oilier, William E.] Univ Manchester, Ctr Integrated Genom Med Res, Manchester M13 9PT, Lancs, England.
   [Mekli, Krisztina; Bagdy, Gyorgy] Semmelweis Univ, Dept Pharmacodynam, Budapest, Hungary.
   [Bagdy, Gyorgy] Hungarian Acad Sci, Grp Neurochem, Budapest, Hungary.
   [Toth, Zoltan G.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.
RP Juhasz, G (corresponding author), Univ Manchester, Neurosci & Psychiat Unit, Sch Community Based Med, Fac Med & Human Sci, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM gabriella.juhasz@manchester.ac.uk
RI Bagdy, Gyorgy/O-3893-2017; Juhasz, Gabriella/O-1753-2017; Miyajima,
   Fabio/K-6587-2012
OI Bagdy, Gyorgy/0000-0001-8141-3410; Juhasz,
   Gabriella/0000-0002-5975-4267; Miyajima, Fabio/0000-0002-1347-4825;
   Anderson, Ian M/0000-0003-2205-9209; Downey,
   Darragh/0000-0003-2755-4049; Elliott, Rebecca/0000-0002-7602-010X;
   Payton, Antony/0000-0003-0335-152X; Chase, Diana/0000-0002-3678-0032;
   Deakin, John/0000-0002-2750-962X
FU EUEuropean Union (EU) [LSHM-CT-2004-503474, ETT 318-0412009,
   TAMOP-4.2.1.B-09/1/KMR-2010-000]; AstraZenecaAstraZeneca; WyethWyeth;
   ServierServier; Eli LillyEli Lilly; LundbeckLundbeck Corporation;
   Cephalon; Bristol Myers SquibbBristol-Myers Squibb; Medical Research
   CouncilMedical Research Council UK (MRC) [G0900950, G0900950B, G9721629,
   G9721629B] Funding Source: researchfish; National Institute for Health
   ResearchNational Institute for Health Research (NIHR) [NF-SI-0509-10229]
   Funding Source: researchfish
FX This study was supported by the Sixth Framework Program of the EU,
   NewMood, LSHM-CT-2004-503474, ETT 318-0412009 and
   TAMOP-4.2.1.B-09/1/KMR-2010-0001. They had no further role in study
   design; in the collection, analysis and interpretation of the data; in
   the writing of the report; and in the decision to submit the paper for
   publication.; Prof Deakin has carried out consultancy and speaking
   engagements for Bristol Myers Squibb, AstraZeneca, Eli Lilly, Schering
   Plough, Janssen-Cilag, and Servier. All fees are paid to the University
   of Manchester to reimburse them for the time taken. He has share options
   in P1vital. Prof Anderson has received grant support from AstraZeneca,
   consultancy fees/honoraria for speaking/support to attend conferences
   from Wyeth, Servier, Eli Lilly, Lundbeck, Cephalon and Bristol Myers
   Squibb. Drs Juhasz, Thomas, Chase, Elliott, Downey, Miyajima and Payton,
   Prof Oilier, Mrs Lloyd-Williams, Ms Mekli, Ms Platt and Mr Toth report
   no relevant financial interest.
CR Anttila S, 2007, J NEURAL TRANSM, V114, P1065, DOI 10.1007/s00702-007-0705-9
   Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Benko A, 2010, AM J MED GENET B, V153B, P592, DOI 10.1002/ajmg.b.31025
   BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132
   BOHMAKER K, 1993, NEUROPHARMACOLOGY, V32, P527, DOI 10.1016/0028-3908(93)90048-8
   BREZO J, 2009, MOL PSYCHIAT ELECT
   BRUGHA T, 1985, PSYCHOL MED, V15, P189, DOI 10.1017/S003329170002105X
   Brunner D, 1997, ANN NY ACAD SCI, V836, P81, DOI 10.1111/j.1749-6632.1997.tb52356.x
   Bukh JD, 2009, J AFFECT DISORDERS, V119, P107, DOI 10.1016/j.jad.2009.02.023
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Caspi A, 2010, AM J PSYCHIAT, V167, P509, DOI 10.1176/appi.ajp.2010.09101452
   Cervilla JA, 2006, AM J MED GENET B, V141B, P912, DOI 10.1002/ajmg.b.30455
   Clark MS, 2002, J NEUROSCI, V22, P4550, DOI 10.1523/JNEUROSCI.22-11-04550.2002
   Clark MS, 2004, BRAIN RES, V1007, P86, DOI 10.1016/j.brainres.2004.01.070
   Conner TS, 2010, AM J MED GENET B, V153B, P67, DOI 10.1002/ajmg.b.30955
   Contreras J, 2009, ACTA PSYCHIAT SCAND, V119, P117, DOI 10.1111/j.1600-0447.2008.01273.x
   Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98
   Das-Munshi J, 2008, BRIT J PSYCHIAT, V192, P171, DOI 10.1192/bjp.bp.107.036707
   David SP, 2005, J NEUROSCI, V25, P2586, DOI 10.1523/JNEUROSCI.3769-04.2005
   Derogatis L.R., 1993, BSI BRIEF SYMPTOM IN
   Domschke K, 2006, INT J NEUROPSYCHOPH, V9, P349, DOI 10.1017/S1461145705005869
   Drago A, 2010, EUR J CLIN PHARMACOL, V66, P5, DOI 10.1007/s00228-009-0724-6
   Drevets WC, 2008, BRAIN STRUCT FUNCT, V213, P93, DOI 10.1007/s00429-008-0189-x
   Duan J, 2003, MOL PSYCHIATR, V8, P901, DOI 10.1038/sj.mp.4001403
   Ekman P., 1976, PICTURES FACIAL AFFE
   Fakra E, 2009, ARCH GEN PSYCHIAT, V66, P33, DOI 10.1001/archpsyc.66.1.33
   First M, 2002, STRUCTURED CLIN INTE
   Fisher PM, 2006, NAT NEUROSCI, V9, P1362, DOI 10.1038/nn1780
   Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738
   Fusar-Poli P, 2009, J PSYCHIATR NEUROSCI, V34, P418
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a
   GUR RC, 1992, PSYCHIAT RES, V42, P241, DOI 10.1016/0165-1781(92)90116-K
   Hall H, 1997, BRAIN RES, V745, P96, DOI 10.1016/S0006-8993(96)01131-6
   Harmer CJ, 2008, NEUROPHARMACOLOGY, V55, P1023, DOI 10.1016/j.neuropharm.2008.06.036
   Harmer CJ, 2004, AM J PSYCHIAT, V161, P1256, DOI 10.1176/appi.ajp.161.7.1256
   Harmer CJ, 2003, NEUROPSYCHOPHARMACOL, V28, P148, DOI 10.1038/sj.npp.1300004
   Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049
   Hettema JM, 2008, AM J MED GENET B, V147B, P661, DOI 10.1002/ajmg.b.30656
   Hettema JM, 2008, DEPRESS ANXIETY, V25, P300, DOI 10.1002/da.20491
   Hong CJ, 2006, PHARMACOGENOMICS J, V6, P27, DOI 10.1038/sj.tpj.6500340
   Huang YY, 2003, NEUROPSYCHOPHARMACOL, V28, P163, DOI 10.1038/sj.npp.1300000
   Illi A, 2009, NEUROREPORT, V20, P1125, DOI 10.1097/WNR.0b013e32832eb708
   Juhasz G, 2009, NEUROPSYCHOPHARMACOL, V34, P2019, DOI 10.1038/npp.2009.19
   Kato M, 2009, AM J MED GENET B, V150B, P115, DOI 10.1002/ajmg.b.30783
   Kendler KS, 2007, PSYCHOL MED, V37, P453, DOI 10.1017/S0033291706009135
   Kendler KS, 1996, BRIT J PSYCHIAT, V168, P68, DOI 10.1192/S0007125000298437
   KENNETT GA, 1987, EUR J PHARMACOL, V138, P53, DOI 10.1016/0014-2999(87)90336-0
   Kraus MR, 2007, GASTROENTEROLOGY, V132, P1279, DOI 10.1053/j.gastro.2007.02.053
   Lanfumey L, 2004, CNS NEUROL DISORD-DR, V3, P1, DOI 10.2174/1568007043482570
   Lazary J, 2008, BIOL PSYCHIAT, V64, P498, DOI 10.1016/j.biopsych.2008.03.030
   Le Francois B, 2008, NEUROPHARMACOLOGY, V55, P977, DOI 10.1016/j.neuropharm.2008.06.046
   Lemonde S, 2004, INT J NEUROPSYCHOPH, V7, P501, DOI 10.1017/S1461145704004699
   Lemonde S, 2003, J NEUROSCI, V23, P8788
   Levinson DF, 2006, BIOL PSYCHIAT, V60, P84, DOI 10.1016/j.biopsych.2005.08.024
   Merens W, 2007, J AFFECT DISORDERS, V103, P43, DOI 10.1016/j.jad.2007.01.032
   Mineka S, 1998, ANNU REV PSYCHOL, V49, P377, DOI 10.1146/annurev.psych.49.1.377
   Moffitt TE, 2005, ARCH GEN PSYCHIAT, V62, P473, DOI 10.1001/archpsyc.62.5.473
   Mogg K, 2002, BEHAV RES THER, V40, P1403, DOI 10.1016/S0005-7967(02)00017-7
   Mogg K, 2007, BIOL PSYCHOL, V76, P163, DOI 10.1016/j.biopsycho.2007.07.005
   Mosing MA, 2009, DEPRESS ANXIETY, V26, P1004, DOI 10.1002/da.20611
   Neff CD, 2009, MOL PSYCHIATR, V14, P621, DOI 10.1038/mp.2008.8
   Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734
   Parsey RV, 2006, NEUROPSYCHOPHARMACOL, V31, P1745, DOI 10.1038/sj.npp.1300992
   Parsey RV, 2006, BIOL PSYCHIAT, V59, P106, DOI 10.1016/j.biopsych.2005.06.016
   PAZOS A, 1985, BRAIN RES, V346, P205, DOI 10.1016/0006-8993(85)90856-X
   Plomin R, 2000, PSYCHOL BULL, V126, P806, DOI 10.1037/0033-2909.126.6.806
   Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476
   Rijsdijk FV, 2001, PSYCHOL MED, V31, P401, DOI 10.1017/S0033291701003361
   Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878
   Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259
   Rothe C, 2004, INT J NEUROPSYCHOPH, V7, P189, DOI 10.1017/S1461145703004061
   ROY MA, 1995, PSYCHOL MED, V25, P1037, DOI 10.1017/S0033291700037533
   Rutter M, 2009, ARCH GEN PSYCHIAT, V66, P1287, DOI 10.1001/archgenpsychiatry.2009.167
   Sari Y, 2004, NEUROSCI BIOBEHAV R, V28, P565, DOI 10.1016/j.neubiorev.2004.08.008
   Savitz J, 2009, PROG NEUROBIOL, V88, P17, DOI 10.1016/j.pneurobio.2009.01.009
   Serretti A, 2007, AM J MED GENET B, V144B, P291, DOI 10.1002/ajmg.b.30432
   Serretti A, 2009, J PSYCHIATR RES, V43, P519, DOI 10.1016/j.jpsychires.2008.06.005
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Strobel A, 2003, J NEURAL TRANSM, V110, P1445, DOI 10.1007/s00702-003-0072-0
   Surguladze SA, 2004, NEUROPSYCHOLOGY, V18, P212, DOI 10.1037/0894-4105.18.2.212
   Uher R, 2010, MOL PSYCHIATR, V15, P18, DOI 10.1038/mp.2009.123
   Wasserman Danuta, 2006, Behav Brain Funct, V2, P14, DOI 10.1186/1744-9081-2-14
   Wray NR, 2009, BIOL PSYCHIAT, V66, P468, DOI 10.1016/j.biopsych.2009.04.030
   Wu Y, 2008, CHINESE MED J-PEKING, V121, P874, DOI 10.1097/00029330-200805020-00002
   Yevtushenko OO, 2010, J AFFECT DISORDERS, V123, P308, DOI 10.1016/j.jad.2009.09.007
   Yu YWY, 2006, EUR NEUROPSYCHOPHARM, V16, P498, DOI 10.1016/j.euroneuro.2005.12.004
   Zalsman G, 2006, AM J PSYCHIAT, V163, P1588, DOI 10.1176/appi.ajp.163.9.1588
   Zhang KR, 2009, J AFFECT DISORDERS, V114, P224, DOI 10.1016/j.jad.2008.07.012
   Zhuang XX, 1999, NEUROPSYCHOPHARMACOL, V21, pS52, DOI 10.1038/sj.npp.1395371
NR 91
TC 26
Z9 29
U1 1
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-977X
EI 1873-7862
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD JAN
PY 2011
VL 21
IS 1
SI SI
BP 129
EP 139
DI 10.1016/j.euroneuro.2010.06.013
PG 11
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 713BW
UT WOS:000286711000013
PM 20638825
DA 2020-12-17
ER

PT J
AU Talkowski, ME
   McCann, KL
   Chen, M
   McClain, L
   Bamne, M
   Wood, J
   Chowdari, KV
   Watson, A
   Prasad, KM
   Kirov, G
   Georgieva, L
   Toncheva, D
   Mansour, H
   Lewis, DA
   Owen, M
   O'Donovan, M
   Papasaikas, P
   Sullivan, P
   Ruderfer, D
   Yao, JK
   Leonard, S
   Thomas, P
   Miyajima, F
   Quinn, J
   Lopez, AJ
   Nimgaonkar, VL
AF Talkowski, Michael E.
   McCann, Kathleen L.
   Chen, Michael
   McClain, Lora
   Bamne, Mikhil
   Wood, Joel
   Chowdari, Kodavali V.
   Watson, Annie
   Prasad, Konasale M.
   Kirov, George
   Georgieva, Lyudmilla
   Toncheva, Draga
   Mansour, Hader
   Lewis, David A.
   Owen, Michael
   O'Donovan, Michael
   Papasaikas, Panagiotis
   Sullivan, Patrick
   Ruderfer, Douglas
   Yao, Jeffrey K.
   Leonard, Sherry
   Thomas, Pramod
   Miyajima, Fabio
   Quinn, John
   Lopez, A. Javier
   Nimgaonkar, Vishwajit L.
TI Fine-Mapping Reveals Novel Alternative Splicing of the Dopamine
   Transporter
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE dopamine transporter; schizophrenia; alternative splicing; genetic
   association
ID PRE-MESSENGER-RNA; NAIVE SCHIZOPHRENIC-PATIENTS; MONOAMINE TRANSPORTERS;
   PARKINSONS-DISEASE; TRANSCRIPTIONAL ACTIVITY; PREFRONTAL CORTEX;
   BINDING-SITES; HUMAN BRAIN; GENE; ASSOCIATION
AB The dopamine transporter gene (SLC6A3, DAT) has been implicated in the pathogenesis of numerous psychiatric and neuro-developmental disorders, including schizophrenia (SZ). We previously detected association between SZ and intronic SLC6A3 variants that replicated in two independent Caucasian samples, but had no obvious function. In follow-up analyses, we sequenced the coding and intronic regions of SLC6A3 to identify complete linkage disequilibrium patterns of common variations. We genotyped 78 polymorphisms, narrowing the potentially causal region to two correlated clusters of associated SNPs localized predominantly to introns 3 and 4. Our computational analysis of these intronic regions predicted a novel cassette exon within intron 3, designated E3b, which is conserved among primates. We confirmed alternative splicing of E3b in post-mortem human substantia nigra (SN). As E3b introduces multiple in-frame stop codons, the SLC6A3 open reading frame is truncated and the spliced product may undergo nonsense mediated decay. Thus, factors that increase E3b splicing could reduce the amount of unspliced product available for translation. Observations consistent with this prediction were made using cellular assays and in post-mortem human SN. In mini-gene constructs, the extent of splicing is also influenced by at least two common haplotypes, so the alternative splicing was evaluated in relation to SZ risk. Meta-analyses across genome-wide association studies did not support the initial associations and further post-mortem studies did not suggest case-control differences in splicing. These studies do not provide a compelling link to schizophrenia. However, the impact of the alternative splicing on other neuropsychiatric disorders should be investigated. (C) 2010 Wiley-Liss, Inc.
C1 [Talkowski, Michael E.; McClain, Lora; Bamne, Mikhil; Wood, Joel; Chowdari, Kodavali V.; Watson, Annie; Prasad, Konasale M.; Mansour, Hader; Lewis, David A.; Yao, Jeffrey K.; Thomas, Pramod; Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
   [Talkowski, Michael E.; Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA.
   [McCann, Kathleen L.; Chen, Michael; Papasaikas, Panagiotis; Lopez, A. Javier] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA.
   [Kirov, George; Georgieva, Lyudmilla; Owen, Michael; O'Donovan, Michael] Cardiff Univ, Sch Med, Dept Psychol Med & Neurol, MRC Ctr Neuropsychiat Genet & Gen, Cardiff, S Glam, Wales.
   [Toncheva, Draga] Med Univ, Sofia, Bulgaria.
   [Sullivan, Patrick] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
   [Sullivan, Patrick] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA.
   [Ruderfer, Douglas] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Ruderfer, Douglas] Broad Inst, Boston, MA USA.
   [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Leonard, Sherry] Univ Colorado, Dept Psychiat, Denver, CO 80202 USA.
   [Miyajima, Fabio; Quinn, John] Univ Liverpool, Div Human Anat & Cell Biol, Liverpool L69 3BX, Merseyside, England.
   [Miyajima, Fabio; Quinn, John] Univ Liverpool, Sch Biomed Sci, Liverpool L69 3BX, Merseyside, England.
RP Nimgaonkar, VL (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat & Human Genet, Room 441,3811 OHara St, Pittsburgh, PA 15213 USA.
EM nimga@pitt.edu
RI Prasad, Konasale/O-6593-2018; Miyajima, Fabio/K-6587-2012; O'Donovan,
   Michael C/P-7005-2018; Papasaikas, Panagiotis/J-8581-2015; Lewis, David
   A/G-4053-2014; Ruderfer, Douglas M/M-5795-2016; Quinn, John/A-2972-2010
OI Prasad, Konasale/0000-0003-0245-1393; Miyajima,
   Fabio/0000-0002-1347-4825; O'Donovan, Michael C/0000-0001-7073-2379;
   Papasaikas, Panagiotis/0000-0002-1640-7636; Lewis, David
   A/0000-0002-3225-6778; Ruderfer, Douglas M/0000-0002-2365-386X; Kirov,
   George/0000-0002-3427-3950; Toncheva, Draga/0000-0002-7451-6363;
   Talkowski, Michael/0000-0003-2889-0992; McCann,
   Kathleen/0000-0002-7144-4851; Quinn, John/0000-0003-3551-7803
FU Bristol-Myers Squibb FoundationBristol-Myers Squibb; Bristol-Myers
   SquibbBristol-Myers Squibb; Curridium Ltd; PfizerPfizer;
   AstraZenecaAstraZeneca; Hoffman-Roche; LillyEli Lilly; MerckMerck &
   Company; Neurogen; National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [MH56242, MH63480, GM081293]; NSFNational Science Foundation (NSF)
   [0821202]; Pennsylvania Department of Health [4100043365]; NIMH National
   Research Service AwardUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [F31MH080582]; National Institute of Mental
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [N01 MH90001]; National Center for Research Resources
   (NCRR)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1 RR 024153]; VA Research Career Scientist and Merit
   Review Awards; NIH Roadmap for Medical ResearchUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA;
   Medical Research CouncilMedical Research Council UK (MRC) [G0801418B]
   Funding Source: researchfish; Direct For Biological SciencesNational
   Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)
   [0821202] Funding Source: National Science Foundation; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW006167, D43TW006167, D43TW006167,
   D43TW006167, D43TW006167] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153, UL1RR024153,
   UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM081293, R01GM081293,
   R01GM081293, R01GM081293] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [N01MH090001, N01MH090001, F31MH080582,
   K23MH072995, R10MH056242, N01MH090001, R01MH056242, R01MH063480,
   R01MH063480, R01MH056242, R01MH063480, R10MH056242, R01MH063480,
   N01MH090001, N01MH090001, N01MH090001, N01MH090001, R10MH056242,
   R01MH063480, R10MH056242, K23MH072995, K23MH072995, R01MH056242,
   N01MH090001, R01MH063480, R01MH063480, R01MH063480, R01MH063480,
   N01MH090001, F31MH080582, K23MH072995, R10MH056242, R10MH056242,
   R01MH063480, N01MH090001, N01MH090001, R01MH063480, N01MH090001,
   R01MH063480, R01MH056242, R01MH063480, R01MH063480, K23MH072995,
   N01MH090001, N01MH090001, R10MH056242, R01MH056242, R01MH056242] Funding
   Source: NIH RePORTER
FX Grant sponsor: Bristol-Myers Squibb Foundation; Grant sponsor:
   Bristol-Myers Squibb; Grant sponsor: Curridium Ltd; Grant sponsor:
   Pfizer; Grant sponsor: AstraZeneca; Grant sponsor: Hoffman-Roche; Grant
   sponsor: Lilly; Grant sponsor: Merck; Grant sponsor: Neurogen; Grant
   sponsor: National Institutes of Health; Grant numbers: MH56242, MH63480,
   GM081293; Grant sponsor: NSF; Grant number: 0821202; Grant sponsor:
   Pennsylvania Department of Health; Grant number: SAP# 4100043365; Grant
   sponsor: NIMH National Research Service Award; Grant number:
   F31MH080582; Grant sponsor: National Institute of Mental Health; Grant
   number: N01 MH90001; Grant sponsor: National Center for Research
   Resources (NCRR); Grant number: UL1 RR 024153.; This work was supported
   by National Institutes of Health (grant numbers MH56242, MH63480 to
   V.L.N., GM081293 to A.J.L.), NSF (grant 0821202 to A.J.L.), VA Research
   Career Scientist and Merit Review Awards (J.K.Y., S.L.), and
   Pennsylvania Department of Health (SAP# 4100043365; PI, R. Loeber). M.
   Talkowski was supported by an NIMH National Research Service Award
   (F31MH080582). K. McCann was an Undergraduate Research Scholar of the
   Arnold and Mabel Beckman Foundation. The CATIE project was funded by
   National Institute of Mental Health (contract N01 MH90001). Funding for
   the MGS sample was provided by the National Institute of Mental Health
   and the genotyping of samples was provided through the Genetic
   Association Information Network (GAIN). We thank Bernie Devlin, PhD for
   helpful advice and Jeffrey Muller of Applied Biosystems, Inc. for
   technical support. The data set used for the analyses described in this
   manuscript were obtained from the GAIN Database
   (http://view.ncbi.nlm.nih.gov/dbgap-controlled through dbGaP); accession
   number phs000017.v1.p1. Samples and associated phenotype data for the
   Linking Genome-Wide Association Study of Schizophrenia were provided by
   P. Gejman, MD. We thank Pamela Sklar, MD PhD for enabling access to the
   International Schizophrenia Consortium GWAS data. The project described
   was supported by grant number UL1 RR 024153 from the National Center for
   Research Resources (NCRR), a component of the National Institutes of
   Health (NIH) and NIH Roadmap for Medical Research, and its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official view of NCRR or NIH.
CR Akil M, 1999, AM J PSYCHIAT, V156, P1580, DOI 10.1176/ajp.156.10.1580
   AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445
   ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775
   Bamne MN, 2010, SCHIZOPHRENIA BULL, V36, P977, DOI 10.1093/schbul/sbp005
   Bannon MJ, 2002, P NATL ACAD SCI USA, V99, P6382, DOI 10.1073/pnas.092654299
   Bannon MJ, 2001, EUR NEUROPSYCHOPHARM, V11, P449, DOI 10.1016/S0924-977X(01)00122-5
   Bellgrove MA, 2005, NEUROPSYCHOLOGIA, V43, P1847, DOI 10.1016/j.neuropsychologia.2005.03.011
   Bertolino A, 2009, BRAIN, V132, P417, DOI 10.1093/brain/awn248
   Black D L, 2003, Prog Mol Subcell Biol, V31, P187
   Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720
   Brookes KJ, 2006, ARCH GEN PSYCHIAT, V63, P74, DOI 10.1001/archpsyc.63.1.74
   Cragg SJ, 2004, TRENDS NEUROSCI, V27, P270, DOI 10.1016/j.tins.2004.03.011
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Dean B, 2001, SCHIZOPHR RES, V52, P107, DOI 10.1016/S0920-9964(00)00096-7
   Fackenthal JD, 2008, DIS MODEL MECH, V1, P37, DOI 10.1242/dmm.000331
   FARDE L, 1994, SYNAPSE, V16, P93, DOI 10.1002/syn.890160203
   Fuke S, 2005, J BIOCHEM, V137, P205, DOI 10.1093/jb/mvi020
   Gainetdinov RR, 2002, TRENDS PHARMACOL SCI, V23, P367, DOI 10.1016/S0165-6147(02)02044-8
   Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964
   Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478
   GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J
   GIROS B, 1992, MOL PHARMACOL, V42, P383
   Gorwood P, 2003, BIOL PSYCHIAT, V53, P85, DOI 10.1016/S0006-3223(02)01440-3
   Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103
   Guindalini C, 2006, P NATL ACAD SCI USA, V103, P4552, DOI 10.1073/pnas.0504789103
   Hall DA, 1999, BIOCHEM PHARMACOL, V58, P285, DOI 10.1016/S0006-2952(99)00101-X
   Hashimoto T, 2005, J NEUROSCI, V25, P372, DOI 10.1523/JNEUROSCI.4035-04.2005
   Hiller M, 2008, TRENDS GENET, V24, P246, DOI 10.1016/j.tig.2008.03.003
   HIRAI M, 1988, JPN J PHARMACOL, V47, P237, DOI 10.1254/jjp.47.237
   HITRI A, 1995, BIOL PSYCHIAT, V37, P175, DOI 10.1016/0006-3223(94)00202-E
   Johnson MB, 2009, NEURON, V62, P494, DOI 10.1016/j.neuron.2009.03.027
   Kawarai T, 1997, GENE, V195, P11, DOI 10.1016/S0378-1119(97)00131-5
   Kelada SN, 2005, PHARMACOGENET GENOM, V15, P659, DOI 10.1097/01.fpc.0000170917.04275.d6
   Kirov G, 2004, BIOL PSYCHIAT, V55, P971, DOI 10.1016/j.biopsych.2004.01.025
   Laakso A, 2000, CURR PHARM DESIGN, V6, P1611, DOI 10.2174/1381612003398799
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D
   Laruelle M, 2000, BIOL PSYCHIAT, V47, P371, DOI 10.1016/S0006-3223(99)00257-7
   Lee CJ, 2003, BIOL PSYCHIAT, V54, P771, DOI 10.1016/S0006-3223(03)00375-5
   Lejeune F, 2005, CURR OPIN CELL BIOL, V17, P309, DOI 10.1016/j.ceb.2005.03.002
   Mansour HA, 2005, ANN MED, V37, P590, DOI 10.1080/07853890500357428
   Mateos JJ, 2005, PSYCHOPHARMACOLOGY, V181, P401, DOI 10.1007/s00213-005-2250-2
   Mateos JJ, 2007, PSYCHOPHARMACOLOGY, V191, P805, DOI 10.1007/s00213-006-0570-5
   Michelhaugh SK, 2005, J NEUROCHEM, V95, P1342, DOI 10.1111/j.1471-4159.2005.03458.x
   Mick E, 2008, AM J MED GENET B, V147B, P1182, DOI 10.1002/ajmg.b.30745
   Miyajima F, 2006, AM J MED GENET B, V141B, P769
   Mozley LH, 2001, AM J PSYCHIAT, V158, P1492, DOI 10.1176/appi.ajp.158.9.1492
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   O'Gara C, 2007, PHARMACOGENET GENOM, V17, P61, DOI 10.1097/01.fpc.0000236328.18928.4c
   Osborne RJ, 2006, HUM MOL GENET, V15, pR162, DOI 10.1093/hmg/ddl181
   Pellicano C, 2007, J NEURAL TRANSM, V114, P935, DOI 10.1007/s00702-006-0623-2
   Prata DP, 2009, ARCH GEN PSYCHIAT, V66, P1162, DOI 10.1001/archgenpsychiatry.2009.147
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185
   Ranum LPW, 2006, ANNU REV NEUROSCI, V29, P259, DOI 10.1146/annurev.neuro.29.051605.113014
   Richtand NM, 2006, NEUROPSYCHOPHARMACOL, V31, P2368, DOI 10.1038/sj.npp.1301163
   Rieder MJ, 2008, DRUG METAB REV, V40, P241, DOI 10.1080/03602530801952880 
   Schmauss C, 1996, J NEUROSCI, V16, P7902
   Schmitt GJE, 2006, EUR ARCH PSY CLIN N, V256, P115, DOI 10.1007/s00406-005-0618-2
   SEEMAN P, 1990, FASEB J, V4, P2737
   SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x
   Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192
   Sjoholm H, 2004, PSYCHOPHARMACOLOGY, V173, P27, DOI 10.1007/s00213-003-1700-y
   Sotnikova Tatyana D., 2006, CNS & Neurological Disorders-Drug Targets, V5, P45, DOI 10.2174/187152706784111579
   Stalder L, 2008, TRENDS CELL BIOL, V18, P315, DOI 10.1016/j.tcb.2008.04.005
   Steiner B, 2004, HUM MUTAT, V24, P120, DOI 10.1002/humu.20064
   Stroup TS, 2006, AM J PSYCHIAT, V163, P611, DOI 10.1176/appi.ajp.163.4.611
   Sugnet CW, 2006, PLOS COMPUT BIOL, V2, P22, DOI 10.1371/journal.pcbi.0020004
   Sullivan PF, 2008, MOL PSYCHIATR, V13, P570, DOI 10.1038/mp.2008.25
   Talkowski ME, 2008, HUM MOL GENET, V17, P747, DOI 10.1093/hmg/ddm347
   Talkowski ME, 2007, SCHIZOPHRENIA BULL, V33, P1071, DOI 10.1093/schbul/sbm076
   Tarnok Z, 2007, AM J MED GENET B, V144B, P900, DOI 10.1002/ajmg.b.30517
   Tobler Andreas R, 2005, J Biomol Tech, V16, P398
   Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008
   VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8
   VANDENBERGH DJ, 1992, GENOMICS, V14, P1104, DOI 10.1016/S0888-7543(05)80138-7
   Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x
   Yang YK, 2004, AM J PSYCHIAT, V161, P1496, DOI 10.1176/appi.ajp.161.8.1496
   Yoder KK, 2004, SCHIZOPHR RES, V71, P371, DOI 10.1016/j.schres.2004.03.015
   Zatkova A, 2004, HUM MUTAT, V24, P491, DOI 10.1002/humu.20103
NR 79
TC 10
Z9 10
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1552-4841
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD DEC
PY 2010
VL 153B
IS 8
BP 1434
EP 1447
DI 10.1002/ajmg.b.31125
PG 14
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 685IU
UT WOS:000284623200007
PM 20957647
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Payton, A
   Miyajima, F
   Ollier, W
   Rabbitt, P
   Pickles, A
   Weiss, V
   Pendleton, N
   Horan, M
AF Payton, Antony
   Miyajima, Fabio
   Ollier, William
   Rabbitt, Patrick
   Pickles, Andrew
   Weiss, Volkmar
   Pendleton, Neil
   Horan, Michael
TI Investigation of a functional quinine oxidoreductase (NQO2) polymorphism
   and cognitive decline
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE NAD(P)H dehydrogenase quinone 2; NQO2; Polymorphism; Cognition; Genes;
   Association
AB NAD(P)H dehydrogenase quinone 2 (NQO2) is a quinone reductase whose functions include the reduction of both oxidative stress during the redox cycle and neurotoxicity caused by the metabolism of catecholamines. We have investigated a functional non-synonymous exon 3 single nucleotide polymorphism (rs1143684) within the NQO2 gene for association with cognitive decline using a cohort of 722 community-dwelling older individuals aged 50 years and over. The volunteers had completed tests that measured fluid intelligence, processing speed, immediate/delayed verbal recall and semantic memory. We observed a nominal significant association between this polymorphism and the trajectory of delayed memory recall over time (p = 0.029). No other associations were seen with the decline of other cognitive abilities. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Payton, Antony; Miyajima, Fabio; Ollier, William; Weiss, Volkmar] Univ Manchester, Ctr Integrated Genom Med Res, Manchester M13 9PT, Lancs, England.
   [Pendleton, Neil; Horan, Michael] Univ Manchester, Hope Hosp, Salford M6 8HD, Greater Manches, England.
   [Rabbitt, Patrick] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England.
   [Pickles, Andrew] Univ Manchester, Biostat Grp, Manchester M13 9PT, Lancs, England.
RP Payton, A (corresponding author), Univ Manchester, Ctr Integrated Genom Med Res, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM tony.payton@manchester.ac.uk; fmiyajima@postgrad.manchester.ac.uk;
   bill.ollier@manchester.ac.uk; patrick.rabbitt@psy.ox.ac.uk;
   andrew.pickles@manchester.ac.uk; volkmar-weiss@t-online.de;
   neil.pendleton@manchester.ac.uk; mike.horan@hope.man.ac.uk
RI Miyajima, Fabio/K-6587-2012; Pickles, Andrew/A-9625-2011; Pendleton,
   Neil/F-2333-2015
OI Miyajima, Fabio/0000-0002-1347-4825; Pickles,
   Andrew/0000-0003-1283-0346; Pendleton, Neil/0000-0003-0794-2386; Payton,
   Antony/0000-0003-0335-152X
FU Research into Ageing; Medical Research CouncilMedical Research Council
   UK (MRC) [G0100594, G0600237, G0900753, G0901461] Funding Source:
   researchfish
FX Blood collection and DNA extraction was partly funded by Research into
   Ageing.
NR 0
TC 6
Z9 7
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD FEB
PY 2010
VL 31
IS 2
BP 351
EP 352
DI 10.1016/j.neurobiolaging.2008.04.014
PG 2
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 584NN
UT WOS:000276759400015
PM 18538895
DA 2020-12-17
ER

PT J
AU Ali, FR
   Vasiliou, SA
   Haddley, K
   Paredes, UM
   Roberts, JC
   Miyajima, F
   Klenova, E
   Bubb, VJ
   Quinn, JP
AF Ali, Fahad R.
   Vasiliou, Sylvia A.
   Haddley, Kate
   Paredes, Ursula M.
   Roberts, Julian C.
   Miyajima, Fabio
   Klenova, Elena
   Bubb, Vivien J.
   Quinn, John P.
TI Combinatorial interaction between two human serotonin transporter gene
   variable number tandem repeats and their regulation by CTCF
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE behaviour; CCCTC-binding factor; human serotonin transporter;
   polymorphism; variable number tandem repeat
ID MESSENGER-RNA; AFFECTIVE-DISORDERS; POLYMORPHIC REGION; ALLELIC
   EXPRESSION; BIPOLAR DISORDER; PROMOTER REGION; RAT-BRAIN; ASSOCIATION;
   5-HTTLPR; ENHANCER
AB Two distinct variable number tandem repeats (VNTRs) within the human serotonin transporter gene (SLC6A4) have been implicated as predisposing factors for CNS disorders. The linked polymorphic region in the 5'-promoter exists as short (s) and long (l) alleles of a 22 or 23 bp elements. The second within intron 2 (Stin2) exists as three variants containing 9, 10 or 12 copies of a 16 or 17 bp element. These VNTRs, individually or in combination, supported differential reporter gene expression in rat neonate prefrontal cortical cultures. The level of reporter gene activity from the dual VNTR constructs indicated combinatorial action between the two domains. Chromatin immunoprecipitation demonstrated that both these VNTR domains can bind the CCCTC-binding factor and this correlated with the ability of exogenously supplied CCCTC-binding factor to modulate the expression supported by these reporter gene constructs. We suggest that the potential for interaction between multiple polymorphic domains should be incorporated into genetic association studies.
C1 [Ali, Fahad R.; Vasiliou, Sylvia A.; Haddley, Kate; Paredes, Ursula M.; Roberts, Julian C.; Miyajima, Fabio; Bubb, Vivien J.; Quinn, John P.] Univ Liverpool, Sch Biomed Sci, Liverpool L69 3GE, Merseyside, England.
   [Klenova, Elena] Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England.
RP Quinn, JP (corresponding author), Univ Liverpool, Sch Biomed Sci, Liverpool L69 3GE, Merseyside, England.
EM jquinn@liv.ac.uk
RI Miyajima, Fabio/K-6587-2012; Quinn, John/A-2972-2010; Paredes Esquivel,
   Ursula/C-2204-2012
OI Miyajima, Fabio/0000-0002-1347-4825; Quinn, John/0000-0003-3551-7803;
   Paredes Esquivel, Ursula/0000-0003-4777-9202
FU Wellcome TrustWellcome Trust [074955/Z/04/Z]; BBSRCBiotechnology and
   Biological Sciences Research Council (BBSRC) [BB/DO16754/9];
   Biotechnology and Biological Sciences Research CouncilBiotechnology and
   Biological Sciences Research Council (BBSRC) [BB/D016754/1] Funding
   Source: researchfish; Medical Research CouncilMedical Research Council
   UK (MRC) [G0401088, G0701003] Funding Source: researchfish
FX This work was supported by the Wellcome Trust (074955/Z/04/Z) and the
   BBSRC (BB/DO16754/9). The authors acknowledge Karen Collard and Iain
   Kirk for technical assistance.
CR Ansorge MS, 2004, SCIENCE, V306, P879, DOI 10.1126/science.1101678
   Barr CS, 2003, GENES BRAIN BEHAV, V2, P336, DOI 10.1046/j.1601-1848.2003.00051.x
   Battersby S, 1996, PSYCHIATR GENET, V6, P177, DOI 10.1097/00041444-199624000-00001
   Bengel D, 1999, MOL PSYCHIATR, V4, P463, DOI 10.1038/sj.mp.4000550
   Bennett AJ, 2002, MOL PSYCHIATR, V7, P118, DOI 10.1038/sj/mp/4000949
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Cervilla JA, 2006, AM J MED GENET B, V141B, P912, DOI 10.1002/ajmg.b.30455
   Champoux M, 2002, MOL PSYCHIATR, V7, P1058, DOI 10.1038/sj.mp.4001157
   Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200
   Cho HJ, 2005, MOL PSYCHIATR, V10, P771, DOI 10.1038/sj.mp.4001663
   Fumagalli F, 1996, BRAIN RES, V719, P225, DOI 10.1016/0006-8993(96)00119-9
   Guindalini C, 2006, P NATL ACAD SCI USA, V103, P4552, DOI 10.1073/pnas.0504789103
   Haddley K, 2008, NEUROCHEM RES, V33, P652, DOI 10.1007/s11064-007-9521-8
   Hansson SR, 1998, NEUROSCIENCE, V83, P1185, DOI 10.1016/S0306-4522(97)00444-2
   Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829
   Heils A, 1996, J NEUROCHEM, V66, P2621
   Heils A, 1997, J NEURAL TRANSM, V104, P1005, DOI 10.1007/BF01273314
   Hoehe MR, 1998, AM J MED GENET, V81, P1, DOI 10.1002/(SICI)1096-8628(19980207)81:1<1::AID-AJMG1>3.0.CO;2-2
   Hranilovic D, 2004, BIOL PSYCHIAT, V55, P1090, DOI 10.1016/j.biopsych.2004.01.029
   Hu XZ, 2005, ALCOHOL CLIN EXP RES, V29, P8, DOI 10.1097/01.ALC.0000150008.68473.62
   Kaiser R, 2002, AM J MED GENET, V114, P323, DOI 10.1002/ajmg.10119
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Klenova E, 2004, J NEUROSCI, V24, P5966, DOI 10.1523/JNEUROSCI.1150-04.2004
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   Lasky-Su JA, 2005, AM J MED GENET B, V133B, P110, DOI 10.1016/j.ajmg.b.30104
   Lebrand C, 1998, J COMP NEUROL, V401, P506
   Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527
   Lesch KP, 1997, J NEURAL TRANSM, V104, P1259, DOI 10.1007/BF01294726
   Lim JE, 2006, MOL PSYCHIATR, V11, P649, DOI 10.1038/sj.mp.4001797
   Lovejoy EA, 2003, EUR J NEUROSCI, V17, P417, DOI 10.1046/j.1460-9568.2003.02446.x
   MacKenzie A, 1999, P NATL ACAD SCI USA, V96, P15251, DOI 10.1073/pnas.96.26.15251
   Martin J, 2007, MOL PSYCHIATR, V12, P421, DOI 10.1038/sj.mp.4001952
   Mortensen OV, 1999, MOL BRAIN RES, V68, P141, DOI 10.1016/S0169-328X(99)00083-2
   Murphy DL, 2001, BRAIN RES BULL, V56, P487, DOI 10.1016/S0361-9230(01)00622-0
   Nakamura M, 2000, MOL PSYCHIATR, V5, P32, DOI 10.1038/sj.mp.4000698
   Ogilvie AD, 1996, LANCET, V347, P731, DOI 10.1016/S0140-6736(96)90079-3
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Parsey RV, 2006, AM J PSYCHIAT, V163, P48, DOI 10.1176/appi.ajp.163.1.48
   Philibert R, 2007, AM J MED GENET B, V144B, P101, DOI 10.1002/ajmg.b.30414
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Rees M, 1997, MOL PSYCHIATR, V2, P398, DOI 10.1038/sj.mp.4000256
   Roberts J, 2007, J NEUROSCI, V27, P2793, DOI 10.1523/JNEUROSCI.0892-06.2007
   Sakai K, 2002, NEUROSCI LETT, V327, P13, DOI 10.1016/S0304-3940(02)00348-8
   Wallace JA, 2007, CURR OPIN GENET DEV, V17, P400, DOI 10.1016/j.gde.2007.08.005
   Wendland JR, 2006, MOL PSYCHIATR, V11, P224, DOI 10.1038/sj.mp.4001789
   Willeit M, 2001, BIOL PSYCHIAT, V50, P8, DOI 10.1016/S0006-3223(00)01123-9
   Zalsman G, 2006, AM J PSYCHIAT, V163, P1588, DOI 10.1176/appi.ajp.163.9.1588
   Zlatanova J, 2009, CELL MOL LIFE SCI, V66, P1647, DOI 10.1007/s00018-009-8647-z
NR 48
TC 43
Z9 44
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD JAN
PY 2010
VL 112
IS 1
BP 296
EP 306
DI 10.1111/j.1471-4159.2009.06453.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 535UK
UT WOS:000272997000027
PM 19860858
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Dunham, JS
   Deakin, JFW
   Miyajima, F
   Payton, A
   Toro, CT
AF Dunham, J. S.
   Deakin, J. F. W.
   Miyajima, F.
   Payton, A.
   Toro, C. T.
TI Expression of hippocampal brain-derived neurotrophic factor and its
   receptors in Stanley consortium brains
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Neurotrophin; Expression; Polymorphism; Postmortem; Schizophrenia; Mood
   disorders
ID TRKB MESSENGER-RNA; FAMILY-BASED ASSOCIATION; ANTIPSYCHOTIC-DRUGS; MOOD
   DISORDERS; SCHIZOPHRENIC PSYCHOSES; PREFRONTAL CORTEX; BIPOLAR DISORDER;
   RAT HIPPOCAMPUS; FACTOR BDNF; FACTOR GENE
AB Several lines of evidence implicate BDNF in the pathophysiology of psychiatric illness. BDNF polymorphisms have also been associated with the risk of schizophrenia and mood disorders. We therefore investigated whether levels of (pro)BDNF and receptor proteins, TrkB and p75, are altered in hippocampus in schizophrenia and mood disorder and whether polymorphisms in each gene influenced protein expression. Formalin-fixed paraffin-embedded hippocampal sections from subjects with schizophrenia, major depressive disorder (MDD), bipolar disorder (BPD) and non-psychiatric controls were obtained from the Stanley Foundation Neuropathology Consortium. (pro)BDNF, TrkB(T1) and p75 protein densities were quantified by immunoautoradiography and DNA extracted from each subject was used to determine the effect of genotype on protein expression. In MDD, reductions in (pro)BDNF were seen in all layers of the right but not the left hippocampus with no changes in the dentate gyrus. The pattern was similar but less marked for BPD. In addition, BPD but not MDD patients, had bilateral reductions in p75 in hippocampal layers but not in dentate gyrus. No changes in TrkB(T1) density were seen in any diagnosis. These findings suggest MDD and BPD may share impairment in (pro)BDNF expression. However, BPD may involve impairments of both (pro)BDNF and p75 receptor, whereas MDD may involve impaired (pro)BDNF alone. Moreover, the lateralisation of changes may indicate a role of asymmetry in vulnerability to MDD. Hippocampal (pro)BDNF and receptor levels were also affected by genotype, suggesting that allelic variations are important in the hippocampal abnormalities seen in these psychiatric disorders. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Toro, C. T.] Cranfield Univ, Translat Med Res Grp, Cranfield Hlth, Cranfield MK43 0AL, Beds, England.
   [Dunham, J. S.; Deakin, J. F. W.] Univ Manchester, Stanley Brain Res Lab, Neurosci & Psychiat Unit, Manchester M13 9PT, Lancs, England.
   [Miyajima, F.; Payton, A.] Univ Manchester, CIGMR, Manchester M13 9PT, Lancs, England.
RP Toro, CT (corresponding author), Cranfield Univ, Translat Med Res Grp, Cranfield Hlth, 1st Floor,Vincent Bldg, Cranfield MK43 0AL, Beds, England.
EM c.toro@cranfield.ac.uk
RI Miyajima, Fabio/K-6587-2012
OI Miyajima, Fabio/0000-0002-1347-4825; Deakin, John/0000-0002-2750-962X;
   Toro, Carla/0000-0001-6351-1340; Payton, Antony/0000-0003-0335-152X
FU Stanley Medical Research Institute [LSHM-CF-2004-503474]
FX Postmortem brains were donated by The Stanley Medical Research
   Institutes' Brain Collection, courtesy of Drs. Michael B. Knable, E.
   Fuller Torrey, Maree J. Webster, Serge Weis, and Robert H. Yolken. The
   laboratory and salary of J.S. Dunham was funded by an International
   Collaborating Centre grant from the Stanley Medical Research Institute
   and by NewMood EU Integrated Research Programme LSHM-CF-2004-503474.
   Sincere thanks also to Miss Hazel Platt at the Centre for Integrated
   Genomics Research (CIGMR), University of Manchester, UK.
CR Adams JH, 2005, AM J MED GENET B, V132B, P90, DOI 10.1002/ajmg.b.30084
   ALLEN SJ, 1994, NEUROSCIENCE, V60, P825, DOI 10.1016/0306-4522(94)90507-X
   Angelucci F, 2005, MOL PSYCHIATR, V10, P345, DOI 10.1038/sj.mp.4001637
   Ashe PC, 2002, BRAIN RES, V956, P126, DOI 10.1016/S0006-8993(02)03176-1
   Bai O, 2003, J NEUROSCI RES, V71, P127, DOI 10.1002/jnr.10440
   Bai O, 2002, J NEUROSCI RES, V69, P278, DOI 10.1002/jnr.10290
   Baxter GT, 1997, J NEUROSCI, V17, P2683
   BIFFO S, 1995, DEVELOPMENT, V121, P2461
   BROUHA AKW, 1996, SOC NEUR ABSTR, P1680
   Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6
   Chlan-Fourney J, 2002, BRAIN RES, V954, P11, DOI 10.1016/S0006-8993(02)03215-8
   Chuang DM, 2005, ANN NY ACAD SCI, V1053, P195, DOI 10.1196/annals.1344.018
   Connor B, 1996, MOL BRAIN RES, V42, P1, DOI 10.1016/S0169-328X(96)00040-X
   COSTAFTEDA SG, 2007, BRAIN RESERACH REV
   Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131
   Del-Ben CM, 2005, NEUROPSYCHOPHARMACOL, V30, P1724, DOI 10.1038/sj.npp.1300728
   Djalali S, 2005, J NEUROCHEM, V92, P616, DOI 10.1111/j.1471-4159.2004.02911.x
   Dowlatshahi D, 1999, J NEUROCHEM, V73, P1121, DOI 10.1046/j.1471-4159.1999.0731121.x
   Durany N, 2001, SCHIZOPHR RES, V52, P79, DOI 10.1016/S0920-9964(00)00084-0
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Eide FF, 1996, J NEUROSCI, V16, P3123
   Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738
   Guillin O, 2004, INT REV NEUROBIOL, V59, P425
   Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092
   Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593
   Harrison PJ, 2004, PSYCHOPHARMACOLOGY, V174, P151, DOI 10.1007/s00213-003-1761-y
   Harrison PJ, 2002, BRAIN, V125, P1428, DOI 10.1093/brain/awf149
   Hashimoto K, 2004, BRAIN RES REV, V45, P104, DOI 10.1016/j.brainresrev.2004.02.003
   Heckers S, 2002, J NEURAL TRANSM, V109, P891, DOI 10.1007/s007020200073
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Iritani S, 2003, PROG NEURO-PSYCHOPH, V27, P801, DOI 10.1016/S0278-5846(03)00112-X
   Knable MB, 2004, MOL PSYCHIATR, V9, P609, DOI 10.1038/sj.mp.4001471
   Kunugi H, 2004, AM J MED GENET B, V129B, P44, DOI 10.1002/ajmg.b.30062
   Lessmann V, 1998, GEN PHARMACOL-VASC S, V31, P667
   Levinson DF, 2006, BIOL PSYCHIAT, V60, P84, DOI 10.1016/j.biopsych.2005.08.024
   Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445
   Li XM, 1999, J NEUROSCI RES, V56, P72, DOI 10.1002/(SICI)1097-4547(19990401)56:1<72::AID-JNR9>3.0.CO;2-0
   Lipska BK, 2001, EUR J NEUROSCI, V14, P135, DOI 10.1046/j.1460-9568.2001.01633.x
   Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x
   Nelson MD, 1998, ARCH GEN PSYCHIAT, V55, P433, DOI 10.1001/archpsyc.55.5.433
   Neves-Pereira M, 2005, MOL PSYCHIATR, V10, P208, DOI 10.1038/sj.mp.4001575
   Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288
   NIBUYA M, 1995, J NEUROSCI, V15, P7539
   Norbury R, 2007, BRIT J PSYCHIAT, V190, P531, DOI 10.1192/bjp.bp.106.031393
   Ozbas-Gerceker F, 2004, NEUROPATH APPL NEURO, V30, P651, DOI 10.1111/j.1365-2990.2004.00582.x
   Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x
   Saarelainen T, 2003, J NEUROSCI, V23, P349
   Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058
   Spires TL, 2004, J NEUROSCI, V24, P2270, DOI 10.1523/JNEUROSCI.1658-03.2004
   Strauss J, 2004, AM J MED GENET B, V131B, P16, DOI 10.1002/ajmg.b.30041
   Szekeres G, 2003, SCHIZOPHR RES, V65, P15, DOI 10.1016/S0920-9964(02)00505-4
   Takahashi M, 2000, MOL PSYCHIATR, V5, P293, DOI 10.1038/sj.mp.4000718
   Thome J, 1998, J NEURAL TRANSM, V105, P85, DOI 10.1007/s007020050040
   Toro C, 2005, SCHIZOPHR RES, V80, P323, DOI 10.1016/j.schres.2005.07.003
   Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957
   Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009
   Webster MJ, 2002, DEV BRAIN RES, V139, P139, DOI 10.1016/S0165-3806(02)00540-0
   WEBSTER MJ, 2004, COMMUNICATION
   Wright IC, 2000, AM J PSYCHIAT, V157, P16, DOI 10.1176/ajp.157.1.16
   Yang JM, 2009, NAT NEUROSCI, V12, P113, DOI 10.1038/nn.2244
NR 60
TC 101
Z9 109
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD SEP
PY 2009
VL 43
IS 14
BP 1175
EP 1184
DI 10.1016/j.jpsychires.2009.03.008
PG 10
WC Psychiatry
SC Psychiatry
GA 509VJ
UT WOS:000271046700007
PM 19376528
DA 2020-12-17
ER

PT J
AU Luciano, M
   Miyajima, F
   Lind, PA
   Bates, TC
   Horan, M
   Harris, SE
   Wright, MJ
   Ollier, WE
   Hayward, C
   Pendleton, N
   Gow, AJ
   Visscher, PM
   Starr, JM
   Deary, IJ
   Martin, NG
   Payton, A
AF Luciano, M.
   Miyajima, F.
   Lind, P. A.
   Bates, T. C.
   Horan, M.
   Harris, S. E.
   Wright, M. J.
   Ollier, W. E.
   Hayward, C.
   Pendleton, N.
   Gow, A. J.
   Visscher, P. M.
   Starr, J. M.
   Deary, I. J.
   Martin, N. G.
   Payton, A.
TI Variation in the dysbindin gene and normal cognitive function in three
   independent population samples
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE Cognitive ability; DTNBP1; haplotypes; memory; normal population
ID DTNBP1 GENE; PREFRONTAL CORTEX; RISK HAPLOTYPE; SCHIZOPHRENIA;
   ASSOCIATION; LINKAGE; INTELLIGENCE; EXPRESSION; LOCUS; IDENTIFICATION
AB The association between DTNBP1 genotype and cognitive abilities was investigated in three population samples (1054 Scottish, 1806 Australian and 745 English) of varying age. There was evidence in each of the cohorts for association (P < 0.05) to single nucleotide polymorphisms (SNPs) and haplotypes previously shown to relate to cognition. By comparison with previous findings, these associations included measures of memory, and there was at best equivocal evidence of association with general cognitive ability. Of the SNPs typed in all three cohorts, rs2619528 and rs1011313 showed significant association with measures of executive function in two cohorts, rs1018381 showed significant association with verbal ability in one cohort and rs2619522 showed significance/marginal significance with tests of memory, speed and executive function in two cohorts. For all these SNPs, the direction and magnitude of the allelic effects were consistent between cohorts and with previous findings. In the English cohort, a previously untested SNP (rs742105) located in a distinct haplotype block upstream of the other SNPs showed the strongest significance (P < 0.01) for measures of memory but weaker significance for general cognitive ability. Our results therefore support involvement of the dysbindin gene in cognitive function, but further work is needed to clarify the specific functional variants involved and the cognitive abilities with which they are associated.
C1 [Luciano, M.; Bates, T. C.; Harris, S. E.; Gow, A. J.; Deary, I. J.] Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland.
   [Miyajima, F.; Ollier, W. E.; Payton, A.] Univ Manchester, Ctr Integrated Genom Med Res, Manchester, Lancs, England.
   [Lind, P. A.; Wright, M. J.; Visscher, P. M.; Martin, N. G.] Queensland Inst Med Res, Genet Epidemiol Unit, Brisbane, Qld 4006, Australia.
   [Horan, M.; Pendleton, N.] Univ Manchester, Salford, Greater Manches, England.
   [Hayward, C.] Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Starr, J. M.] Univ Edinburgh, Royal Victoria Hosp, Dept Geriatr Med, Edinburgh, Midlothian, Scotland.
RP Luciano, M (corresponding author), Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland.
EM michelle.luciano@ed.ac.uk
RI Deary, Ian J/C-6297-2009; Pendleton, Neil/F-2333-2015; Gow, Alan
   J/A-6070-2009; Luciano, Michelle/F-7277-2010; Visscher,
   Peter/ABB-6151-2020; Miyajima, Fabio/K-6587-2012; Wright, Margaret
   J/H-3308-2014; Starr, John/C-8951-2011; Wright, Margaret
   Jane/A-4560-2016; Bates, Timothy C/C-9637-2010; Lind, Penelope
   A/B-2553-2009; Hayward, Caroline/M-8818-2016
OI Deary, Ian J/0000-0002-1733-263X; Pendleton, Neil/0000-0003-0794-2386;
   Gow, Alan J/0000-0002-3320-4531; Luciano, Michelle/0000-0003-0935-7682;
   Visscher, Peter/0000-0002-2143-8760; Miyajima,
   Fabio/0000-0002-1347-4825; Wright, Margaret Jane/0000-0001-7133-4970;
   Bates, Timothy C/0000-0002-1153-9007; Lind, Penelope
   A/0000-0002-3887-2598; Hayward, Caroline/0000-0002-9405-9550; Martin,
   Nicholas/0000-0003-4069-8020; Payton, Antony/0000-0003-0335-152X
FU Research Into Ageing [LBC1936]; Biotechnology and Biological Sciences
   Research CouncilBiotechnology and Biological Sciences Research Council
   (BBSRC); Engineering and Physical Sciences Research CouncilEngineering &
   Physical Sciences Research Council (EPSRC); Economic and Social Research
   CouncilEconomic & Social Research Council (ESRC); Medical Research
   CouncilMedical Research Council UK (MRC); ARCAustralian Research Council
   [A79600334, A79906588, A79801419, DP0212016, DP0343921]; Human Frontiers
   of Science ProgramHuman Frontier Science Program [rg0154/1998-B];
   Australian National Health and Medical Research CouncilNational Health
   and Medical Research Council of Australia; Centre for Integrated Genomic
   Medical Research/University of Manchester and Capes Foundation; Medical
   Research CouncilMedical Research Council UK (MRC) [G0700704, G0700704B]
   Funding Source: researchfish
FX We thank the participants and their families for their co-operation. The
   LBC1936 data collection was supported by a programme grant from Research
   Into Ageing. The work was undertaken by the University of Edinburgh
   Centre for Cognitive Ageing and Cognitive Epidemiology, part of the
   cross-council Lifelong Health and Wellbeing Initiative. Funding from the
   Biotechnology and Biological Sciences Research Council, Engineering and
   Physical Sciences Research Council, Economic and Social Research Council
   and Medical Research Council is gratefully acknowledged. We thank the
   study Secretary Paula Davies; Michelle Taylor, Janie Corley, Caroline
   Brett and Caroline Cameron for data collection and data entry; the
   nurses and other staff at the Wellcome Trust Clinical Research Facility
   where the data were collected; and the staff at Lothian Health Board and
   at the SCRE Centre, University of Glasgow. Australian data collection
   was funded by ARC grants (A79600334, A79906588, A79801419, DP0212016 and
   DP0343921) and the Human Frontiers of Science Program ( grant
   rg0154/1998-B). We thank Marlene Grace and Ann Eldridge for data
   collection. P. M. V. is supported by the Australian National Health and
   Medical Research Council. Blood collection and DNA extraction for the
   Dyne Steele cohort was partly funded by Research into Ageing. F. M.
   would like to acknowledge the Centre for Integrated Genomic Medical
   Research/University of Manchester and Capes Foundation for their
   support.
CR Beardsall L, 1998, BRIT J CLIN PSYCHOL, V37, P229, DOI 10.1111/j.2044-8260.1998.tb01297.x
   Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200
   Bray NJ, 2008, HUM MOL GENET, V17, P1169, DOI 10.1093/hmg/ddn006
   Bray NJ, 2005, HUM MOL GENET, V14, P1947, DOI 10.1093/hmg/ddi199
   Burdick KE, 2007, SCHIZOPHR RES, V89, P169, DOI 10.1016/j.schres.2006.09.008
   Burdick KE, 2006, HUM MOL GENET, V15, P1563, DOI 10.1093/hmg/ddi481
   Deary Ian J, 2007, BMC Geriatr, V7, P28, DOI 10.1186/1471-2318-7-28
   Donohoe G, 2008, BIOL PSYCHIAT, V63, P484, DOI 10.1016/j.biopsych.2007.07.022
   Donohoe G, 2007, NEUROPSYCHOLOGIA, V45, P454, DOI 10.1016/j.neuropsychologia.2006.06.016
   Fallgatter AJ, 2006, NEUROPSYCHOPHARMACOL, V31, P2002, DOI 10.1038/sj.npp.1301003
   FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198
   Funke B, 2004, AM J HUM GENET, V75, P891, DOI 10.1086/425279
   Hallmayer JF, 2005, AM J HUM GENET, V77, P468, DOI 10.1086/432816
   HEIM A, 1970, INTELLIGENCE PERSONA
   JACKSON DN, 1984, MANUAL MULTIDIMENSIO
   JACKSON DN, 1998, MULTIDIMENSIONAL APT
   Jensen A. R., 1998, G FACTOR SCI MENTAL
   Lezak M, 2004, NEUROPSYCHOLOGICAL T
   Luciano M, 2006, BEHAV GENET, V36, P45, DOI 10.1007/s10519-005-9003-1
   Maziade M, 1997, AM J MED GENET, V74, P311, DOI 10.1002/(SICI)1096-8628(19970531)74:3<311::AID-AJMG13>3.0.CO;2-R
   McGregor B, 1999, GENET EPIDEMIOL, V16, P40, DOI 10.1002/(SICI)1098-2272(1999)16:1<40::AID-GEPI4>3.0.CO;2-1
   NELSON HE, 1991, NATL ADULT READING 2
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Pomarol-Clotet E, 2008, PSYCHOL MED, V38, P1185, DOI 10.1017/S0033291708003565
   Posthuma D, 2005, AM J HUM GENET, V77, P318, DOI 10.1086/432647
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rabbitt PMA, 2004, AGING NEUROPSYCHOL C, V11, P245, DOI 10.1080/13825580490511116
   Raven J. C, 1965, MILL HILL VOCABULARY
   SCHONELL FJ, 1960, DIAGNOSTIC ATTAINMEN
   Scottish Council for Research in Education, 1949, TREND SCOTT INT COMP
   *SPSS INC, 2005, SPSS 14 0 WIND
   Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750
   Tang JX, 2003, MOL PSYCHIATR, V8, P717, DOI 10.1038/sj.mp.4001287
   van den Oord EJCG, 2003, MOL PSYCHIATR, V8, P499, DOI 10.1038/sj.mp.4001263
   Wainwright M, 2004, BEHAV GENET, V34, P365, DOI 10.1023/B:BEGE.0000023642.34853.cb
   Wechsler D., 1981, WECHSLER ADULT INTEL
   WECHSLER D, 1998, WMS IIIUK ADM SCORIN
   Weickert CS, 2004, ARCH GEN PSYCHIAT, V61, P544, DOI 10.1001/archpsyc.61.6.544
   Weinberger DR, 1996, PHILOS T R SOC B, V351, P1495, DOI 10.1098/rstb.1996.0135
   Williams NM, 2004, ARCH GEN PSYCHIAT, V61, P336, DOI 10.1001/archpsyc.61.4.336
   Wright M, 2001, Twin Res, V4, P48, DOI 10.1375/1369052012146
   Zinkstok JR, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-19
NR 43
TC 39
Z9 41
U1 0
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1601-1848
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD MAR
PY 2009
VL 8
IS 2
BP 218
EP 227
DI 10.1111/j.1601-183X.2008.00462.x
PG 10
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 412WY
UT WOS:000263756100010
PM 19077176
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Quinn, JP
   Horan, M
   Pickles, A
   Ollier, WE
   Pendleton, N
   Payton, A
AF Miyajima, F.
   Quinn, J. P.
   Horan, M.
   Pickles, A.
   Ollier, W. E.
   Pendleton, N.
   Payton, A.
TI Additive effect of BDNF and REST polymorphisms is associated with
   improved general cognitive ability
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE association; BDNF; cognition; general cognitive ability; interaction;
   polymorphism; REST; VNTR
ID NEUROTROPHIC FACTOR; VAL66MET POLYMORPHISM; HUMAN-MEMORY; TRANSCRIPTION;
   REST/NRSF; GENOTYPE; AGE
AB Brain-derived neurotrophic factor (BDNF) is a pleiotropic protein involved in neuronal proliferation, differentiation, synaptic plasticity and survival. Independent studies investigating association between the functional BDNF Val66Met polymorphism and cognitive abilities have reported some conflicting findings, which may reflect inadequate sample size, variation in testing methods, population stratification or the confounding effects of other genes. To test the latter hypothesis, we screened and genotyped polymorphisms in the RE1-silencing transcription factor (REST) gene whose function includes the downregulation of BDNF expression. We identified an exon 4 hexadecapeptide variable number tandem repeat (VNTR) with either four or five copies that was located within a proline-rich domain and investigated a further five single nucleotide polymorphisms (SNPs). Using a cohort of 746 community-dwelling older volunteers, we analysed REST genotype data both independently and in combination with the BDNF Val66Met polymorphism. A haplotype within the REST gene containing the four copy VNTR and a non-synonymous SNP showed a weak but significant association with a higher score of general intelligence (P = 0.05). Analysis of this haplotype and the BDNF Val66Met polymorphism in combination showed a significant interaction (global P-value = 0.0003) with an additive increase in cognitive performance for those possessing the BDNF Val66 allele and the REST haplotype containing the four copy repeat (P = 0.004). The REST haplotypes in combination with the BDNF Met66 polymorphism did not reduce cognitive performance more than the independent influence of the Met66 allele. Our results suggest that investigation of a common REST polymorphism may be necessary to help reduce contrasting reports based around BDNF Val66Met and cognition.
C1 [Miyajima, F.; Ollier, W. E.; Payton, A.] Univ Manchester, Ctr Integrated Genom Med Res, Sch Med, Manchester M13 9PT, Lancs, England.
   [Quinn, J. P.] Univ Liverpool, Sch Biomed Sci, Dept Human Anat & Cell Biol, Liverpool L69 3BX, Merseyside, England.
   [Horan, M.; Pendleton, N.] Univ Manchester, Hope Hosp, Sch Translat Med, Salford, Greater Manches, England.
   [Pickles, A.] Univ Manchester, Biostat Grp, Manchester M13 9PT, Lancs, England.
RP Payton, A (corresponding author), Univ Manchester, Ctr Integrated Genom Med Res, Sch Med, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM tony.payton@manchester.ac.uk
RI Pendleton, Neil/F-2333-2015; Miyajima, Fabio/K-6587-2012; Quinn,
   John/A-2972-2010; Pickles, Andrew/A-9625-2011
OI Pendleton, Neil/0000-0003-0794-2386; Miyajima,
   Fabio/0000-0002-1347-4825; Quinn, John/0000-0003-3551-7803; Pickles,
   Andrew/0000-0003-1283-0346; Payton, Antony/0000-0003-0335-152X
FU Capes FoundationCAPES; Medical Research CouncilMedical Research Council
   UK (MRC) [G0701003] Funding Source: researchfish
FX We thank Research into Ageing for funding of blood collection and DNA
   extraction and Capes Foundation for supporting FM and part of this work.
   J. P. Q. thank the Biotechnology and Biological Sciences Research
   Council (BBSRC).
CR Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101
   Dempster E, 2005, AM J MED GENET B, V134B, P73, DOI 10.1002/ajmg.b.30150
   Echeverria D, 2005, NEUROTOXICOL TERATOL, V27, P781, DOI 10.1016/j.ntt.2005.08.001
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Hansell NK, 2007, GENES BRAIN BEHAV, V6, P260, DOI 10.1111/j.1601-183X.2006.00254.x
   Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003
   Harris SE, 2006, MOL PSYCHIATR, V11, P505, DOI 10.1038/sj.mp.4001799
   Heim AW, 1970, AH4 GROUP TEST GEN I
   Hranilovic D, 2004, BIOL PSYCHIAT, V55, P1090, DOI 10.1016/j.biopsych.2004.01.029
   Liguori M, 2007, GENES BRAIN BEHAV, V6, P177, DOI 10.1111/j.1601-183X.2006.00245.x
   Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x
   Okada T, 2006, MOL PSYCHIATR, V11, P695, DOI 10.1038/sj.mp.4001822
   Oroszi G, 2006, ANN RHEUM DIS, V65, P1330, DOI 10.1136/ard.2006.051623
   Payton A, 2005, MOL PSYCHIATR, V10, P1133, DOI 10.1038/sj.mp.4001733
   Plomin R, 2003, MOL PSYCHIATR, V8, P1, DOI 10.1038/sj.mp.4001249
   Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004
   Pruunsild P, 2007, GENOMICS, V90, P397, DOI 10.1016/j.ygeno.2007.05.004
   Rabbitt PMA, 2004, AGING NEUROPSYCHOL C, V11, P245, DOI 10.1080/13825580490511116
   Raven J. C, 1965, MILL HILL VOCABULARY
   Rybakowski JK, 2003, BIPOLAR DISORD, V5, P468, DOI 10.1046/j.1399-5618.2003.00071.x
   Rybakowski JK, 2006, PSYCHIAT CLIN NEUROS, V60, P70, DOI 10.1111/j.1440-1819.2006.01462.x
   SAVAGE RD, 1984, ALPHBET CODING TASK
   *STATACORP, 2003, STAT STAT SOFTW REL, V1
   Strauss J, 2004, NEUROMOL MED, V5, P181, DOI 10.1385/NMM:5:3:181
   Tan YL, 2005, SCHIZOPHR RES, V77, P355, DOI 10.1016/j.schres.2005.03.012
   Westfall F.H., 1993, RESAMPLING BASED MUL
   Zivadinov R, 2007, HUM MOL GENET, V16, P2659, DOI 10.1093/hmg/ddm189
   Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219
NR 28
TC 22
Z9 22
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1601-1848
EI 1601-183X
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD OCT
PY 2008
VL 7
IS 7
BP 714
EP 719
DI 10.1111/j.1601-183X.2008.00409.x
PG 6
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 355AK
UT WOS:000259680800002
PM 18518926
OA Bronze
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Ollier, W
   Mayes, A
   Jackson, A
   Thacker, N
   Rabbitt, P
   Pendleton, N
   Horan, M
   Payton, A
AF Miyajima, F.
   Ollier, W.
   Mayes, A.
   Jackson, A.
   Thacker, N.
   Rabbitt, P.
   Pendleton, N.
   Horan, M.
   Payton, A.
TI Brain-derived neurotrophic factor polymorphism Val66Met influences
   cognitive abilities in the elderly
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE association; BDNF; cognition; elderly; genes; memory; polymorphism
ID HUMAN-MEMORY; MET ALLELE; BDNF; ASSOCIATION; VOLUME; SECRETION;
   GENOTYPE; GENES; AGE
AB A functional brain-derived neurotrophic factor (BDNF) gene polymorphism (Val66Met) that alters activity-dependent secretion has previously been reported to influence cognitive functioning. A large proportion of these reports suggest that the Met allele, which results in reduced secretion of BDNF, impairs long-term memory as a direct consequence of its influence on hippocampal function but has little influence on working memory. In contrast, other studies have found that the Met allele can also play a protective role in certain neurological conditions and is associated with improved non-verbal reasoning skills in the elderly suggesting effects that appear disease, domain and age specific. We have investigated six haplotype-tagging single nucleotide polymorphisms (SNPs) using a cohort of 722 elderly individuals who have completed cognitive tests that measured the domains of fluid intelligence, processing speed and memory. We found that the presence of the Met allele reduced cognitive performance on all cognitive tests. This reached nominal significance for tests of processing speed (P = 0.001), delayed recall (P = 0.037) and general intelligence (g) (P = 0.008). No association was observed between cognitive tests and any other SNPs once the Val66Met was adjusted for. Our results support initial findings that the Met allele is associated with reduced cognitive functioning. We found no evidence that the Met allele plays a protective role in older non-demented individuals. Magnetic resonance imaging data collected from a subgroup of 61 volunteers showed that the left and right hippocampus were 5.0% and 3.9% smaller, respectively, in those possessing the Met allele, although only a non-significant trend was observed.
C1 [Miyajima, F.; Ollier, W.; Payton, A.] Univ Manchester, Ctr Integrated Genom Med Res, Manchester M13 9PT, Lancs, England.
   [Mayes, A.] Univ Manchester, Div Psychol Sci, Dept Psychol, Manchester M13 9PT, Lancs, England.
   [Thacker, N.] Univ Manchester, Div Canc & Imaging Sci, Dept Imaging Sci & Biomed Engn, Manchester M13 9PT, Lancs, England.
   [Rabbitt, P.] Univ Oxford, Dept Expt Psychol, Oxford OX1 2JD, England.
   [Pendleton, N.; Horan, M.] Univ Manchester, Div Translat Med, Dept Clin Neurosci, Manchester, Lancs, England.
RP Miyajima, F (corresponding author), Univ Manchester, Ctr Integrated Genom Med Res, Manchester M13 9PT, Lancs, England.
EM tony.payton@manchester.ac.uk
RI Pendleton, Neil/F-2333-2015; Miyajima, Fabio/K-6587-2012; Kennedy,
   Kristen M/B-4699-2008
OI Pendleton, Neil/0000-0003-0794-2386; Miyajima,
   Fabio/0000-0002-1347-4825; Kennedy, Kristen M/0000-0001-5373-9026;
   JACKSON, ALAN/0000-0002-1623-0383; Payton, Antony/0000-0003-0335-152X
CR Bueller JA, 2006, BIOL PSYCHIAT, V59, P812, DOI 10.1016/j.biopsych.2005.09.022
   Dempster E, 2005, AM J MED GENET B, V134B, P73, DOI 10.1002/ajmg.b.30150
   Devlin B, 1997, NATURE, V388, P468, DOI 10.1038/41319
   Echeverria D, 2005, NEUROTOXICOL TERATOL, V27, P781, DOI 10.1016/j.ntt.2005.08.001
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Frodl T, 2007, ARCH GEN PSYCHIAT, V64, P410, DOI 10.1001/archpsyc.64.4.410
   Hansell NK, 2007, GENES BRAIN BEHAV, V6, P260, DOI 10.1111/j.1601-183X.2006.00254.x
   Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003
   Harris SE, 2006, MOL PSYCHIATR, V11, P505, DOI 10.1038/sj.mp.4001799
   Heim AW, 1970, AH4 GROUP TEST GEN I
   Huang R, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.044883
   Liu QR, 2005, AM J MED GENET B, V134B, P93, DOI 10.1002/ajmg.b.30109
   Mackay CE, 1998, BEHAV NEUROL, V11, P3, DOI 10.1155/1998/285061
   Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002
   Oroszi G, 2006, ANN RHEUM DIS, V65, P1330, DOI 10.1136/ard.2006.051623
   Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004
   Plomin R, 1999, NATURE, V402, pC25, DOI 10.1038/35011520
   Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004
   Rabbitt PMA, 2004, AGING NEUROPSYCHOL C, V11, P245, DOI 10.1080/13825580490511116
   Rybakowski JK, 2003, BIPOLAR DISORD, V5, P468, DOI 10.1046/j.1399-5618.2003.00071.x
   Rybakowski JK, 2006, PSYCHIAT CLIN NEUROS, V60, P70, DOI 10.1111/j.1440-1819.2006.01462.x
   Savage RD, 1984, ALPHABET CODING TASK, V15
   Strauss J, 2004, NEUROMOL MED, V5, P181, DOI 10.1385/NMM:5:3:181
   Tan YL, 2005, SCHIZOPHR RES, V77, P355, DOI 10.1016/j.schres.2005.03.012
   Tsai SJ, 2004, NEUROPSYCHOBIOLOGY, V49, P13, DOI 10.1159/000075333
   Wang H, 2006, J NEUROCHEM, V96, P694, DOI 10.1111/j.1471-4159.2005.03572.x
   Zivadinov R, 2007, HUM MOL GENET, V16, P2659, DOI 10.1093/hmg/ddm189
NR 27
TC 149
Z9 153
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1601-1848
EI 1601-183X
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD JUN
PY 2008
VL 7
IS 4
BP 411
EP 417
DI 10.1111/j.1601-183X.2007.00363.x
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 292SK
UT WOS:000255286200004
PM 17973920
OA Bronze
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Haddley, K
   Bubb, J
   Deakin, JFW
   Pendleton, N
   Horan, M
   Ollier, W
   Payton, A
   Quinn, J
AF Miyajima, Fabio
   Haddley, Kate
   Bubb, Jill
   Deakin, J. F. William
   Pendleton, Neil
   Horan, Mike
   Ollier, William
   Payton, Antony
   Quinn, John
TI Functionality and association study of a novel variable number of tandem
   repeat (VNTR) polymorphism of dopamine transporter (SLC6A3) with general
   cognitive abilities
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Meeting Abstract
CT 14th World Congress on Psychiatric Genetics
CY OCT 28-NOV 01, 2006
CL Cagliari, ITALY
SP Int Soc Psychiat Genet
C1 Univ Manchester, Manchester M13 9PL, Lancs, England.
   Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
RI Pendleton, Neil/F-2333-2015; Miyajima, Fabio/K-6587-2012
OI Pendleton, Neil/0000-0003-0794-2386; Miyajima, Fabio/0000-0002-1347-4825
CR Badcock JC, 2005, J PSYCHIATR RES, V39, P11, DOI 10.1016/j.jpsychires.2004.05.002
NR 1
TC 1
Z9 1
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4841
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD OCT 5
PY 2006
VL 141B
IS 7
BP 769
EP 769
PG 1
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 089JW
UT WOS:000240877700377
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Payton, A
   Pendleton, N
   Horan, M
   Ollier, W
   Deakin, W
   John, S
AF Miyajima, F
   Payton, A
   Pendleton, N
   Horan, M
   Ollier, W
   Deakin, W
   John, S
TI Positive association of brain-derived neurotrophic factor (BDNF)
   polymorphism with cognition and memory recall in a healthy elderly
   population
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Meeting Abstract
CT 13th World Congress on Psychiatric Genetics
CY SEP 04-08, 2005
CL Boston, MA
SP Int Soc Psychiat Genet
C1 Univ Manchester, Manchester, Lancs, England.
EM miyajima@fs1.ser.man.ac.uk
RI Pendleton, Neil/F-2333-2015
OI Pendleton, Neil/0000-0003-0794-2386
CR Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
NR 1
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD SEP 5
PY 2005
VL 138B
IS 1
BP 51
EP 51
PG 1
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 971BY
UT WOS:000232357300180
DA 2020-12-17
ER

PT J
AU Payton, A
   Miyajima, F
   Pendleton, N
   Horan, M
   Pickles, A
   Ollier, W
AF Payton, A
   Miyajima, F
   Pendleton, N
   Horan, M
   Pickles, A
   Ollier, W
TI Dopamine transporter (SLC6A3) polymorphism associated with extraversion
   and immediate recall in a non-demented elderly population
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Meeting Abstract
CT 13th World Congress on Psychiatric Genetics
CY SEP 04-08, 2005
CL Boston, MA
SP Int Soc Psychiat Genet
C1 Univ Manchester, Manchester, Lancs, England.
EM tony@fs1.ser.man.ac.uk
RI Pickles, Andrew/A-9625-2011; Pendleton, Neil/F-2333-2015
OI Pickles, Andrew/0000-0003-1283-0346; Pendleton, Neil/0000-0003-0794-2386
CR Badcock JC, 2005, J PSYCHIATR RES, V39, P11, DOI 10.1016/j.jpsychires.2004.05.002
   Frazier TW, 2004, NEUROPSYCHOLOGY, V18, P543, DOI 10.1037/0894-4105.18.3.543
   Salthouse TA, 1998, DEV PSYCHOL, V34, P851, DOI 10.1037/0012-1649.34.5.851
NR 3
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD SEP 5
PY 2005
VL 138B
IS 1
BP 89
EP 90
PG 2
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 971BY
UT WOS:000232357300321
DA 2020-12-17
ER

PT S
AU Miyajima, F
AF Miyajima, F
BE Urey, H
TI MEMS electromagnetic optical scanner for a commercial laser scanning
   microscope
SO MOEMS DISPLAY AND IMAGING SYSTEMS
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on MOEMS Display and Imaging Systems
CY JAN 28-29, 2003
CL SAN JOSE, CA
SP SPIE, Semicond Equipment & Mat Int, SolidState Technol, Sandia Natl Lab
DE optical scanner; laser scanning microscope; hinge; electromagnetic;
   closed-loop control; reliability
AB A MEMS electromagnetic optical scanner for horizontal scanning in a commercial laser scanning microscope has been developed. Major specifications include mirror size: 4.5 x 33 mm(2), resonant frequency. 4 kHz, changeable scan angle: 21 - 16degrees mirror flatness: <244 nm; and scan angle stability: <0.1%. Initial development started with prototyping a scanner with polyimide hinge, but the stiffness and the Q-factor of polyimide hinge were found insufficient to realize the required resonant frequency and scan angle. On the other hand, a scanner with single crystal silicon hinge has been successfully developed. The electromagnetic scanner has a copper-electroplated driving coil and an improved magnetic circuit to reduce power consumption. A scanner controller using the output signal from an integrated sensing coil was also developed, and sufficient scan angle stability was obtained. The scanner has survived the life test of over 140 billion cycles. It has successfully satisfied all the specifications including not only the fundamentals such as resonant frequency and maximum scan angle but also the ones for commercial products such as scanning stability and durability. It has been commercialized as a part of our product OLS1100 (remodeled as OLS1200 as of Aug 2002).
CR ASADA N, 1999, SILICON MICROOPTICAL, P778
   Dewa A. S., 2000, Technical Digest. Solid-State Sensor and Actuator Workshop (TRF Cat. No.00TRF-0001), P93
   Dickensheets DL, 1998, J MICROELECTROMECH S, V7, P38, DOI 10.1109/84.661382
   Hofmann U, 1999, P SOC PHOTO-OPT INS, V3878, P29, DOI 10.1117/12.361269
   Kaneko S, 1997, PROC IEEE MICR ELECT, P471, DOI 10.1109/MEMSYS.1997.581905
   Miller RA, 1997, OPT ENG, V36, P1399, DOI 10.1117/1.601348
   Miyajima H, 2002, PROC IEEE MICR ELECT, P552, DOI 10.1109/MEMSYS.2002.984331
   Miyajima H, 2001, J MICROELECTROMECH S, V10, P418, DOI 10.1109/84.946797
   MIYAJIMA H, 1999, ELECTROMAGNETIC OPTI, P372
   MIYAJIMA H, 2001, STUDY NONLINEAR TORS, P1402
   NEUKERMANS A, 2001, 4 INT TOP WORKSH CON, P19
   PIYAWATTANAMETH.W, 2001, MEMS NONINTERFEROMET, P590
   Wilson T., 1990, CONFOCAL MICROSCOPY
   Wine DW, 2000, PROC SPIE, V4178, P186, DOI 10.1117/12.396487
NR 14
TC 4
Z9 4
U1 0
U2 2
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-4785-4
J9 P SOC PHOTO-OPT INS
PY 2003
VL 4985
BP 95
EP 105
DI 10.1117/12.478564
PG 11
WC Optics; Imaging Science & Photographic Technology
SC Optics; Imaging Science & Photographic Technology
GA BW40H
UT WOS:000181866900010
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Pereira, CB
   Daruge, E
AF Miyajima, F
   Pereira, CB
   Daruge, E
TI "Digital images employment: juridical and forensic aspects in medicine
   and odontology"
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Meeting Abstract
CT 18th Annual Meeting of the International-Association-for-Dental-Research
CY SEP 02-05, 2001
CL SAO PAULO, BRAZIL
SP Int Assoc Dent Res
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT AMER ASSOC DENTAL RESEARCHI A D R/A A D R
PI ALEXANDRIA
PA 1619 DUKE ST, ALEXANDRIA, VA 22314-3406 USA
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PD DEC
PY 2002
VL 81
SI B
BP B205
EP B205
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 632HM
UT WOS:000180217901512
DA 2020-12-17
ER

PT J
AU Miyajima, F
   Iijima, T
   Tomoi, M
   Kimura, Y
AF Miyajima, F
   Iijima, T
   Tomoi, M
   Kimura, Y
TI Aromatic nucleophilic fluorination with KF catalyzed by
   polymer-supported phosphonium salts under solid-solid-liquid phase
   transfer conditions
SO REACTIVE & FUNCTIONAL POLYMERS
LA English
DT Article
DE phase transfer reaction; triphase reaction; fluorination; potassium
   fluoride; polymer-supported phosphonium salt
ID ARYL FLUORIDES; MECHANISMS; ION
AB Fluorination of 2,4-dinitrochlorobenzene (DNCB) with solid KF was conducted in the presence of polymer-supported tetraphenylphosphonium chloride catalyst under solid-solid-liquid (S-S-L) phase transfer conditions. The triphase fluorination obeyed zero-order kinetics with respect to DNCB concentration and first-order kinetics with respect to the catalyst concentration. The apparent activation energy for the fluorination was estimated as about 40 kJ/mol. On the basis of these results, the ion exchange reaction between the Cl- ion of the supported catalyst and the F- ion of KF was concluded to be rate-determining in this S-S-L triphase fluorination. The addition effect of water on the triphase fluorination was discussed by means of both the prompted dissolution of solid KF and the decreased reactivity of the F- ion, induced by increased hydration. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Yokohama Natl Univ, Fac Engn, Dept Synthet Chem, Yokohama, Kanagawa 2408501, Japan.
   Ihara Chem Ind Co Ltd, Dept Res & Dev, Shizuoka 42133, Japan.
RP Tomoi, M (corresponding author), Yokohama Natl Univ, Fac Engn, Dept Synthet Chem, Yokohama, Kanagawa 2408501, Japan.
OI KIMURA, YOSHIKAZU/0000-0003-1586-842X
CR ARRAD O, 1988, J AM CHEM SOC, V110, P185, DOI 10.1021/ja00209a030
   BRUNELLE DJ, 1984, TETRAHEDRON LETT, V25, P3383, DOI 10.1016/S0040-4039(01)91026-3
   Clark J. H., 1996, AROMATIC FLUORINATIO
   CLARK JH, 1987, TETRAHEDRON LETT, V27, P11
   DEUTSCH J, 1991, SYNTHETIC COMMUN, V21, P505, DOI 10.1080/00397919108016776
   FORD WT, 1984, ADV POLYM SCI, V55, P49
   GonzalezTrueba G, 1996, GAZZ CHIM ITAL, V126, P457
   KUNIN R, 1958, ION EXCHANGE RESINS, P69
   LANDINI D, 1989, J ORG CHEM, V54, P328, DOI 10.1021/jo00263a013
   LANDINI D, 1993, GAZZ CHIM ITAL, V123, P19
   LIOTTA CL, 1974, J AM CHEM SOC, V96, P2250, DOI 10.1021/ja00814a044
   Sasson Y, 1996, CHEM COMMUN, P297, DOI 10.1039/cc9960000297
   TOMOI M, 1981, J AM CHEM SOC, V103, P3821, DOI 10.1021/ja00403a032
   TOMOI M, 1997, HDB PHASE TRANSFER C, pCH13
   TOMOI M, UNPUB
   YOSHIDA Y, 1990, CHEM LETT, P769, DOI 10.1246/cl.1990.769
   YOSHIDA Y, 1989, TETRAHEDRON LETT, V30, P7199, DOI 10.1016/S0040-4039(01)93933-4
NR 17
TC 10
Z9 13
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1381-5148
J9 REACT FUNCT POLYM
JI React. Funct. Polym.
PD MAR 15
PY 2000
VL 43
IS 3
BP 315
EP 324
DI 10.1016/S1381-5148(99)00067-X
PG 10
WC Chemistry, Applied; Engineering, Chemical; Polymer Science
SC Chemistry; Engineering; Polymer Science
GA 295CD
UT WOS:000085947700008
DA 2020-12-17
ER

EF